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ABSTRACT
The cycling changes of the human endometrium are regulated by the effects of sex
steroids such as oestrogen, progesterone (P) and androgens. Molecular studies have
elucidated the mechanism of action of sex steroids via sex steroid receptors. This has
led to the development of sex steroid receptor ligands, which modulate their
function. Progesterone receptor modulators (PRMs) appear promising in their ability
to improve common gynaecological symptoms. Only two PRMs are currently
licensed for clinical application, mifepristone for medical termination of pregnancy
and ulipristal for emergency contraception. However, there is also evidence to
demonstrate their potential for the management of benign gynaecological conditions.
Asoprisnil is a PRM with partial agonist and antagonist properties and is the most
clinically advanced compound in its group. It has been shown to have an endometrial
antiproliferative effect in non-human primates and humans and as such to cause
reversible amenorrhoea. This effect has been demonstrated in the presence of
follicular phase oestradiol (E) levels and is therefore not associated with the side
effects of hypo-oestrogenism.
The data presented within this thesis are derived from a phase II multi-centre
randomised double-blind placebo-controlled study of asoprisnil administered for 12
weeks to women with symptomatic uterine fibroids scheduled for hysterectomy.
Subjects of investigation were clinical effects of asoprisnil on symptoms associated
with uterine fibroids. Following hysterectomy, full thickness endometrial tissue
samples were obtained for histological assessment, immunohistochemistry and RNA
extraction for subsequent quantitative RT-PCR. Effects of asoprisnil on endometrial
protein and mRNA expression of proliferation markers, nuclear sex steroid receptors
and markers of local immune cell function were subsequently assessed. The
extracted RNA was also forwarded for microarray analysis to study the endometrial
gene expression profiles after administration of asoprisnil. The aim was to
thoroughly evaluate the effects of PRMs, and specifically this novel compound
asoprisnil, on endometrium to elucidate its mechanism of action and specify its
potential for future clinical applications.
Clinically, asoprisnil showed a remarkable effect on menstrual bleeding pattern with
profound suppression and minimal breakthrough bleeding. Quality of life in women
with symptomatic uterine fibroids was favourably influenced. Consistent with
previous studies, these effects were achieved with maintained serum E levels. A
moderate reduction in uterine artery blood flow was demonstrated with asoprisnil
indicating that a vascular effect may contribute to its mechanism of action.
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The morphology of endometrium following exposure to asoprisnil was thoroughly
studied and found to exhibit a unique pattern, inconsistent with previously known
histological classifications. Most notable were changes of the glandular appearances
as well as the vasculature. Cystic glandular dilatation, previously known to be
associated with hyperplasia, was demonstrated without any accompanying
hyperplastic features. Specifically, mitotic counts were very low and further studies
into proliferation marker expression showed that asoprisnil did not induce
endometrial proliferation with a significant inhibitory effect in the stroma. This study
lent evidence to the conclusion that administering asoprisnil for 12 weeks does not
increase the risk of endometrial hyperplasia or cytological atypia. This was further
consolidated by the finding of maintained expression of the tumour suppressor gene
PTEN. Distinct vascular changes were found with exposure to asoprisnil, which
appeared specific to the endometrium. They consisted of a more frequent occurrence
of both aggregates of thin-walled vessels and clusters of vessels with thickened
muscularized walls compared to controls. These unique morphological features
supported the hypothesis that the effects of asoprisnil are mediated via the
endometrial vasculature.
As asoprisnil belongs to the family of sex steroids, its effect on endometrial sex
steroid receptor expression was studied on both protein and mRNA level. Sex steroid
receptor expression was significantly altered. Notably there was a differential effect
in endometrial stroma and epithelium. Specifically, PR was up-regulated in the
glands and down-regulated in the stroma. Interestingly, PR was also suppressed in
the perivascular cells, which may be significant for the effects of asoprisnil on
vascular remodelling. Both ERa and AR expression were up-regulated. The changes
in AR expression have previously been cited as a possible mechanism of action for
the endometrial antiproliferative effect of asoprisnil.
Microarray analysis was carried out to evaluate endometrial gene expression profiles
after administration of asoprisnil compared to controls. There was a notable down-
regulation of genes known to be involved in local immune cell function and
apoptosis, in particular IL-15.1L-15 was also down-regulated on mRNA level, and as
IL-15 is a uterine natural killer (uNK) cell recruiter, the uNK cell marker CD56 was
further investigated. CD56 was significantly suppressed by asoprisnil in endometrial
stroma and perivascular cells. There is evidence to associate the function of uNK
cells with endometrial vascular remodelling. Hence, these effects of asoprisnil on
local immune responses may play an important role in the morphological and
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A more detailed review on relevant subjects may be found within individual chapters
1.1. The Endometrium
1.1.1. The Clinical Perspective
Menstruation is a physiological event. This pivotal reproductive phenomenon may
however be associated with a variety of clinically significant symptoms. The severity
of symptoms may range from mildly distressing to debilitating, and often there is a
disparity between the objective events and the subjective perception of their impact
on quality of life. The most common symptoms for which medical advice is sought
are heavy menstrual bleeding (HMB) and pelvic pain. Such symptoms may be
exacerbated by coexisting uterine or pelvic benign pathology such as fibroids,
endometriosis or adenomyosis. Complaints associated with menstruation constitute a
significant proportion of the workload in primary care as well as gynaecological
specialist clinics. Consultations and subsequent interventions attract considerable
cost. Not infrequently do menstrual disturbances indicate surgical intervention, as
they are the main presenting symptom for half of the hysterectomies performed in the
UK1. Further, these complaints appear to be of increasing prevalence. Due to earlier
menarche, increased life expectancy, the ability to regulate fertility and less time
spent breastfeeding, women nowadays experience more periods than their
predecessors a century ago2. The average woman in developed countries may expect
to menstruate over 400 times during her reproductive life span, and menstrual
symptoms are possibly less well tolerated due to more demanding lifestyles of
• 3
working women . On the other hand, there is a trend to postpone childbearing into
later life with the result that management options impairing fertility and certainly
hysterectomy are undesirable. Women also increasingly tend to prefer to avoid major
surgery when adequately counselled4. Hence there is a demand for medical therapies,
which are effective and acceptable in the management of symptoms associated with
menstruation. In order to develop therapeutic concepts to ameliorate menstrual
symptoms, it is essential to have detailed understanding of the mechanisms
regulating endometrial events3.
1.1.2. Endometrial morphology
Human and old-world primate endometrium differs from any other tissue type in its
ability to proliferate, transform in preparation for implantation, menstruate in the
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absence of pregnancy and then regenerate. Particularly distinctive is its capacity to
undergo tissue breakdown at the time of menstruation and subsequent repair5.
The menstrual cycle may be divided into the proliferative phase, the secretory phase
and menstruation in response to the sequential exposure of the endometrium to
oestrogen from the developing ovarian follicle, progesterone from the corpus luteum
(CL) and progesterone withdrawal with demise of the CL in the absence of
pregnancy. Any endometrial section may be morphologically categorized into one of
these phases according to the Noyes criteria6. Endometrial morphology may be
divided into the basal layer adjacent to the myometrium and the uppermost
functional layer, where most morphological changes across the cycle are detected.
The proliferative phase is characterized by extensive mitoses with proliferation of
glandular, stromal and vascular elements. The stroma is compact and the glands
narrow and tubular with a thin columnar surface epithelium (Figure 1.1). During the
secretory phase, the endometrium differentiates and matures in preparation for
implantation. The glands are increasingly tortuous, eventually taking a "saw-toothed"
appearance, and the stroma becomes oedematous (Figure 1.2). Finally, in the absence
of pregnancy, focal areas of necrosis develop within the functional layer, which is
< n
shed at menstruation .
Unique to human and old-world primate endometrium are the spiral arterioles, which
are crucial to the process of menstruation. These coiled branches of arterial
vasculature are present throughout the functional layer of the endometrium (Figure
1.3.) and undergo intense vasoconstriction during the menstrual phase of the cycle.
The striking changes in the spiral arterioles were first described by Markee8, who
transplanted endometrium into the anterior chamber of the eye of the rhesus monkey
for direct observation during menstruation. These experiments and the findings of
arteriolar coiling and constriction at the time the endometrium is shed, constituted the
first step towards the understanding of menstrual bleeding. Since then it has been
postulated that the perivascular cells, stromal myofibroblasts with contractile activity
surrounding the spiral arterioles, are also relevant to the process of menstruation9.
For the understanding of menstrual disturbances, it is equally important to elucidate
the mechanisms of postmenstrual endometrial regeneration and repair5'10. Re-
epithelialization of the vasculature is required, and therefore factors influencing
angiogenesis are potentially significant. Based on the experiments by Markee, it was
suggested that the observed vasoconstriction led to reduced blood flow and
o
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Figure 1.1. Morphology of proliferative phase endometrium
Endometrium in the proliferative phase of the menstrual cycle with
narrow and tubular glands and compact stroma stained with
haematoxylin and eosin (H&E); the different layers of the
endometrium are highlighted; G: glandular epithelium; S: stroma
(Stained by Miss Morag Hamilton, CRB, Edinburgh;
previously used in MSc thesis by Mrs Teresa A Henderson,
University of Edinburgh, 2004)
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Figure 1.2. Morphology of secretory phase endometrium
Endometrium in the secretory phase of the menstrual cycle
with tortuous glands and oedematous stroma stained with
haematoxylin and eosin (H&E) in low power (A) and high
power (B)
(Reproduced with permission from Dr Alistair Williams,
Department of Pathology, University of Edinburgh)
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Figure 1.3. Endometrial spiral arterioles
A & B Spiral arterioles are coiled branches of the uterine
arterial vasculature, which may be found throughout
the functional layer of the endometrium (arrows)
(Reproduced with permission from






Since then, a role for hypoxia in the menstrual process via the hypoxia-inducible
factor-1 alpha has been demonstrated11 with possible relevance for the onset of
menstruation but very likely also for the initiation of subsequent endometrial repair.
Hypoxia has been shown to be a strong stimulus for vascular endothelial growth
factor (VEGF) expression in endometrial stromal cells12, and recent studies have
indicated VEGF to be essential for endometrial neo-angiogenesis during
11
postmenstrual regeneration .
1.1.3. Endometrial proliferation and carcinogenesis
Following tissue injury and repair during menstruation, the endometrium re-enters
the proliferative phase under the influence of oestrogen (E). This phase is mainly
characterized by proliferation and thickening of the functional layer. Numerous
forms of mitosis, which may be directly observed mainly in the early proliferative
phase, evidence proliferation. Fewer mitotic cells are observed in the early secretory
phase, whilst there is another significant decrease in mitosis in the progesterone (P)
dominated mid- and late secretory phases with hardly any detectable cells with
mitotic features14.
The difficult and time-consuming process of determining the mitotic index may be
reliably replaced by immunocytochemical assessment. Such assessment across the
menstrual cycle has been carried out with anti-phosphorylated histone H3 (phospho
H3) and found to be highly correlated with the mitotic cell count. Analysis of
variation in mitotic index and immunocytochemistry with both phospho H3 and the
less specific proliferation marker Ki-67 have all indicated that most proliferation
occurs during the proliferative phase with negligible evidence in the mid- and late
secretory phases14 (Figure 1.4.).
Endometrial proliferation is essential for the maintenance of the menstrual cycle and
to prepare for implantation. As such, it is a physiological event. There is a potential
for persistent proliferation to initiate endometrial pathology, when it leads to
hyperplasia, particularly when complex and associated with cellular atypia.
Morphological changes and an increased mitotic index are indicators of an increased
risk of malignant transformation. Even prior to any histological changes, the down-
regulation of the tumour suppressor gene phosphatase and tensin homologue (PTEN)
has been described as an early event in endometrial carcinogenesis and can be
detected by immunohistochemistry15"17. PTEN has been suggested as a biomarker for
premalignant endometrial disease, as it appears to serve as a gatekeeper for the
initiation of carcinogenesis.
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Figure 1.4. Mitosis and proliferation marker expression across the menstrual
cycle
Comparison of three proliferative indices in human endometrium
during the menstrual cycle
Both direct count of mitosis and proliferation marker expression
indicate a pattern of elevated mitotic activity in the proliferative
phase, which significantly decreases in the secretory phase;
there is a high correlation between the Phospho H3 index and direct
count of mitotic figures (R2 = 0.89, P < 0.001) and also between the
mitotic index and Ki-67 expression (R2 = 0.74, P < 0.05)
(Derived with permission from:
Brenner et al., Human Reproduction 2003; 18: 1185-93)
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The most common form of endometrial cancer, endometrioid endometrial
adenocarcinoma, shows inactivation of PTEN in up to 83% with frequent mutations
and deletions15. Endometrioid endometrial cancer has also been associated with the
risk factor of exposure to unopposed E. P has been shown to play an important role
in eliminating PTEN-deficient endometrial cells18, indicating the dependency of
endometrial physiological and pathological events on sex steroid hormones.
1.1.4. Regulation of endometrial events by sex steroid hormones
It has been firmly established that the endometrial changes through the menstrual
cycle are regulated by the sequential exposure to the ovarian steroids oestradiol (E)
and progesterone (P)19. The level of E rises during the proliferative phase, when the
ovarian follicle matures, whilst P depends on ovulation having occurred, as it is
produced by the CL, and therefore peaks in the secretory phase. E is essential for
endometrial proliferation, and secretory transformation with stromal decidualization
in preparation for implantation is dependent on P. Menstruation is the endometrial
response to withdrawal of P due to the demise of the CL in the absence of pregnancy.
Concerted ovarian production and release of both E and P is essential to induce
consequent changes within the endometrium and a regular cycle pattern. Other sex
steroids such as androgens and glucocorticosteroids have also been shown to have a
modulating effect20.
The action of sex steroid hormones is mediated via their respective receptors.
Relevant for endometrial function are the progesterone receptor (PR), oestrogen
receptor (ER) with its subtypes ERa and ERp, androgen receptor (AR) and the
glucocorticoid receptor (GR). Endometrial expression of these receptors is
temporally and spatially regulated in the respective endometrial tissue compartments.
It is particularly variable in the glandular epithelium and most pronounced in the
functional layer. These variations occur in relation to the menstrual cycle phases
suggesting a feedback mechanism between sex steroid hormones and their receptors.
PR expression is under dual control of E and P with up-regulation in the proliferative
phase and subsequent down-regulation by its own ligand21. As PR synthesis is
dependent on ligand interaction with the ER, the presence of PR indicates a
functional ER-mediated pathway20. Similarly, ER expression increases throughout
the proliferative and until the early secretory phase with a subsequent decline in the
mid- and late secretory phases. Both GR22'23 and AR24 are predominantly expressed
in endometrial stroma with AR gradually decreasing from the early proliferative
through to the late secretory phase24. Steroid receptor co-activators and co-repressors
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are also likely to play an important role in regulating endometrial function. Such
roles however have as yet not been fully determined25"27.
Crucial to the process of menstruation is the regulation of the endometrial
vasculature, and whilst the straight arteries in the basal layer are not influenced by
hormonal changes, the spiral arterioles are steroid responsive. In this context, it is
notable that stromal PR is specifically localized in the perivascular regions19. The
findings that perivascular but not endothelial cells express PR"8, indicate that the
perivascular cells may act as a mediator for the effect of P on the vasculature.
Endothelial cells have been shown to express ER(3 and GR. It has been demonstrated
in the rhesus macaques as well as the human29'30 that the ER subtype expressed in
endothelial cells is ER(3, whilst ERa, PR and AR are all absent. Isolated and cultured
human endometrial endothelial cells have been found to express ERp mRNA but not
ERa, and interestingly also PR mRNA31. Up-regulation of stromal and vascular ERp
expression has been shown in the late secretory phase, with concurrent down-
regulation in the glandular epithelium. The stromal cells expressing ERp in this
32
phase of the cycle were observed mostly around spiral arterioles . The hypothesis
for the modulation of endometrial vasculature by sex steroids is therefore either a
direct effect via the endothelial ERp or an indirect effect through paracrine signalling
30from the perivascular cells or both . Interestingly, the endothelial cells express
22GR , which is also present in the endometrial stroma, fibroblasts, lymphocytes and
uterine-specific natural killer (uNK) cells23 but absent from the glandular epithelium.
The exact significance of these sex steroid receptor expression patterns for vascular
function has not been fully elucidated.
1.1.5. The role of the local endometrial immune system
Menstruation is triggered by a change in sex steroid levels, in particular P
withdrawal. However, sex steroids are not the only regulators of the menstrual
process, and the immune system has been attributed an important role33'34. P
withdrawal initiates a cascade of events leading to the influx of leukocytes into the
endometrium via the expression of cytokines. This leukocytic invasion and
subsequent production of inflammatory mediators has led to the description of
menstruation as an inflammatory event35. The menstrual process may be divided into
two phases36. The early events of vasoconstriction of the spiral arterioles and
cytokine changes are hormone dependent and reversible by adding back P within 36
hours. The subsequent activation of lytic mechanisms, probably as a consequence of
hypoxia, is inevitable and independent of the sex steroid environment. Activation of
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matrix metalloproteinases (MMPs) such as MMP-3 with the potential to degrade the
extracellular matrix (ECM) can lead to a whole cascade of subsequent lytic enzyme
activation and eventually to tissue sloughing and menstrual bleeding10.
Particular significance for this process appears to be attributable to the perivascular
cell, which is in close relation to the endothelial cells and, unlike those, expresses sex
steroid receptors. The perivascular cell is responsive to changes in P levels and also
expresses chemokines, cytokines and prostaglandins (PG), all important for the
control of leukocyte entry into the endometrium. It has also been shown to express
CD40, activation of which up-regulates interleukin-8 (IL-8) and the enzyme
responsible for PG synthesis cyclo-oxygenase 2 (COX-2)9. Indeed, an increase of
key inflammatory mediators IL-8 and COX-2 has been demonstrated at both mRNA
and protein level 48 hours following P withdrawal37. The properties of the
perivascular cell are very likely to facilitate the invasion of leukocytes in the
immediate premenstrual phase.
A significant population of leukocytes may be found in the endometrium including
neutrophils, lymphocytes, macrophages, mast cells and other haematopoetic cells.
Whilst their proportion remains stable in the basal layer, there is considerable
fluctuation in the functional layer from around 8% bone marrow derived cells in the
stroma in the proliferative phase to at least 20% in the late secretory phase38. There is
also a variation of leukocyte distribution across the cycle with scattered occurrence
throughout the stroma in the proliferative phase and small aggregates around glands
and spiral arterioles in the late secretory phase. These leukocytes are further sources
of cytokines, which potentially induce a spiralling inflammatory response9. Some
leukocytes also release MMPs and MMP activators initiating the breakdown of the
ECM33'39.
The majority of the leukocyte population in the late secretory phase consists of
uterine natural killer (uNK) cells. The proportion of this cell type rises to 70% in
early pregnancy40. These cells have a unique phenotype (CD56bnght, CD 16", CD3")
and are thus distinguishable from peripheral blood NK cells (CD56dim, CD16bnght,
CD3"). It is yet to be established whether the dramatic increase in uNK cells during
the mid-late secretory phase is due to in situ proliferation or de novo migration from
the peripheral circulation. In any case, the appearance of uNK cells does vary
according to the menstrual cycle suggesting hormonal regulation, even though this
cell type does not express ERa or PR23'41. Once again, the perivascular cells appear
to have a paracrine role, as they have been shown to release IL-1542'43, which
stimulates proliferation of CD56+ve uNK cells. A clear link has been demonstrated
between progesterone levels, IL-15 expression and fluctuation of uNK cells in the
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endometrial stroma43. Interestingly, whilst immunonegative for ERa and PR, uNK
cells have been shown to express ER(31 and GR, raising the possibility that
oestrogens and glucocorticoids may have a directly modulating effect on these cells
via those steroid receptors23. The exact role of uNK cells is incompletely understood
but appears to be important for decidualization, implantation and menstruation44.
Several observations have pointed to the association of uNK cells with the process of
decidualization. There is also some evidence for the significance of the uNK cell for
the initiation of menstruation. Even prior to the morphological signs of impending
menstrual tissue breakdown such as infdtration of neutrophils, stromal cell clumping
and interstitial haemorrhage, there is an apparent apoptosis of uNK cells40 coinciding
with the fall in P levels. Some uNK cells have been shown to produce an enzyme that
can activate latent MMP-2 (MT1-MMP) and hence lead to tissue degradation45. uNK
cells have also been demonstrated to produce angiogenic growth factors (i.e. vascular
endothelial growth factor C (VEGF-C), placenta growth factor (P1GF) and
angiopoietin 2 (Ang-2)) and might therefore contribute to the process of
postmenstrual endometrial regeneration46.
Further studies are clearly required to fully elucidate the mechanisms responsible for
remodelling the endometrium. So far, many studies have examined the regulators of
the endometrial tissue breakdown at the time of menstruation. Far less is known
about the subsequent tissue repair and its modulating factors, and yet the repair
mechanisms are likely to be of equal relevance to the full understanding of normal
and abnormal uterine bleeding5'10. Currently, there is limited insight into the reasons
why in some women menstruation is associated with severely distressing symptoms
such as heavy bleeding and / or dysmenorrhoea in the absence of any pathology.
1.2. The Progesterone Receptor and its Ligands
1.2.1. The Progesterone receptor (PR)
1.2.1.1. Steroid receptor biology
The PR is an intranuclear receptor belonging to a steroid-thyroid-retinoid receptor
superfamily, which includes receptors for steroids, thyroid hormone, vitamin A and
D derived hormones and certain fatty acids47. The steroid receptor subgroup (Type 1
receptors) comprises the PR, ER, AR, GR and the receptor for mineralocorticoids
(MR)20'48. Members of the nuclear receptor superfamily share a common structure
with five functional domains, denoted A/B, C, D, E and F49 (Figure 1.5.).
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Figure 1.5. The sex steroid receptor superfamily
Five functional domains (A/B, C, D, E and F) are common to the
structure of all nuclear receptors;
the DNA-binding domain (DBD) is contained in the C domain and the
ligand-binding domain (LBD) is located in the E domain; A/B is the
N-terminal end (N) and F is the C-terminal end (C); D is the hinge
region; AF indicates activation function
(Adapted from:
Critchley & Saunders, Reproductive Sciences 2009; 16 (2): 191-199)
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The C domain contains a highly conserved DNA-binding domain (DBD)
determining the specificity of the receptor for particular hormone responsive
elements (HREs). It also enables interaction between the receptor and its target
genes. The E domain is the ligand-binding domain (LBD), which determines whether
the receptor is activated. In the absence of specific ligands, the PR is maintained in
an inactive state in the cytoplasm by association with a large complex of chaperone
proteins such as heat shock proteins (HSP) and FK506-binding proteins (FKBPs),
which can be found in complex with several steroid receptors49'50. The interaction
between the PR and the chaperone complex is critical in order to maintain the
functionality of the receptor and the competence to bind P. FKBP4, bound to the
inactive PR via the adapter protein HSP90, has been demonstrated to potentate PR
transcriptional activity, whilst its absence results in reduced uterine receptivity50.
Ligand binding renders the PR transcriptionally active. Alternatively, there is a
ligand-independent mechanism whereby an increase in intracellular kinase activity
and stimulation of phosphorylation pathways can lead to PR activation51. Once
activated through either ligand-dependent or independent mechanisms, the
phosphorylated PR translocates to the nucleus and binds to a progesterone responsive
element (PRE) on target DNA to alter gene expression with a promoting or
repressive effect. Additionally, transcription activation is mediated via recruitment of
co-regulators (co-activators or co-repressors) with an enhancing or inhibiting
27effect . Co-activators such as acetyltransferase proteins and steroid receptor co-
activator members (SRC1, SRC2, SRC3) accelerate the formation or increase the
stability of the pre-initiation complex for activation of transcription. On the other
hand, the non-ligand bound PR can suppress basal transcription through co-
repressors such as nuclear receptor co-repressor (N-CoR) and silencing mediator of
repressed transcription (SMRT). However, the PR has been shown to regulate gene
expression not just directly or via co-regulators but also through crosstalk with other
transcription factors and by activating kinase signalling cascades from the
cytoplasm51'. The target genes of regulation by PR on a molecular level have only
partially been identified so far52. Indian hedgehog (Ihh) has been described as a
target gene induced by P via the PR. Studies in mouse models have shown Ihh to be
expressed in the glandular and surface epithelium with the downstream targets of the
Hedgehog signalling pathway located in the stroma53. It has been suggested that Ihh
may be involved in coordinating communication between the epithelial and stromal
tissue compartments50.
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1.2.1.2. The function of PR and its isoforms
The PR is an essential coordinator for the regulation of female reproductive activities
by P, including endometrial receptivity, implantation and maintenance of pregnancy,
mammary gland development and sexual behaviour. Evidence for the role of PR in
reproductive function has been derived from mouse models, in which the PR has
been ablated (PRKO)51. Ablation of PR results in pleiotropic reproductive
abnormalities. Experiments with PRKO mice have provided proof that PR is an
essential mediator of ovulation in the mouse. PR is specifically required for the
follicular rupture, whilst luteinization of the granulosa cells can still occur in the
PRKO mouse. The effects of P on the endometrium mediated by PR include the
inhibition of E induced epithelial hyperplasia. On the other hand, the stromal effects
of P are proliferation of the spiral arterioles54 and differentiation. PRKO mice are
found to have a markedly hypocellular endometrial stroma, whilst the epithelium is
hyperplastic due to unopposed action of E. The potent anti-inflammatory response
mediated by PR is abolished in these animals, and the stroma is infiltrated by
neutrophils and macrophages. Proliferation and differentiation of the developing
mammary gland has also been demonstrated to depend on the effects of P and PR51.
Several isoforms of the PR have been identified, including PR-A, PR-B, PR-C and
PR-M19. The two main isoforms described in the human are PR-A (Mr 94,000) and
PR-B (Mr 120,000). They arise from a single gene with specific promoters for the
two different subtypes55. PR-A is the shorter isoform and is devoid of 164 amino
acids at the N-terminus, which are present in PR-B. Otherwise the two subtypes are
identical with indistinguishable hormone- and DNA-binding affinities. Both PR-A
and PR-B are co-expressed in endometrial target cells56. Depending on the relative
ratio, they can dimerize into homodimers (A:A or B:B) or heterodimers (A:B). Both
PR-A and PR-B and the dimers are capable of binding P and interacting with PREs,
but they are functionally different51.
Selective ablation of either subtype in mice has provided models (PRAKO and
PRBKO) to study their differential function49'51,57'58. PR-A appears to be less
transcriptionally active than PR-B. Ovarian and uterine functions remain unaffected
in the PRBKO mouse indicating a critical role for PR-A in mediating the ovarian
response to P. Ovulation is severely impaired in the PRAKO mouse. PR-A is
essential for decidualization and for the anti-inflammatory effect of P on the
endometrium. PRAKO mice have an absent decidual response and are infertile.
Regulation of endometrial growth also depends on PR-A, as in the PRAKO mouse E
induces endometrial hyperplasia, which cannot be suppressed by P. The function of
PR-B appears sufficient to elicit a normal proliferative and differentiative response of
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the mammary gland to P. There is no appreciable effect in the PRAKO mouse on
mammary gland function, whilst this is severely impaired in the PRBKO mouse,
particularly the development in pregnancy49'59.
In addition to these findings that the two receptor subtypes appear to regulate
different target genes, PR-A has been suggested as an inhibitor of PR-B activity60
with an effect of overall diminished P responsiveness. This repressive capability of
PR-A also appears to extend to E, glucocorticoid and mineralocorticoid receptor-
dependent transcriptional activation. It appears that the respective cellular response
to P depends on the differential expression of the receptor subtypes, and the ratio of
PR-A and PR-B expression is important51. Notably, there is also a difference in
response of the two PR isoforms to PAs. Whilst the binding of a PA inactivates PR-
A, the effect on PR-B can result in conversion to an active transcription factor with
modulation of intracellular phosphorylation pathways51.
1.2.1.3. Spatio-temporal distribution of PR in the endometrium
The variation of PR expression in the endometrium across the menstrual cycle has
been well described19'56'61'62. Expression in the functional layer, which is shed at
menstruation, and in the basal layer of the endometrium is differentially regulated. In
the basal layer, PR persists both in glands and in stroma throughout the menstrual
cycle. In the functional layer, PR is predominantly expressed in the proliferative
phase. In the epithelium, it is then down-regulated by its own ligand P following
ovulation21. PR persists in the stroma, particularly in perivascular location
surrounding the spiral arterioles, in a distribution similar to pregnancy29'63. The ratio
of PR-A to PR-B expression increases in the secretory phase indicating that P
preferentially down-regulates PR-B in both stroma and glands56'64. This is further
evidence for PR-A being the mediator of P-regulated events in the secretory phase
such as decidualisation65.
1.2.2. PR ligand - Progesterone (P)
1.2.2.1. The hormone
P (pregn-4-ene-3, 20-dione) is a C-21 steroid hormone (C21H30O2), first discovered in
the mid 1930s66'67 (Figure 1.6.). P is the main naturally occurring progestogen, whilst
progestins are synthetic progestogens. P is predominantly produced in the ovaries
with peak levels following ovulation in the secretory phase of the menstrual cycle, as
its main source is the corpus luteum. It is also produced in the brain and in significant
th • 68
amounts in the placenta after the 8 week of gestation .
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Figure 1.6. Chemical structure of progesterone
Pregn-4-ene-3, 20-dione is a C-21 steroid hormone (C21H30O2)
Levels are low in children and postmenopausal women and vary according to the
menstrual cycle phase during the reproductive years. A serum level of >30 nmol/1 on
day 21 of a 28-day cycle is indicative of ovulation having occurred. High levels are
reached in pregnancy and may rise up to 600 nmol/1 at term69.
The precursor of all steroid hormones is cholesterol, which is then oxidized to
pregnenolone (Figure 1.7.). Pregnenolone is converted into P in two steps of
oxidization followed by a keto/enol tautomerization reaction. P itself is a precursor of
other steroid hormones, such as mineralocorticoids and, after conversion into 17-
hydroxyprogesterone, Cortisol and androstenedione. Androgens and oestrogens can
be derived from androstenedione. Total synthesis of P was first described in the
1970s70. P is also found in certain plants, particularly the yam family Dioscorea, and
synthesized by yeast71. P is metabolised in the liver and then excreted by the kidneys
with a half-life of about 25-50 hours.
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Figure 1.7. Synthesis of progesterone from cholesterol
Cholesterol is the precursor of all steroid hormones; it is oxidized to
pregnenolone and then converted into progesterone by oxidation and a
keto/enol tautomerization; other steroid hormones are derived from
progesterone such as mineralocorticoids, Cortisol, androstenedione





P is a key regulator of female reproductive activity, and its effects are mainly
mediated via the PR as described above72. Whilst the reproductive system is its main
target, P also affects other functions such as myelination and neuroprotection73,
regulation of immune responses, regulation of core temperature and relaxation of
smooth muscle, particularly in the bronchi. Within the uterus, P predominantly
contributes to the regulation of endometrial function. P is essential for the
transformation of the endometrium into a state of receptivity in preparation for
implantation74'75. Animal studies have investigated the expression of P-regulated
genes, which may be significant for the successful establishment of a pregnancy and
hence for the management of infertility76"78. Endometrial decidualization is P-
dependent as are the maintenance of pregnancy and the process of menstruation. The
effect of P relies on endometrial priming by E, particularly as E mediates up-
regulation of the PR. The endometrium is most susceptible to a P effect in the mid
secretory phase, which represents both the implantation window and a period of
increased sensitivity to P withdrawal and hence is critical to both events of
implantation and menstruation19.
At the molecular level, markers of P function and endometrial genes regulated by P
have been described, such as insulin-like growth factor binding protein (IGFBP)-l,
prolactin, glycodelin, 15-hydroxyprostaglandin dehydrogenase (PGDH) and
calcitonin. More recently, Dickkopf-1 (Dkk-1) mRNA synthesis and protein
expression has been reported to be regulated by P in human endometrial stromal
cells79. Dkk-1 is an inhibitor of the canonical Wnt signalling pathway and may thus
influence endometrial differentiation. A dramatic up-regulation of Dkk-1 in the
endometrial stroma has been demonstrated in the secretory phase of the menstrual
cycle. At the same time, frizzled related protein (Frp) HE, another inhibitor of the
Wnt signalling pathway, is down-regulated. A role for Wnt signalling in the dialog
between epithelial and stromal compartments has been suggested, and the temporally
differential expression of FrpHE and Dkk-1 highlights the importance of P in the
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regulation of this pathway . Dkk-1 is also involved in control of the homeobox
(HOX) genes. HOX genes are essential regulators of development81, and particularly
HOXA10 plays an important role in implantation82 but also in the development of
endometriosis and polycystic ovarian disease19. Expression of HOXA10 has also
been shown to be regulated by P in a differential tissue-specific manner. Whilst P
induces HOXA10 in the endometrial stroma, the effect of P on HOXA10 in the
myometrium is down-regulation83.
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The implications of P in the modulation of physiological functions but also the
development of pathological conditions have been recognized. Whilst traditionally,
the growth of uterine leiomyomata was thought to be E dependent, the contributory
role of P has now also been appreciated84. There is both in vitro85 and clinical
evidence86 that P as well as E is an important promoter of leiomyoma growth.
1.2.2.3. Progesterone applications
With increasing insight into the mechanism of action of sex steroids, P and
progestins have been used in therapeutic approaches to modulate reproductive
function, to ameliorate associated symptoms such as heavy menstrual bleeding
(HMB) and dysmenorrhoea and to manage other gynaecological conditions. There is
a wide range of applications for progestogens, and they may be administered by
various routes. Progestogens have a major role in contraception, assisted
reproductive technology and hormone replacement therapy. They have a place in the
treatment of endometriosis, polycystic ovarian disease and also endometrial
hyperplasia. Progestogens have been used to control menstrual disturbances and are
particularly effective if these are associated with anovulatory cycles87'88. The route of
administration is important, as any compound will be metabolised passing through
intestine and / or liver, and hence the respective tissue effect will be dependent on the
hormonal activity of the metabolites in the circulation. Additionally, it will be
determined by intracellular mechanisms, which can be used to an advantage, when
tissue-specific steroid metabolising enzymes are regulated by synthetic compounds89.
Currently, an efficient way of administering exogenous progestogens to the
endometrium is via the levonorgestrel releasing intrauterine system (LNG-IUS). This
route achieves maximal levels of the androgenic progestogen levonorgestrel within
the endometrium with relatively low systemic levels90. The LNG-IUS induces
extensive decidualization and endometrial atrophy with a profound effect on
bleeding pattern91. The most frequent indication for discontinuation of treatment with
progestogens has been unscheduled breakthrough bleeding, which has been
attributed to modifications of the endometrial vasculature with increased vessel
fragility and changes in hemostasis19'92"94. A marked down-regulation of ER and PR
has been described in the initial response to the insertion of a LNG-IUS. 170-
hydroxysteroid dehydrogenase (HSD)-2 remains elevated with the effect of
continued conversion of oestradiol to the less potent oestrone. It has been postulated
that the resulting local intracellular E-deficient environment may contribute to
increased vascular fragility93'95. During the first six months after insertion of the
device, an enhanced expression of IL-8 and COX-2 has been demonstrated leading to
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higher local concentrations of prostaglandins. Altered expression of local
inflammatory mediators may affect vascular integrity and hence predispose to the
side effect of unscheduled bleeding episodes91.
1.2.3. PR ligands
The discovery of the PR96"98 opened up the potential for the development of synthetic
PR ligands. The first description of mifepristone (RU 486), a PR and glucocorticoid
receptor antagonist, was published in 1981This was followed by reports on its
effect on menstruation100 highlighting the potential for cycle regulation and birth
control101. Subsequently, numerous compounds have been developed with a varied
spectrum of PR agonistic and antagonistic properties. This large group of synthetic
PR ligands ranges from pure agonists such as progestins to pure antagonists (Figure
1.8.). The compounds exhibiting partial and mixed agonist/antagonist activity have
been classified as selective progesterone receptor modulators (SPRMs) and will be
described further in the next section.
1.2.3.1. Mifepristone (RU 486)
Mifepristone (RU 38486) [1 ip-(4-dimethylaminophenyl)-17P-hydroxy-17a-
propinyl-4,9-estradiene-3-one] is a beta-aryl-substituted, 19-nortestosterone-derived
compound (Figure 1.9.). It strongly antagonizes all effects of P including the
endometrial preparation for implantation and maintenance of pregnancy. Hence, not
surprisingly, its first clinical application was termination of pregnancy102.
Unfortunately, this has subsequently delayed and obstructed further development of
mifepristone and other compounds with P antagonistic properties for alternative
clinical use, as large pharmaceutical companies have distanced themselves from the
negative image of a drug that is capable of inducing abortion. Nevertheless,
mifepristone and other PAs have many other potential indications in gynaecological
and non-gynaecological practice, some of which have been described and tried
previously103.
Long-term administration of mifepristone in benign gynaecology has particularly
been described in the context of contraception104 and management of menstrual
disturbances, uterine fibroids and endometriosis. Administration of low-dose
mifepristone for 3-6 months has been reported to result in significant suppression of


















































Figure 1.8. Spectrum of synthetic PR ligands ranging from progesterone
agonists to antagonists
PR agonist and antagonistic properties of major 1 ip-benzoxime-
substituted progesterone receptor modulators and progesterone
antagonists; ONA, onapristone; RU486, mifepristone; J867, asoprisnil
(Derived with permission from:
Schubert et al., Seminars of Reproductive Medicine 2005; 23: 58-73)
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Figure 1.9. Chemical structure of mifepristone (RU486)
11 P-(4-dimethylaminophenyl)-17P-hydroxy-17a-propinyl-4,9-
estradiene-3-one is a beta-aryl-substituted, 19-nortestosterone-derived
compound
Recent randomised placebo-controlled trials with mifepristone in women with
symptomatic fibroids have demonstrated a decrease in leiomyoma volumes and a
significant reduction in menstrual blood loss with the effect of increased
i r\n i r\o
haemoglobin after treatment for three months ' . Mifepristone has also been
suggested as an adjunct to progestin-only contraception with the aim to reduce the
occurrence of bleeding irregularities109'110.
1.2.3.2. Other progesterone antagonists (PAs)
Mifepristone is currently licensed for clinical use in termination of pregnancy and
ulipristal (CDB-2914) for emergency contraception111. A number of other PAs have
been developed including onapristone, Org 31710, Org 33628, ZK 137 316, ZK 230
211 and others. Pre-clinical112"115 and clinical studies116 on the effects of these PAs
have been published. In rhesus macaque monkeys, the effects of ZK 137 316 and ZK
230 211 have been studied with findings of dose-dependent suppression of menstrual
and ovarian cyclicity113'115. Anovulation and amenorrhoea was demonstrated with
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higher doses of ZK 137 316 and all doses of ZK 230 211, indicating a more potent P
antagonistic activity of ZK 230 211. Studies in macaques have been conducted with
ZK 230 211 administered via an intrauterine system (IUS) with similar results114.
These agents have been suggested for consideration as contraceptives and for
suppression of menstruation in humans. The use of ZK230 211 administered via an
IUS in humans with a view to its potential in contraception and management of
benign gynaecological conditions has been evaluated in one pilot study116.
As unscheduled breakthrough bleeding is the most common reason for
discontinuation of progestin-only contraception, PAs have been proposed to
ameliorate this side effect117. Org 31710 administered monthly in addition to a
desogestrel-only contraceptive pill appeared to regularize the bleeding pattern118.
However, this effect has not been consistently demonstrated with other PAs.
Moreover, the effect on the contraceptive efficacy also remains to be clarified119.
1.3. Selective progesterone receptor modulators (SPRMs)
1.3.1. Discovery
The discovery of mifepristone (RU 486) was only the starting point of the
development of a variety of PR ligands. Initially, the aim was to find a compound
with more profound P antagonistic potency but less antiglucocorticoid activity. In
these early stages, the envisaged applications were fertility control and treatment of
breast cancer120'121. Very soon, the major therapeutic potential of PAs for the
management of benign gynaecological conditions became apparent, when the
endometrial antiproliferative effect resulting in endometrial atrophy and
amenorrhoea was demonstrated initially in non-human primates and rabbits122'123 and
later in women124. The disadvantages of PAs at this point included the unopposed
oestrogenic effects, the high abortifacient activity and the antiglucocorticoid effects
at higher doses. Consequent concerns regarding the administration of PAs led to the
conceptualisation of a drug discovery program to develop a compound with partial
PR agonistic and antagonistic properties in the assumption that this would eliminate
the perceived disadvantages of PAs125.
A large number of compounds were synthesized and subsequently submitted to a
screening program to determine their binding affinity to PR and GR, their labour-
inducing potential in guinea pigs and their PR agonist and antagonist properties. The
latter were assessed qualitatively with the luteolysis inhibition assay in guinea pigs
and then quantitatively with the McPhail assay in immature rabbits. In the luteolysis
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inhibition assay, partial PA effects of a compound were evaluated based on the
potential to suppress endometrial prostaglandin (PGF2a) secretion in non-pregnant
1 96
guinea pigs, as uterine PGF2a is responsible for luteolysis in this species . For the
McPhail assay, immature E primed rabbits are treated with a compound, and the
progestogenic effect on histological endometrial changes is subsequently evaluated
and scored on a scale of 0 - 41 .
The lead compounds selected were the 11 P-benzaldoxime-substituted estratriene
derivatives J867 (asoprisnil (benzaldehyde-4-[(l lb,17b)-17-methoxy-17-
(methoxymethyl)-3-oxoestra-4,9-dien-l l-yl]-l-oxime); Figure 1.10.), J912, J956
(asoprisnil ecamate) and J1042, classified as SPRMs.
Figure 1.10. Chemical structure of asoprisnil (J867)
Benzaldehyde-4-[( 11 b, 17b)-17-methoxy-17-(methoxymethyl)-3-
oxoestra-4,9-dien-l l-yl|-l-oxime is an 11 P-benzaldoxime-substituted
estratriene derivatives
38
They demonstrated high PR binding affinity and PR specificity with much reduced
antiglucocorticoid activity. Their labour-inducing effects in guinea pigs were only
marginal (asoprisnil, J956) or absent (J912, J1042). In the model tested, these J
compounds and particularly asoprisnil and J1042 had the most PR agonistic potency.
The hypothesis that the partial agonistic activity on the PR would result in a more
favourable effect on the endometrium was confirmed in subsequent studies in non-
human primates128'129. Due to its particularly pronounced PR agonistic properties and
the absence of labour-inducing activity, asoprisnil was selected for further clinical
development. Asoprisnil shows a high PR selectivity and a high degree of uterine
selectivity125.
1.3.2. Effects on endometrium
The discovery of the "endometrial antiproliferative effect" of PAs and SPRMs was
• • 1 93 1 3P
an important milestone in their development ' . It was first observed in rabbit and
primate endometrium. The finding of endometrial atrophy induced by some PAs was
unexpected for two reasons. None of the compounds were binding to ER and due to
their PR antagonist activity, the endometrium would have been expected to exhibit
unopposed oestrogenic effects. Instead, it demonstrated functional anti-oestrogenic
effects.
As this phenomenon was further investigated, the importance of primate models
became evident, as the endometrial morphology in rabbits exposed to PAs was
different to primates. In rabbits, PAs induced similar inhibition of endometrial gland
formation but stimulated endometrial stroma and myometrium131. In fact, the unique
endometrial effects of PAs and SPRMs are specific to menstruating primates such as
Old World monkeys and humans. Cynomolgus and rhesus macaques are particularly
suitable models, as their endometrium is of striking similarity to the human with
respect to hormonal regulation and morphological changes during the menstrual
cycle132'133.
Studies in non-human primates showed that PAs in both spayed and intact macaques
induced endometrial atrophy with stromal compaction and inhibited mitotic activity.
These effects were observed following administration of the PAs mifepristone (RU
486), ZK 230 211 and ZK 137 316. Studies with ZK 137 316 in the rhesus monkey
also showed a dose-dependent degradation of the spiral arteries in the basal layer of
the endometrium131. These profound morphological changes occurred irrespective of
ongoing ovulatory cycles and in the presence of follicular phase oestrogen levels.
The functional anti-oestrogenic effect was limited to the endometrium, whilst oviduct
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and vagina remained unaffected. These studies provided the first evidence of the
"endometrial antiproliferative effect" and suggested that PAs and SPRMs may be
targeting the endometrium directly and possibly via the endometrial vasculature123.
Some experiments also highlighted the importance of the dosages, as many effects
were dose-dependent, and in the studies with the PA onapristone, the endometrial
morphological findings at low and high doses were even divergent. Low doses of
onapristone induced a similar pattern with suppressed endometrial maturation and
gland formation, whilst treatment with high doses resulted in cystic endometrial
hyperplasia131.
During the drug discovery program to develop SPRMs with partial agonist activity, a
study was conducted comparing the endometrial effects of J1042 with the PAs ZK
230 211 and ZK 137 316 in cynomolgus monkeys134. All three compounds induced
the antiproliferative effect with decreased endometrial thickness, reduced mitotic
activity in glands and stroma and increased stromal density. However, there were
also interesting differences in the endometrial morphology following treatment with
J1042 compared to the PAs, and for the first time, an SPRM was demonstrated to
induce specific PR-mediated agonistic effects. The appearance of the glands was
normal with no evidence of degeneration as seen after exposure to PAs. Additionally,
the glandular epithelium showed signs of weak secretory activity such as glandular
sacculation with subnuclear vacuolization and secretion. Differences were also seen
in respect to the effects on the endometrial vasculature. Contrary to the PAs, J1042
did not cause hyalinizing degeneration of the spiral arteries but was more effective
with regards to inhibition of endometrial angiogenesis. The intraluminal diameters of
the spiral arteries were notably more reduced by J1042125'131'132. The "endometrial
antiproliferative effect" with atrophy and increased stromal compactness was
subsequently also demonstrated in studies with asoprisnil (J867) and J956 in
cynomolgus monkeys132. As with PAs, these morphological features were observed
in the presence of normal oestradiol levels and well-oestrogenized vaginal tissue
indicating the high degree of endometrial selectivity. Similar to J1042, spiral artery
degeneration did not occur with asoprisnil.
As crucial as these primate models have been for the classification and development
of SPRMs, not all data are necessarily applicable to the human. Important differences
between the responses of human and non-human primate endometrium to SPRMs
have been observed and attributed to possible variances in the steroid receptor
pharmacology. Most notably, formation of thick-walled endometrial spiral arteries
following exposure to asoprisnil has been described in the human only135. Secretory
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glandular changes in response to asoprisnil have also been demonstrated in the
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human but not in the cynomolgus monkey ' .
The endometrial changes following SPRM administration were consistent with
mixed PR agonist and antagonist activity but had never been previously described.
Some of the features had the potential to raise concern to the unfamiliar observer,
and hence a panel of expert gynaecological pathologists convened and classified the
specific effects of asoprisnil on endometrium. New diagnostic categories of "non-
physiologic secretory effect" and "secretory pattern, mixed type" were developed
and defined by weak glandular secretory effects, variable stromal effects mostly with
increased compaction and clusters of thick-walled arterial vessels, and the number of
mitotic figures132'136.
1.3.3. Effects on menstrual bleeding
Consistent with the morphological finding of endometrial atrophy, PAs and also
SPRMs including asoprisnil induce suppression of menstmal bleeding in non-human
primates and in humans125'131. In a Phase I double-blind dose-escalation study, the
effect of asoprisnil on 60 healthy premenopausal women was evaluated. They were
administered different doses of asoprisnil from 5mg once daily to 50mg twice daily
for 28 days commencing during the first four days of their regular menstrual cycle.
As a result, cycle lengths were increased, and the onset of menstruation was
significantly delayed with doses at or above lOmg once daily137. Suppression of
menstruation with asoprisnil has been found to be reversible and not associated with
125 131the adverse systemic side effects of oestrogen deprivation ' . The prolongation of
the menstrual cycle in this Phase I study occurred even in the presence of a normal
luteal phase and luteolysis indicating that the endometrium is directly targeted by
asoprisnil137. Contrary to the experiences with continuous progestin treatment, which
commonly results in unscheduled bleeding episodes particularly during the initial
months of treatment92, spotting or breakthrough bleeding was rarely reported with
asoprisnil.
1.3.4. Effects on other clinical conditions
Asoprisnil has been the first SPRM to reach an advanced stage of clinical
development for the treatment of benign gynaecological conditions such as
symptomatic uterine fibroids and endometriosis128'138'139.
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Phase II studies in women with uterine fibroids reaffirmed the observation that
asoprisnil induces reversible amenorrhoea. In a double-blind, placebo-controlled
study, doses of 5, 10 or 25mg of asoprisnil were administered orally to women with
uterine fibroids for 12 weeks. Duration and intensity of uterine bleeding were
significantly reduced in a dose-dependent manner, and no episodes of unscheduled
bleeding were reported. In addition to the suppression of both normal and heavy
menstrual bleeding, a reduction in the volume of the largest fibroid was demonstrated
resulting in a dose-dependent improvement of pressure symptoms such as bloating
and pelvic pressure138'139.
Phase II studies with asoprisnil have also been conducted in women with pelvic pain
due to endometriosis. The rationale for the use of asoprisnil in this condition was the
presumed positive effect of tissue-selective inhibition of endometrial proliferation
and suppression of endometrial bleeding by targeting the endometrial vasculature
directly on the symptoms of endometriosis128'139. The finding of tissue-specific
suppression of endometrial prostaglandin production in preclinical studies also
appeared promising regarding the potential of asoprisnil to ameliorate endometriosis-
associated pain122'140. In a randomised, placebo-controlled study, doses of 5, 10 or
25mg asoprisnil were administered for 12 weeks to women with a laparoscopic
diagnosis of endometriosis who suffered moderate or severe pain. Indeed, all three
doses significantly reduced non-menstrual pelvic pain and dysmenorrhoea compared
to placebo139.
Therefore, the potential of asoprisnil to become a novel compound for medical
management of heavy menstrual bleeding, symptomatic uterine fibroids and
endometriosis has been highlighted and emphasized by a favourable safety and
tolerability profile in all clinical studies to date.
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1.4. Aims
The data presented within this thesis are derived from a phase II multi-centre
randomised double-blind placebo-controlled study of asoprisnil administered for 12
weeks to women with symptomatic uterine fibroids scheduled for hysterectomy.
The aims of the study were to thoroughly investigate the effects of asoprisnil on:
1 a Clinical symptoms (i.e. menstrual blood loss)
b Uterine artery blood flow
c Ovarian function
d Clinical safety and tolerability
2 Endometrial histomorphology
3 Endometrial proliferation markers and PTEN expression
To elucidate the mechanism of action of asoprisnil, further laboratory investigations
were conducted to study the effects on:
4 Endometrial sex steroid receptor expression
5 Endometrial gene expression and local immune cell function
Ultimately, through enhanced understanding of its mechanism and added evidence of




GENERAL MATERIALS & METHODS
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2.1. The Clinical Study
2.1.1. Study design
A phase II multi-centre, randomized, double-blind, placebo-controlled study was
designed to investigate the effects of asoprisnil in women with symptomatic uterine
fibroids. The study design has previously been described in a publication141.
Selection of the asoprisnil doses was based on previous phase I and phase II studies.
These had shown asoprisnil to be safe and well-tolerated when used for 12 weeks at
doses of 5mg, lOmg and 25mg. Doses of lOmg and 25mg asoprisnil and the
treatment duration of 12 weeks were chosen, as they had been effective in
suppressing uterine bleeding and in reducing fibroid as well as uterine volumes over
a period of 3 months142. The study drug was administered to patients for 12 weeks.
2.1.2. Recruitment of patients
Recruitment of premenopausal women volunteers was carried out in four centres
(Edinburgh, Southampton, Glasgow, Liverpool). The women targeted for this study
had to be in good general health. They had presented for a consultation with a
specialist gynaecologist due to fibroid-related symptoms such as heavy menstrual
bleeding (HMB) and / or pelvic pressure. They were approached for recruitment into
this study after a decision for surgical intervention for their symptomatic uterine
fibroids had been taken and they were scheduled for hysterectomy.
Each patient had at least one intramural non-pedunculated, submucosal or subserous
fibroid with a diameter of > 2cm or multiple small fibroids with a uterine volume of
> 200cm3 confirmed by transvaginal or abdominal ultrasonography. Menstrual cycles
had to be regular but the cycle length could vary between 17 and 42 days in different
individuals. Other inclusion criteria included age over 18 years, negative pregnancy
test, a washout period of 2-12 months for hormonal therapies (Table 2.1.), serum
FSH <30mIU/ml at commencement of the study, a normal cervical smear test and
agreement to use double barrier method of contraception (condom / diaphragm /
sponge plus spermicide) throughout the study until hysterectomy unless surgically
sterile by bilateral tubal ligation or vasectomy of the partner. There was an absolute
requirement for patients to have had a normal endometrial biopsy report based on an
adequate specimen within three months of entering the study. Additional pelvic
pathology such as follicular-type or hemorrhagic ovarian cysts >3.5 cm in diameter,




Therapy (Prior to Dosing)
Medroxyprogesterone acetate (Depo-Provera) 12 months
GnRH analogue - 3 month depot [leuprorelin 9 months
acetate (Lupron), goserelin acetate (Zoladex)]
GnRH analogue - 1 month depot 6 months
Danazol (Danocrine, Cyclomen) 6 months
Nafarelin acetate (Synarel) 6 months
Contraceptive injection (Lunelle Monthly) 4 months
Norethindrone acetate (Aygestin, Norlutate) 2 months
Norethindrone 2 months
Oral contraceptives 2 months
Medroxyprogesterone acetate (Provera) 2 months
Other progestins 2 months
Oestrogen preparations 2 months
Progesterone preparations 2 months
Progesterone- or Levonorgestrel-releasing IUS 2 months
(Mirena®)
Table 2.1. Minimum washout period after hormonal therapy
Minimum period patients were required to have discontinued
hormonal therapy prior to randomization into this study; after
stopping their therapy, they also had to have had two normal periods
before commencing the study medication
GnRH=gonadotrophin-releasing hormone; IUS=intrauterine system
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All patients voluntarily signed a full Informed Consent Form (Appendix I). The
study was performed according to the ethical principles of the Declaration of
Helsinki (1989 revision) and the protocol approved by the Institutional Review
Board (Multicentre Research Ethics Committee) (Appendix II).
2.1.3. Study procedures
As part of the study protocol, patients attended 5-7 study visits, as detailed in table
2.2. In the event of any concerns or adverse reactions, additional visits were arranged
as required. At the first visit, screening data were collected in clinic mostly by
gynaecologists but occasionally by study nurses. Screening procedures (performed
within 45 days prior to study commencement) included pelvic and breast
examination, complete physical examination, cervical smear test by liquid based
cytology, ECG, transvaginal ultrasound (TVU), pipelle endometrial biopsy,
contraception counselling and clinical laboratory investigations - haematology,
biochemistry, endocrine panel, lipid profile, coagulation screen, urinalysis and serum
and urine pregnancy tests. Patients were supplied with menstrual diaries and sanitary
products as well as containers for the twice weekly collection of the first voided
urine in the morning (Table 2.2.).
After successful enrolment based on inclusion and exclusion criteria, patients were
re-assessed at the beginning of their next menses and treatment initiated no later than
the fifth day of the menstrual cycle. Ideally, study procedures were carried out the
day before and certainly within 7 days of commencing the study drug. Colour
Doppler imaging of the uterine artery blood flow was performed during days 20-23
of the preceding menstrual cycle and therefore required an additional study visit for
some patients. All patients were contacted by telephone after 4 weeks of treatment to
enquire about any adverse events and to remind them about the requirements to use
contraception and to continue their twice weekly urine collection. Patients attended
for a visit after 8 weeks for review and for a thorough assessment after 12 weeks, just
prior to or on the day of their hysterectomy (Table 2.2.). The hysterectomy was
performed within 24 hours of the final dose of study drug. The study drug was
supplied at the beginning of treatment with a further supply at week 8. On the
occasions of the week 8 and week 12 visits, used and unused study medication blister
cards were returned for verification of medication compliance. Six weeks after




A randomized double-blind design was applied to this study in order to minimize
selection and subject bias. On the day prior to commencing treatment, patients
received sequential subject numbers in ascending numerical order encoding the
assignment to one of three treatment arms according to a randomization schedule
generated prior to the study by the statistics department at TAP Pharmaceuticals Inc.
The sealed box kits containing identical blister cards of study medication with 32
tablets were stored and dispensed by the pharmacies at the various study sites.
Patients in three parallel dose groups in a 1:1:1 ratio self-administered daily doses of
asoprisnil lOmg, 25mg or placebo orally. Patients and all study personnel including
investigator, clinical research coordinator, monitors and pathologists were blinded to
treatment groups throughout the study.
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Table 2.2. Summary of study procedures
Participation in the study included between 5 and 7 study
visits as detailed in this table:
Screening visit - within 45 days of commencing the
study drug
Day-1 - Day prior to commencing the study dmg
within the first 5 days of the menstrual cycle
Week 4 - Follow up by phone call on day 28
Week 8
Weekl2 - May be combined with hysterectomy visit
OP - Day of the operation - Hysterectomy visit
FU - Follow-up visit 6 weeks post-operatively
1 Clinical safety labs were to be obtained after fasting for
at least 10 hours; they included blood samples for
haematology, biochemistry, coagulation assays, lipid
panel and endocrine panel; at week 8, they also included
measurements of testosterone levels
2 Measurements of endometrial thickness, fibroid and
uterine volumes
3 Colour Doppler imaging prior to commencing the study
drug was done during days 20-23 of the preceding
menstrual cycle; it therefore required a separate study
visit for some patients
4 Collection of first voided urine of the day twice a week;
samples were frozen by patients and then brought in at
the next scheduled study visit
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After removal of the uterus in the operating theatre, the unfixed specimen was placed
on ice and taken without delay to the local pathology laboratory. The specimen was
oriented and a probe inserted through the external os of the cervix to define the
position of the cavity. The uterus was opened using a long-bladed knife along the
plane of the probe. The opened specimen was then placed in an adequate volume of
4% neutral buffered formalin (NBF) and allowed to fix overnight. For large
specimens, parallel parasagittal slices 2cm in thickness were made to permit
adequate fixation. The following day, the specimen was sampled for routine
diagnostic reporting and additional blocks taken for study assessment. Study blocks
included full thickness endometrium with underlying myometrium. All study
samples were routinely wax-embedded using the Tissue-tek embedding station and
5pm sections prepared. Endometrial assessment was carried out by microscopic
examination of haematoxylin-eosin stained sections. Phase of cycle was assessed
using the updated conventional descriptive Noyes criteria of the normal menstrual
cycle as described in Blaustein's Pathology of the Female Genital Tract143.
Additional samples from the endometrium were placed in RNA stabilization
solution, stored overnight at 4°C and then transferred to a cryotube to be frozen at
-70°C for subsequent RNA extraction.
2.2.2. Immunohistochemistry
All antibodies were tested individually at a range of dilutions and different antigen
retrieval conditions to define the protocol resulting in the least background with the
highest specific staining. With every immunohistochemical staining procedure,
negative controls were included replacing the primary antibody with a non-immune
immunoglobulin G (IgG) of a matched antibody concentration and from the same
species as the primary antibody. In some cases, the primary antibody was replaced
with antibody diluent only. Positive controls of samples with a known expression of
the protein of interest were also included with every staining procedure. Whenever
possible, sections for direct comparison were stained in the same
immunohistochemical run.
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Table 2.3. Primary antibodies used for automated immunohistochemical
staining in the Bond-X Immunohistochemistry Staining System
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2.2.2.1. Antigen retrieval
Antigen retrieval was required to break cross links formed during the fixation
process and to allow the antibodies access to previously masked epitopes on the
proteins of interest. 5 pm paraffin embedded tissue sections were de-waxed in
Histoclear for 10 minutes before rehydration in descending grades of alcohol to
distilled water (dH^O). The slides were washed with 0.01M phosphate buffered
saline (PBS) and pressure-cooked in 0.01M sodium citrate (pH 6) for 5 minutes at
setting 2/high for antigen retrieval. The tissue sections were then cooled for 20
minutes.
2.2.2.2. Immunostaining
Most of the immunostaining in this study was carried out using the Bond-X
Immunohistochemistry Staining System. Once cooled down following the antigen
retrieval, the tissue sections were transferred in dFEO for automated staining. The
Bond-X Staining System was loaded with the Bond detection system reagents (Bond
Peroxidase Detection System with Counterstain) and the primary antibodies. For
negative controls, the primary antibody was replaced with non-immune mouse IgG
(MIgG or MIgGI) at a matched concentration or by antibody diluent (Table 2.3.).
The automated staining process was then commenced according to the DEFINE
protocol (3 hour Polymer Protocol, ID 10003, created by VISION-5T27WlUO\Bond
Service - Appendix V). For immunostaining of PTEN and CD56, the 3 hour polymer
REFINE protocol was used (ID 10004, created by BondPowerUser - Appendix VI).
Following completion of staining, the sections were dehydrated in ascending grades
of alcohol to xylene and finally mounted with pertex.
The remaining immunohistochemical staining (Ki-67 / PH3) was performed on the
bench according to the protocols described within section 5.2.1.
2.2.2.3. Scoring and analysis of immunoreactivity
To assess intensity and frequency of immunostaining in endometrium, a histoscore144
was applied to each tissue compartment of surface epithelium, glandular epithelium,
stroma, endothelium and perivascular cells. For each tissue compartment, the
staining intensity was categorized into 0=no immunostaining, l=mild
immunostaining, 2=moderate immunostaining and 3=strong immunostaining. This
score was then multiplied by the percentage of cells showing this particular intensity
of immunostaining in graduations of 10 (10%, 20% etc. up to 100%) giving an
overall score between 0 and 300. Initially, two independent observers blinded to the
treatment groups carried out the scoring. If their score varied by more than 50, the
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section was double-scored jointly by both observers with a double-headed
microscope until a final score was agreed on. Otherwise an average was taken of the
two initial scores.
Due to the very scanty staining pattern, a histoscore was not considered to be
appropriate for assessment of proliferation markers Ki-67 and PH3. Different
methods were applied for scoring as described within section 5.2.2.
2.2.3. RNA extraction and Quantitative reverse transcription polymerase chain
reaction (Q-RT-PCR)
2.2.3.1. RNA extraction
RNA was extracted using Trizol reagent according to manufacturers instructions as
detailed below.
Endometrial samples were immersed in 1ml Trizol RNA isolation reagent and then
homogenized with a hand held homogeniser. Following further incubation in Trizol
for five minutes at room temperature, the samples were transferred to phase lock gel
tubes (PLG tubes). 200pl of chloroform was added and mixed in for 15 seconds
before incubating for three minutes at room temperature. 15 minutes in the centrifuge
at 12,000 x g and 4°C allowed separation of the RNA containing aqueous phase.
PLG tubes contain a gel, which forms a solid barrier between the aqueous RNA
containing layer and the remaining solution. It was therefore possible to pour the
upper aqueous layer into a fresh eppendorf tube without DNA or protein
contamination. 500pl isopropanol was then added to this aqueous layer for
precipitation of the RNA. The samples were briefly vortexed, incubated at room
temperature for 10 minutes and then centrifuged at 12,000 x g for 10 minutes at 4°C.
The supernatant was carefully removed and the pellet washed in 1.5ml 75% ethanol.
After a further spin at 7500 x g for 10 minutes at 4°C, the ethanol was removed and
the remaining pellet allowed to dry for 5-10 minutes before suspending in an RNA
storage solution. Some endometrial RNA was subsequently put through Qiagen
RNeasy mini kit columns for further purification. RNA samples were stored at -70°C
until further use.
2.2.3.2. DNAse treatment and Quality assessment of RNA
Following extraction, RNA was subjected to deoxyribonuclease (DNAse) treatment
using 1U DNAse 1 (amp grade) / pg RNA in DNAse reaction buffer for 15 min at
room temperature to remove genomic DNA contamination. DNA can otherwise lead
to false positive results during taq-man real time RT-PCR. The reaction was stopped
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by adding a final concentration of 2.5mM EDTA followed by heating to 99°C for 5
minutes, giving a final RNA concentration of 100ng/(iil.
The quality of each individual RNA sample was checked with the Agilent RNA 6000
Nano Kit. Only samples of good quality were used for further analysis.
2.2.3.3. Reverse transcription
200ng of DNAse treated RNA was reverse transcribed in a buffered solution
containing 5.5mM MgCl2, 2.5pM random hexamers, 500pM of each deoxy-NTP, 0.4
U/pl ribonuclease inhibitor and 1.25 U/pl multiscribe reverse transcriptase. Samples
were incubated for 60 min at 25°C, 45 min at 48°C and 5 min at 95°C. Negative
controls were included in every run. An RT-negative control had template RNA but
no multiscribe enzyme included, and an H20 RT had nuclease-free water replacing
the template RNA.
2.2.3.4. Taq-man real-time Q-RT-PCR
The method of taq-man real-time Q-RT-PCR detects and quantifies the emission of
fluorescence from a reporter dye, which is produced during the amplification of
target sequences from samples in real time. The technique uses forward and reverse
primers to the sequence of interest along with a probe, which will specifically anneal
between these two primers. Taq-man probes are labelled with two fluorescent dyes:
at the 5' end with a reporter dye (all amplicons except 18S use FAM; 6-
carboxyfluorescein) and at the 3' end with a quencher dye (TAMRA; 6-
carboxytetramethylrhodamine). Prior to the start of the reaction, the quencher dye
suppresses the fluorescence of the reporter dye as it is in close proximity. This
process is known as FRET (Fluorescence Resonance Energy Transfer). When the
target sequence is amplified during the PCR reaction, the polymerase enzyme
AmpliTaq Gold DNA Polymerase first displaces the probe. Subsequently, due to the
5' fork-like structure dependent nuclease activity of AmpliTaq Gold DNA
Polymerase, the probe is cleaved between the reporter and the quencher.
Polymerisation of the strand continues as the probe fragments are displaced from the
target. The quencher dye is separated from the reporter and can no longer suppress its
fluorescence resulting in increased emission. It is the increased fluorescence, which
is measured during each PCR cycle and which is directly proportional to the amount
of target sequence amplified. The increasing fluorescence is plotted against the PCR
cycle number (Figure 2.1.). Fluorescence is only detected if the target sequence of
the probe is amplified during the reaction, and therefore detection of non-specific
amplification is prevented.
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Figure 2.1. Real-time Q-RT-PCR
Stage 1 Polymerization of primers and probes to the sequence of
interest on template complementary DNA (cDNA); probe is
intact and fluorescence is low as quencher dye (TAMRA)
suppresses fluorescence of reporter dye (FAM)
Stage 2 Extension from the primer displaces the Taq-man probe from
the cDNA
Stage 3 The displaced probe is cleaved by the nuclease activity of
AmpliTaq Gold DNA Polymerase; reporter and quencher dye
are separated, fluorescence increases and allows
measurement of the PCR product generated
Stage 4 Polymerisation is complete
Adapted from Taq-man PCR reagent kit protocol
56
































































Table 2.4.A. Primer and probe sequences for amplification
by Taq-man real-time Q-RT-PCR
Positions of the sequences within the cDNA are identified by the




































Table 2.4.B. Primer and probe sequences for amplification
by Taq-man real-time Q-RT-PCR
Positions of the sequences within the cDNA are identified by the
accession number; r denotes reverse strand; * there are 3 transcripts of
the CD56 gene, which would all be detected by the primers
60
It is possible to measure both ribosomal 18S and specific amplicon levels in the same
PCR well in order to normalise the Taq-man reaction for differences in the initial
cDNA loading. The expression of ribosomal 18S remains constant in proportion to
the amount of cDNA. The different reporter dyes (FAM on amplicon and VIC
(chemical name unavailable) on 18S probe) emit fluorescence at different
wavelengths. The changes in the level of target sequence are therefore determined by
comparing the levels of FAM to VIC fluorescence for each sample.
Taq-man real time Q-RT-PCR was used to measure levels of ERa, PR, AR, GR,
ERp, CD56 and IL-15 in endometrium. The reaction mix contained final
concentrations of Taq-man universal PCR master mix (IX), ribosomal 18S forward
and reverse primers and probe (50nM) as well as forward and reverse primers
(300nM) and probe for the sequence of interest (200nM). The sequences of the
previously validated primer/probe sets and their location within the specified cDNAs
are listed in Tables 2.4.A&B. lpl of cDNA was added per 25pi reaction volume, and
each sample was tested in duplicate. A control with water replacing cDNA was
included in every run as well as the controls from the RT step. Plates were sealed
with adhesive covers and the PCR reaction run on the ABI Prism 7900 using
standard settings.
2.3. Analysis of data
Statistical analyses were performed using the SAS® System 8.2. All statistical tests
were two-sided. For each variable, the Hochberg multiple comparison procedure was
used, and the familywise type I error rate was controlled at the level of 0.05. A
subject's data were included in the analysis of immunohistochemistry or Q-RT-PCR
provided there was an evaluable result.
2.3.1. Classification of Placebo Subjects
For analysis of clinical outcomes as detailed in chapter 3, all patients randomized
into the placebo group were included. In the final analysis of immunohistochemistry
and Q-RT-PCR data, patients treated with placebo were only considered for
comparison if they had undergone hysterectomy in the secretory phase of their
menstrual cycle. Samples from the proliferative phase were excluded so that the
physiological variation of variables between different cycle phases would not
influence the results. Patients in the secretory phase were chosen, as the endometrial
effects of the PRM asoprisnil were expected to be most evident in comparison to
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endometrium exposed to P. Patients with an average cycle length were most likely to
be in the secretory phase at the time of hysterectomy after 12 weeks of treatment.
Classification into proliferative or secretory phase was done according to
morphological assessments of endometrial samples form the uterine fundus, mid-
corpus and isthmus. Three categories (l=normal quiescent, 2=normal secretory or
non-physiologic secretory, 3=normal proliferative or nonphysiologic proliferative)
were applied. If all samples from a patient, which were satisfactory for diagnosis,
were categorized as 2 or a mixture of 1 and 2, the patient was classified as secretory.
Likewise, if all samples suitable for analysis were categorized as 3 or a mixture of 1
and 3, the patient was classified as proliferative. Samples from patients not meeting
these criteria would be excluded from further analysis.
2.3.2. Immunohistochemistry
For statistical analysis of immunohistochemical protein expression, descriptive
statistics (mean, standard deviation, median, minimum and maximum) were provided
for each treatment group. Each group of asoprisnil treated patients (10 and 25mg)
was then compared to the subgroup of placebo / secretory subjects. For comparison
of each variable, the Wilcoxon's rank sum test was performed and significance
determined at 0.05 level using Hochberg's multiple comparison procedure.
2.3.3. Taq-man real-time Q-RT-PCR
The data from the taq-man real-time Q-RT-PCR were analysed by calculating the
threshold cycle (CT) for each sample. The threshold cycle (range 0-40) during the
PCR amplification is reached, when the accumulation of PCR product shows
exponential growth and the PCR signal crosses a defined threshold. A low CT value
indicates a high initial amount of the sequence of interest, as the product accumulates
earlier during the PCR reaction. ACT is calculated as the difference between CT
values for the specific amplicon and 18S, in order to normalize for the initial cDNA
load. The ACT value is then related to an endogenous control reference resulting in a
AACT value for each sample. The AACT values were summarized and each
asoprisnil group compared to the placebo / secretory subjects using Wilcoxon's rank
sum test with statistical significance determined at 0.05 level using Hochberg's
multiple comparison procedure. The amount of target normalized to the reference





UTERINE ARTERY BLOOD FLOW AND OVARIAN ACTIVITY
63
The data presented in this chapter have previously been peer-reviewed and published
in the manuscript:
Wilkens J, Chwalisz K, Han C, Walker J, Cameron IT, Ingamells S, Lawrence AC,
Lumsden MA, Hapangama D, Williams AR, Critchley HO
Effects of the selective progesterone receptor modulator asoprisnil on uterine artery
blood flow, ovarian activity and clinical symptoms in patients with uterine
leiomyomata scheduled for hysterectomy
Journal of Clinical Endocrinology & Metabolism 2008; 93(12): 4664-71
The author's personal involvement in this part of the study was the recruitment and
clinical care of the patients in the centre with the most cases (Edinburgh). This
involved the performance of the screening procedures and all clinical examinations
throughout the study period, the coordination of all clinical visits, study
investigations and sample collections and the maintenance of the case report forms.
3.1. Introduction
Heavy menstrual bleeding (HMB) is a common complaint, which frequently prompts
women to seek medical advice. It may be a debilitating symptom and in some cases
even indicates major abdominal surgery in the absence of any pathology. In the
United States, HMB is the most common indication for 600,000 hysterectomies
performed annually145. HMB is defined as blood loss of more than 80ml per
month146. Not only is it rather impractical to accurately determine the amount of
bleeding but more importantly, the subjective complaint correlates poorly with the
actual blood loss147. For many reasons, the number of women seeking help for heavy
bleeding seems to have risen. There is therefore a demand for improved and practical
management options, particularly as many women with this complaint may be keen
to preserve their fertility. The mechanisms of HMB are still not fully understood, and
hence there remains an ongoing need to search for effective and acceptable
therapies3.
Uterine fibroids are an entity of benign gynaecological disease, which are known to
affect menstrual bleeding pattern with a tendency to increase blood loss. Fibroids are
benign smooth muscle tumours originating from the myometrium and clinically
affect approximately 20-25% of all women of reproductive age148'149. The true
incidence may be over 70%150. Whilst uterine fibroids may be entirely asymptomatic,
HMB is one symptom commonly associated with the presence of fibroids.
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Depending on their size and location within the uterus, fibroids may also cause
pressure-related symptoms. For effective treatment strategies, it would therefore be
desirable if there were an improvement of both bleeding pattern and symptoms due
to fibroid size. Currently, medical management options are limited and their use
restricted by side effects. As a result, uterine fibroids are with approximately 30% the
second most frequent indication for hysterectomy in the United Kingdom151'152.
The idea that fibroid-related symptoms may be managed by impairing uterine artery
blood flow is the underlying principle of uterine artery embolization (UAE). With
UAE, uterine arteries are occluded with Polyvinyl alcohol particles leading to
ischaemic necrosis of fibroids whilst normal myometrial tissue is preserved via
collateral blood vessels153. Fibroid tissue is rarely revascularized, and therefore the
tumour mass shrinks with consequent resolution of symptoms. UAE has been shown
to significantly reduce the amount of menstrual blood loss and also the severity of
pelvic pressure and discomfort154. The outcome of UAE versus surgery in patients
with symptomatic uterine fibroids has been evaluated to compare favourably152.
Other less invasive methods of temporarily occluding uterine blood flow with the
aim to manage the symptoms associated with fibroids have also been explored155.
Whilst these techniques reduce uterine artery blood flow mechanically, it has been
demonstrated that this can also be achieved pharmacologically. A decrease in uterine
artery blood flow has been shown in women with a fibroid uterus with both the
GnRH analogue leuprolide acetate and the progesterone receptor antagonist
mifepristone and stipulated as a potential mechanism of action for the observed
tumour shrinkage156.
In the case of mifepristone, a reduction in fibroid volume may also be due to a direct
antiprogestogenic effect. Evidence has been mounting to highlight a key role of
progesterone (P) and the progesterone receptor (PR) in the development of uterine
fibroids. Whilst traditionally, oestrogen has been regarded as the main hormone
responsible for fibroid growth, more recent data from clinical and in vitro studies
indicate that P also plays a pivotal role84'85. Up-regulation of both PR isoforms (PR-
A and PR-B) has been shown in fibroid tissue compared to adjacent
myometrium157'158. In addition, increased mitotic activity in fibroids was
demonstrated during the luteal phase159, and P increased the expression of the
proliferation marker Ki-67 within fibroid tissue160. Synthetic progestins have been
shown to reverse the effects of GnRH analogues on the size of uterine fibroids. This
indicates that the clinical effects of GnRH analogues in women with a fibroid uterus
may be due to the cessation of P secretion161. Fibroid volumes have also been
demonstrated to decrease in small, uncontrolled, clinical studies with the
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administration of mifepristone162. Collectively, these data suggest a stimulatory
effect of P on the development of fibroids with the implication that PR antagonism
may directly result in inhibition of fibroid growth.
The clinical effects of the selective progesterone receptor modulator (SPRM)
asoprisnil (J867) with its partial and mixed PR agonist and antagonist properties have
previously been evaluated in women with uterine fibroids. Doses of 5, 10 or 25mg
were administered for three months to 129 patients with uterine fibroids in a
multicentre, prospective randomized, double-blind, placebo-controlled, parallel-
group study. The results demonstrated that asoprisnil suppressed uterine bleeding in
28%, 64%, 83% of subjects at 5, 10 and 25 mg, respectively, and reduced fibroid and
uterine volumes142. The mechanism of action of these effects on symptoms and on
fibroid size has not been elucidated.
There are many advantages of medical management of HMB and other fibroid-
related symptoms over surgical intervention3. Even though endometrial resection and
UAE carry a lower risk of morbidity than hysterectomy152'163 and preserve the uterus,
potential adverse effects on fertility and future pregnancies164 still make them
unsuitable options for women who have not completed their families. Successful
pregnancies have been reported following UAE, but experience is still limited and
the exact effect on placental function unknown165. Medical therapy is therefore the
preferable option if further pregnancies are planned. It is also less expensive and less
invasive. The main factors currently limiting its success are lack of evidence-based
practice, poor compliance and unpleasant side effects166.
The main classes of hormonal compounds used in drug therapy are progestogens and
GnRH analogues. In both cases, compliance is limited by side effects. Even though
systemic progestogenic side effects are minimal with the localized application of
levonorgestrel via the intrauterine system (IUS), the issue of unscheduled
breakthrough bleeding remains and is the main reason for discontinuation of
Q "5 #
treatment . GnRH analogues exert their effects via suppression of ovarian hormones
and are therefore associated with symptoms of hypo-oestrogenism. This limits their
applicability and even during the six months they may be administered unopposed,
hypo-oestrogenic side effects may become intolerable. Asoprisnil on the other hand,
has been demonstrated to suppress menstrual bleeding profoundly with minimal
breakthrough bleeding137. In the studies to date, the clinical and endometrial effects
of asoprisnil have been observed in the presence of follicular phase oestrogen
142
concentrations .
In this study, the clinical effects of asoprisnil in women with symptomatic uterine
fibroids scheduled for hysterectomy were evaluated. The specific aims were:
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1. To assess the effects on clinical symptoms associated with uterine
fibroids such as menstrual blood loss, pelvic pain and discomfort and also
fibroid-related quality of life
2. To perform ultrasonographic Doppler measurements of impedance
(resistance and pulsatility indices) before and after treatment and assess
the effects of asoprisnil on uterine artery blood flow as a possible
mechanism of action
3. To determine ovarian activity during treatment by measuring the renally
excreted metabolites of ovarian hormones
4. To depict the safety and tolerability profile of asoprisnil when
administered for 12 weeks at doses of 10 and 25 mg
3.2. Materials & Methods
3.2.1. Study patients
Patients were recruited and enrolled as described in section 2.1. All patients were
scheduled for hysterectomy due to symptomatic uterine fibroids and required to
comply with all inclusion and exclusion criteria as cited in section 2.1.2. Once they
had successfully undergone all screening procedures, they were randomised and
administered the study drug for 12 weeks commencing within the first five days of a
menstrual period.
3.2.2. Record of uterine bleeding
All patients were issued a daily diary and a menstrual pictogram (MP) at the
screening visit, which they kept throughout the study period until hysterectomy. The
diary was to record whether any uterine bleeding occurred including spotting. The
use of any tranexamic acid or non-steroidal anti-inflammatory drugs (NSAID) was
also noted. Whenever the amount of bleeding exceeded spotting and required more
than a panty shield for protection, the MP was used to document and quantify the
blood loss. Consistency of the record of uterine bleeding was enhanced by supplying
patients with standardized sanitary products167. The MP reflected the type and
number of sanitary products used (Tampax Regular, Super, and Super Plus, Kotex
Maxi-Super and Maxi-Nighttime napkins) as well as the amount of blood soaked up
by the products estimated by comparison of its appearance with the supplied
pictogram (Figures 3.1 and 3.2.).
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Figure 3.1. Menstrual Pictogram (MP)
The MP supplies visual analogues of the appearance of standardized
sanitary products (Tampax Regular, Super, and Super Plus, Kotex
Maxi-Super and Maxi-Nighttime napkins) after use and the equivalent
estimated blood loss;
patients recorded daily the number of sanitary products in each
category enabling a calculation of estimated blood loss in millilitres
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Figure 3.2. Example of daily diary with Menstrual Pictogram scores
Each day during the study, patients noted the absence or
presence of bleeding requiring more protection than a panty
shield; standardized sanitary products were used for
protection and inspected after usage; they were compared to
the visual analogues on the Menstrual Pictogram and the
number of products in each category was noted each day; a
total amount of blood loss was subsequently calculated for
each day accordingly;
this example reflects a patient's diary from day -32 to day -4
during the screening period prior to commencing the study
drug; it represents a menstrual blood loss of 42, 149, 86, 29
and 8 millilitres on days -32 to -28, respectively and 48
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At each study visit, new diaries and sanitary products were dispensed and the
previous diaries reviewed and collected by site personnel.
As described previously, the MP scores represent blood loss in milliliters167. For each
patient, the MP scores were summed for the last full menstrual cycle before the
randomization menses normalized to 28 days and for each 28-day treatment period.
A total score was therefore calculated for baseline, weeks 1-4, weeks 5-8 and weeks
9-12. To evaluate the improvement in uterine bleeding, changes of MP scores from
baseline to each month and from baseline to the final month was calculated and
summarized. The number of days with bleeding requiring more protection than a
panty shield were summarized according to the record in the diary for the pre-
treatment cycle as well as for the three 28-day treatment periods as above. Changes
from baseline to each month were calculated and summarized. The percentage of
patients experiencing amenorrhoea throughout the study was calculated for each
treatment group. Amenorrhoea was defined as having no days with bleeding or at
least 42 days without bleeding requiring protection greater than a panty shield from
the end of the pre-treatment menses through the end of dosing.
3.2.3. Assessment of fibroid-related symptoms
Fibroid-related symptoms except uterine bleeding over the month preceding
treatment were assessed prior to dosing and after 8 and 12 weeks, respectively. They
were recorded in the Leiomyoma Symptom Assessment Questionnaire (LSAQ) with
four-point symptom scales (0=none or not applicable, l=mild, 2=moderate,
3=severe) for bloating, pelvic pressure, dysmenorrhoea, urinary frequency and
urinary incontinence. Nocturia was assessed as present or absent (Table 3.1.)168. For
each of these symptoms, responses were summarized by 2-way contingency tables
for each treatment group. For analysis, the number and percentage of patients in each
treatment group with a decrease of at least 1 point was calculated for each symptom.
Prior to commencing the study drug and prior to hysterectomy, patients also
completed the Uterine Fibroid Symptom and Health-Related Quality-of-Life
questionnaire (UFS-QOL) with its subscales of concern, effect on activities,
energy/mood, control, self-consciousness, sexual function and symptom severity169.
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Table 3.1. Leiomyoma Symptom Assessment Questionnaire
This Leiomyoma Symptom Assessment Questionnaire
(LSAQ) was used to assess fibroid-related symptoms during









None Symptom not present.
Mild Can be ignored.
Moderate Cannot be ignored but does not interfere with daily
activities and/or medication or other treatment for bloating
used occasionally.
Severe Cannot be ignored and affects concentration on daily









None Symptom not present.
Mild Can be ignored.
Moderate Cannot be ignored but does not interfere with daily
activities and/or medication or other treatment for pelvic
pressure used occasionally.
Severe Cannot be ignored and affects concentration on daily




NA Not applicable; no menses since last visit.
None No pain during menses.
Mild Some loss of work efficiency.
Moderate In bed part of day, occasional loss of work.
Severe In bed 1 or more days.
URINARY
INCONTINENCE
- leakage of urine
None Symptom not present.
Mild Can be ignored. Does not require protection.
Moderate Cannot be ignored but does not interfere with daily
activities. Requires protection intermittently.
Severe Cannot be ignored and affects concentration on daily
activities. Requires frequent protection for leakage.
URINARY None Need to empty bladder <6 times during waking hours.
FREOUENCY
- feeling that you need
to urinate frequently
Mild Need to empty bladder 6-8 times during waking hours.
Moderate Need to empty bladder 9-10 times during waking hours.
Severe Need to empty bladder >10 times during waking hours.
NOCTURIA
- feeling that you
need to urinate
during night hours
Absent Need to empty bladder <1 time during the night.
Present Need to empty bladder >2 times during the night.
3.2.4. Sonographic assessment
Transvaginal ultrasound (TVU) (and abdominal ultrasound (TAS), if necessary) to
assess the size of the uterus and of fibroids was performed at screening (within 45
days of study commencement) and prior to the start of dosing (during days 20-23 of
the menstrual cycle prior to dosing). The volumes of the largest fibroid and the uterus
were measured based on an estimation of the volume of an ellipsoid (V=ttLDW/6
cm3) where L, W, and D represent length, width and depth. A second TVU / TAS
was performed after 12 weeks and the same measurements obtained to record any
changes from baseline. The position of the fibroids within the uterus was not
specifically recorded further to previous evidence that fibroid location does not
necessarily correlate with the amount of uterine bleeding170.
Colour Doppler imaging to determine blood flow of the main uterine arteries was
carried out prior to the first study drug dose and after 12 weeks. Blood flow was
estimated using two impedance indices: the resistance index (RI = systolic - end-
diastolic peak velocity / systolic peak velocity) and the pulsatility index (PI =
systolic - end-diastolic peak velocity / time-averaged maximum velocity)171. For
each impedance index, two measurements were taken from both left and right
arteries, respectively. The mean of the two measurements was calculated for each
side, and for further analysis the mean of both sides was used172. In order to
minimize variability, ultrasonographers were experienced in gynaecological
procedures, and at each site all scans were performed by the same ultrasonographer
throughout the study. All sites used the same colour Doppler imaging methods.
3.2.5. Ovarian activity
Patients were asked to collect a sample of the first voided urine of the day twice
weekly throughout screening and treatment periods. These samples were kept in the
freezer at -20°C for subsequent analysis. Urinary levels of the metabolites
pregnandiol glucuronide (PdG) and oestrone glucuronide (EiG) were measured using
enzyme-linked immunoabsorbent assays (ELISA). Hormone concentrations were
corrected for creatinine excretion and expressed as ratios of the creatinine
17T •
concentration to urine volume (Figure 3.3.). The results were used to determine
ovarian follicular and luteal activity during the cycle prior to dosing and under the
influence of study drug. Additionally, serum oestradiol and progesterone levels were
also measured on the day of hysterectomy.
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Figure 3.3. Examples of urinary ovarian hormone assays
A Example of a placebo treated patient's urinary
creatinine oestrone glucuronide (E]G) levels in mcmol/mol
from study day -28 (screening period) to study day 90
B Example of a placebo treated patient's urinary
creatinine corrected pregnandiol glucuronide (PdG) levels in
mmol/mol from study day -28 (screening period) to 90
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Creatinine Corrected Oestrone Glucuronide (E:G)
Study day
Creatinine Corrected Pregnandiol Glucuronide (PdG)
Study day
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In order to evaluate the ovarian follicular activity during the 12-week treatment
period, EiG concentrations were compared to the pre-treatment follicular phase
concentrations for each patient. The baseline ovarian function was the mean of the
samples collected during the follicular phase of the pre-treatment cycle (i.e. the first
14 days of the screening menstrual cycle). To classify the follicular activity during
treatment, the method previously described by Brown et al174 was applied as follows:
1. Totally suppressed - E]G <50% above baseline throughout treatment period
2. Partially suppressed - EiG concentration >50% above baseline on at least one
occasion but not meeting the definition of continued follicular activity
3. Continued - E]G >50% above baseline on at least 2 occasions, separated by at
least 13 calendar days during which there were no EiG concentrations >50%
above baseline
Number and percentage of patients belonging to each category as well as plots of
EiG concentrations during treatment over time for each patient, expressed as
percentages of baseline level, were presented for each treatment group.
Urinary PdG levels were used to define evidence of luteal activity (ELA) versus no
evidence of luteal activity (NELA). For each patient, each 4-week period during
treatment (weekl-4, week 5-8, week 9-12) was classified as having ELA or NELA
175with the aid of two different algorithms :
Algorithm 1: A PdG concentration was considered ELA if it was at least 3 times as
high as the minimum 3-concentration moving average of the PdG levels over the past
four weeks. The first concentration to be classified as ELA or NELA was from the
earliest sample obtained on or after Day 11, if it was at least the fourth available
sample since Day 1 (inclusive). For each 28-day period during treatment, a subject
was determined as having NELA, if no concentration was considered ELA during
that period.
Algorithm 2: In addition to the requirements for the definition of ELA in algorithm
1, a PdG level at least 3 times as high as the 3-concentration moving average of the
previous four weeks also had to be greater than 0.5 mmol/mol creatinine to be
considered ELA.
For each 4-week period, each treatment group, and each algorithm, 95% exact
confidence intervals on the percentage of patients with NELA were calculated.
3.2.6. Safety parameters
Throughout the duration of the study, each patient was closely monitored for the
occurrence of adverse events (AEs). Physical examinations including check of vital
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signs and breast and pelvic examinations were carried out at regular intervals.
Further safety evaluation was by laboratory parameters (haematology, biochemistry,
endocrine and lipid determinations, coagulation assays, urinalysis), pregnancy tests
and electrocardiograms (ECG). Endometrial thickness and the adnexae were assessed
during all TVUs as safety parameters. Patients who did not have both ovaries
removed during the hysterectomy underwent a further TVU at the 6-week follow-up
visit in order to inspect the remaining ovaries.
3.2.7. Data analysis and statistical methods
For the purpose of data analysis, each group of patients treated with asoprisnil (10
and 25mg) was compared to those who had received placebo and were in the
secretory phase of their menstrual cycle at the time of hysterectomy. Pairwise
comparisons within the framework of analysis of covariance (ANCOVA) models
were used for assessments of change in RI, PI, MP scores, number of days with
bleeding and UFS-QOL scores. The ANCOVA models for RI and PI included factors
of treatment and investigator as fixed effects and baseline value as a covariate. In
addition, a paired t-test was performed for RI and PI on the change from baseline to
final visit for each treatment group. The models for MP scores, number of days with
bleeding, and UFS-QOL scores included treatment as a factor and baseline value as a
covariate. Wilcoxon's rank sum test was used to determine percent change in volume
of the largest fibroid and the uterus. Percentage of patients with amenorrhoea and
improvement in fibroid-related symptoms were compared by Fisher's exact test. For
efficacy endpoints, Hochberg's multiple comparison method was applied to control
for pairwise comparisons at a significance level of 0.05. No statistical inference was
performed on safety variables.
At the outset of the study, it was planned to include 15 patients per treatment arm.
This sample size would have provided greater than 95% power to detect a 0.08
difference in RI between an asoprisnil group and the placebo group using a two-
tailed two-sample t-test with a common standard deviation of 0.05 (with a 0.05
significance level). The study was closed with a total of 33 patients due to
recruitment delays. With 11 patients per group and the same assumptions as above,




A total of 33 patients were enrolled in this study at the four investigative sites
(Edinburgh - 19, Southampton -11, Glasgow - 2, Liverpool - 1). Thirteen patients
underwent the screening procedures but then failed to meet the inclusion criteria.
Ten, 12 and 11 patients received placebo, asoprisnil lOmg and 25mg, respectively,
following assignment to each treatment group according to a 1:1:1 randomization
scheme. The study was completed by all 33 patients who underwent 12 weeks of
treatment, the scheduled hysterectomy and a follow-up assessment six weeks
postoperatively (Figure 3.4.).
The majority of patients were Caucasian (87.9%) and the mean age across all groups
was 43.9 years (range 35 to 52 years, inclusive). Treatment and placebo groups were
well matched in terms of race, age, height, and weight (Table 3.2.). Dmg compliance
was calculated by comparing the number of study treatment days with the number of
tablets taken according to the returned medication blister cards. Patients in all groups
were at least 93% compliant, some patients had taken more tablets than expected,
and their compliance therefore exceeded 100% (Table 3.3.). No patients developed
withdrawal criteria during the study. No patient received the wrong treatment or an
incorrect dose.
3.3.2. Uterine bleeding
Uterine bleeding was substantially decreased by treatment with asoprisnil. According
to the MP scores, there was a large mean reduction in blood loss in the final month
compared to baseline in both groups treated with asoprisnil (-154 ml after treatment
with lOmg asoprisnil (95% confidence interval (CI) -276.2 to -57.6) and -215 ml
with 25mg asoprisnil (95% CI -349.1 to -106.9)). These results indicate with 95%
certainty that reduction of blood loss with administration of 1 Omg asoprisnil is at
least -58 ml and at least -107 ml with 25mg asoprisnil. This was statistically
significantly different from the mean increase of 13 ml in the placebo group (Figure
3.5. / Table 3.4.). These decreases were already apparent during the first four weeks
of treatment.
The number of days with bleeding and percentage of patients with complete
suppression of bleeding were calculated from the patient's diaries.
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Figure 3.4. CONSORT diagram
Numbers of patients at different stages of the clinical study
The figures for the numbers of patients whose notes were
looked at to assess for eligibility and who were approached
and given a patient information leaflet, are estimates based
on best possible information at the time of assembling this
diagram; numbers are divided into the information from the
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Placebo 10 mg 25 mg All Subjects
Variable (N=10) (N-12) (N=ll) (N=33)
Race (n [%0
Black 1 [101 2 [16.7] 1 [9.1] 4 ri2.ii
Caucasian 9 [90] 10 [83.3] 10 [90.9] 29 [87.91
Age (y)
Mean (SD) 41.8(3.6) 45.1 (3.5) 44.6 (6.0) 43.9 (4.6)
Range 37-48 39-50 35-52 35-52
Weight (kg)
Mean (SD) 73.4(11.7) 73.8 (17.7) 75.9 (11.8) 74.4(13.8)
Range 54-89 45-105 60-96 45-105
Height (cm)
Mean (SD) 165.3 (6.4) 164.3 (4.7) 165.6 (7.3) 165.1 (6.0)
Range 158-177 156-172 157-178 156-178
Table 3.2. Demographic data at baseline
Race, age, weight and height distribution across the three treatment
groups at the time of screening
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Treatment Group
Placebo Asoprisnil 10 mg Asoprisnil 25 mg
% Compliance (N=10) (N=12) (N=ll)
Mean +/- SD 98.9 +/- 2.8 102.3 +/- 10.2 98.3 +/- 2.6
Minimum-Maximum 93-102 98-135 94-100
Table 3.3. Treatment Compliance
Compliance was calculated by dividing the number of tablets taken
(according to the used and returned medication blister cards) by the
number of study days (equal to the number of tablets expected to have
been taken); some patients took more tablets than expected and had














Baseline 213.0 ± 128.0 156.7+ 103.8 217.9+115.4
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Table 3.4. Menstrual pictogram (MP) scores
Mean changes of MP scores (in millilitres) from baseline to final visit
in the three treatment groups (placebo, asoprisnil lOmg, asoprisnil
25mg)
a From ANCOVA model for change from baseline to final month with
fixed effect of treatment and baseline score as a covariate
s Denotes statistical significance at 0.05 level using Hochberg's
multiple comparison procedure





















Placebo Asoprisnil 10mg Asoprisnil 25mg
Figure 3.5. Menstrual Pictogram (MP) scores
Mean changes of MP scores (in millilitres) from baseline to final visit
in the three treatment groups (placebo, asoprisnil lOmg, asoprisnil
25mg);
the significance of the difference of change from baseline between
placebo and asoprisnil groups was determined using Hochberg's
multiple comparison procedure at 0.05 level (*)
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Analysis of the change from baseline during the treatment period showed that there
was a statistically significantly larger decrease (p<0.001) in the number of days with
bleeding for the asoprisnil groups compared to placebo.
Patients treated with asoprisnil lOmg and 25mg on average had bleeding of 7.0 and
8.0 days prior to dosing, which decreased to 1.2 and 0.2 days during the final month,
respectively. The placebo group had a mean number of 7.3 bleeding days at baseline,
which was unchanged in the final month. This difference between the groups treated
with asoprisnil and the placebo group was statistically significant (p<0.001). The
95% confidence intervals for the change in the number of days with bleeding were
-8.65 to -2.85 for asoprisnil lOmg and -10.28 to -5.2 for asoprisnil 25mg, indicating
that the higher dose of 25mg asoprisnil leads to a reduction of at least -5 days.
The decrease in days with bleeding in the asoprisnil groups was evident during the
first month and continued throughout the treatment period. Suppression of uterine
bleeding, defined as having no days of bleeding requiring protection greater than a
panty shield, occurred in 33% of patients treated with asoprisnil lOmg and 91% of
those treated with 25mg. None of the patients in the placebo group showed
suppression of uterine bleeding. The difference between the asoprisnil 25mg and
placebo groups was statistically significant (p<0.001).
3.3.3. Fibroid-related symptoms
Evaluation of the LSAQs showed a statistically significantly greater proportion of
patients with improvement in dysmenorrhoea at the final visit after treatment with
asoprisnil than with placebo. Improvement in a symptom was defined as a decrease
of at least one point on the symptom assessment scale. 100% improvement in the
group treated with asoprisnil 25mg was already observed after eight weeks of
treatment. At the final visit, bloating, pelvic pressure, urinary incontinence, urinary
frequency and nocturia had improved but differences were not statistically significant
in the asoprisnil groups compared to placebo (Figure 3.6.).
There was an improvement in UFS-QOL Total Scores from baseline to final visit for
both asoprisnil groups and no change in the placebo group. The difference in change
between asoprisnil groups and placebo-treated patients was statistically significant
(p=0.022 for asoprisnil lOmg vs placebo; p<0.001 for asoprisnil 25mg vs placebo).
These results indicate a significant effect of asoprisnil on quality of life in women
with symptomatic uterine fibroids. In particular, there was statistically significantly
greater improvement with asoprisnil for the scales of concern, activities, control and
self-consciousness.
86
Analysis of responses to

















































Figure 3.6. Analysis of responses to Leiomyoma Symptom Assessment
Questionnaire (LSAQ)
Percentage of patients reporting improvement from baseline at the
final visit on the LSAQ; symptom improvement is defined as decrease
of at least one point on the symptom assessment scale; statistical
analysis is by Fisher's exact tests; statistical significance is
determined at 0.05 level using Hochberg's multiple comparison
procedure(*)
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Analysis of Uterine Fibroid Symptom
and Quality of Life (UFS-QOL) questionnaire
Figure 3.7. Analysis of Uterine Fibroid Symptom and Quality of Life
(UFS-QOL) questionnaires
Mean changes in Uterine Fibroid Symptom and Quality of Life (UFS-
QOL) total score and subscales (concern, activities, energy/mood,
control, self-consciousness, sexual function, symptom severity) from
baseline to final visit in the three treatment groups (placebo, asoprisnil
lOmg, asoprisnil 25mg); the significance of the difference of change
from baseline between placebo and asoprisnil groups was determined
using Hochberg's multiple comparison procedure at 0.05 level (*); for
symptom severity, a lower score indicates lower severity, for all other
scales, a higher score corresponds to better quality of life
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There was a trend towards greater improvement in energy/mood and sexual function
even though the difference between changes in asoprisnil and placebo groups was
not statistically significant. Reduced symptom severity was observed in both
asoprisnil groups but only statistically significant after treatment with asoprisnil
25mg compared to placebo (Figure 3.7.).
3.3.4. Volume of largest fibroid and uterus
Treatment with 25mg asoprisnil resulted in a reduction of the volume of the largest
fibroid with a median percent change of -25.8% from baseline to final visit. The
decrease with lOmg asoprisnil was very minor (-0.4%), and there was an increase of
4.9% in the placebo group. The differences between asoprisnil groups and placebo
were not statistically significant. There were also no statistically significant
differences in the median percent change in volume of the uterus between asoprisnil
and placebo groups.
3.3.5. Uterine artery blood flow
The change in RI between baseline and final visit was not statistically significantly
different after treatment with either dose of asoprisnil compared to placebo.
However, the increase in RI was statistically significant within the group
administered 25mg asoprisnil (Figure 3.8. / Table 3.5.). The rise in PI from baseline
to final visit in both asoprisnil groups was not statistically significant unlike the
decrease following placebo treatment. The difference in change from baseline was
statistically significantly different in both asoprisnil groups compared to placebo
(Figure 3.9. / Table 3.5.). Overall, these results are indicative of moderately reduced
uterine blood flow following administration of asoprisnil for 12 weeks.
3.3.6. Ovarian activity
Using two different algorithms as described above, luteal activity for three different
time periods during treatment was calculated using urinary PdG levels. The mean
PdG levels are presented in Table 3.6. Both methods of analysis gave similar results.
These were summarized by indicating the number and percentage of patients
showing no evidence of luteal activity (NELA) (Table 3.7.). During weeks 9-12,
there was NELA in 70-80% of patients who had received 25mg asoprisnil compared
with up to 20% in the placebo group. Even during weeks 1-4, there was evidence of
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dose-dependent suppression of luteal activity with 10-20% of patients showing
NELA in the placebo group compared to 33% following treatment with lOmg and
80-90% with 25mg asoprisnil.
Urinary EiG levels (Table 3.6.) were used to assess follicular activity. Partial or total
suppression was seen 22% of patients on placebo compared to 33% on asoprisnil
lOmg and 60% on asoprisnil 25mg. On the other hand, continued follicular activity
was seen in 78% of patients in the placebo group versus 67% and 40% in the
asoprisnil lOmg and 25mg groups, respectively. These results indicate that asoprisnil
has a dose-dependent suppressive effect on follicular activity.
Serum oestradiol (E) and progesterone (P) concentrations were measured after 12
weeks of treatment prior to hysterectomy. According to histological endometrial
assessments, 80% of the placebo-treated patients underwent their hysterectomy
during the secretory cycle phase. The mean E value was lower in the group on
asoprisnil 25mg (0.5 pg/ml) compared to placebo and asoprisnil lOmg (1.34pg/ml
and 1.32 pg/ml, respectively). The mean P level was substantially lower in the
groups on asoprisnil lOmg and 25mg (35.5 pg/ml and 5.7 pg/ml, respectively)
compared to placebo (76.0 pg/ml).
3.3.7. Safety parameters
No serious adverse effect (AE) occurred in any asoprisnil-treated patient. No AEs
led to discontinuation of the study. Even though over 90% of patients in each group
experienced at least one AE during the treatment period, the majority of these events
were mild or moderate in severity. The timing of many AEs indicated them to be a
result of complications from the hysterectomy, and AEs exhibited no drug-related or
dose-dependent pattern. The most common AEs reported by >4 patients in any group
during the treatment period were headache, upper respiratory tract infections, nausea
and vomiting, back pain or pain in extremities, procedural complications (intra- or
post-operative haemorrhage) and abdominal pain. There were no clinically
meaningful mean changes from baseline in hematology, coagulation, general
chemistry, or urinalysis laboratory values. No clinically significant changes from
baseline occurred for vital signs, physical findings, or ECG results.
Endometrial thickness measured by TVU increased slightly from screening to the
final visit in the placebo (0.93mm) and asoprisnil lOmg (0.05mm) groups,
respectively, and decreased by 4.5mm after treatment with asoprisnil 25mg. Pap test
results revealed no clinically concerning changes in the asoprisnil groups. No patient
had a symptomatic ovarian cyst during the study.
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Table 3.5. Analysis of resistance and pulsatility indices (RI and PI)
Mean changes of RI and PI (impedance indices to determine
uterine artery blood flow as determined by Colour Doppler
imaging) from baseline to final visit in the three treatment
groups (placebo, asoprisnil lOmg, asoprisnil 25mg)
a
Change from baseline to final visit was analysed by a t-test
with statistical significance at 0.05 level (*)
b From ANCOVA model for change from baseline to final
visit with fixed effect of treatment and investigator and
baseline mean RI / PI as a covariate;
statistical significance at 0.05 level using Hochberg's
multiple comparison procedure ($)















Baseline 0.73 + 0.10 0.76 ± 0.09 0.71+0.08
Final Visit 0.71 ±0.17 0.75 + 0.10 0.77 + 0.08
Change -
Baseline to Final Visit
-0.02 + 0.13 -0.01 ±0.06 0.06 ± 0.08
Within-group P-valuea
(change from baseline) 0.629 0.689 0.034*
Between groups P-valueb
Comparison vs placebo NA 0.756 0.146
PI
Baseline 1.69 + 0.60 1.80 + 0.72 1.52 + 0.44
Final Visit 1.27 + 0.33 1.81+0.67 1.81+0.48
Change -
Baseline to Final Visit -0.42 ± 0.42 0.01+0.56 0.30 + 0.54
Within-group P-valuea
(change from baseline) 0.012* 0.956 0.099
Between groups P-vaIueb



































Analysis of Resistance Index
Placebo Asoprisnil 10mg Asoprisnil 25mg
Figure 3.8. Analysis of Resistance Index (RI)
Mean changes of resistance index (RI; impedance index determined
by colour Doppler imaging) from baseline to final visit in the three
treatment groups (placebo, asoprisnil lOmg, asoprisnil 25mg); the
significance of the change from baseline was determined using t-test



























Analysis of Pulsatility Index
**
•k-k
Asoprisnil 10mg Asoprisnil 25mg
Figure 3.9. Analysis of pulsatility index (PI)
Mean changes of pulsatility index (PI; impedance index determined
by colour Doppler imaging) from baseline to final visit in the three
treatment groups (placebo, asoprisnil lOmg, asoprisnil 25mg); the
significance of the change from baseline was determined using t-test
at 0.05 level (*); the significance of the difference of change from
baseline between placebo and asoprisnil groups was determined using




Placebo 10 mg 25 mg
(N=10) (N=12) (N=ll)
Mean ± SD Mean ± SD Mean ± SD
EIG (pmol/mol)
Screening 11.5 + 4.0 18.0 + 7.2 15.0 + 5.5
Weeks 1-4 12.0 + 4.9 16.2 + 4.5 11.6 + 3.3
Weeks 5-8 13.3 + 3.4 17.5 + 6.6 12.5 + 5.4
Weeks 9-12 12.0 + 4.0 21.0 + 4.4 10.7 + 2.0
PdG (mmol/mol)
Screening 0.42 + 0.15 0.37 + 0.15 0.39 ± 0.22
Weeks 1-4 0.39 + 0.17 0.45 ± 0.26 0.17 + 0.11
Weeks 5-8 0.50 + 0.25 0.45 ± 0.33 0.23 + 0.19
Weeks 9-12 0.45 + 0.19 0.46 ± 0.27 0.15 + 0.10
Table 3.6. Urinary EiG and PdG levels
Mean levels of urinary oestrone glucuronide (EiG) and pregnandiol
glucuronide (PdG) collected twice weekly over four-week intervals
during the screening cycle and during treatment with placebo,
asoprisnil lOmg or asoprisnil 25mg; EiG and PdG levels were
measured using enzyme-linked immunoabsorbent assays and hormone
concentrations corrected for creatinine excretion; levels are expressed












Weeks 1 to 4
Algorithm 1 1/10(10) 4/12 (33) 8/10 (80)
Algorithm 2 2/10 (20) 4/12 (33) 9/10 (90)
Weeks 5 to 8
Algorithm 1 0/10 4/12 (33) 7/10 (70)
Algorithm 2 0/10 4/12 (33) 7/10 (70)
Weeks 9 to 12
Algorithm 1 0/10 2/11 (18) 7/10 (70)
Algorithm 2 2/10 (20) 2/11 (18) 8/10 (80)
Table 3.7. Number and percentage of patients with no evidence of luteal
activity (NELA)
Numbers of patients in each treatment group with no evidence of
luteal activity (NELA) over three consecutive time periods during the
clinical study as evidenced by urinary pregnandiol glucuronide (PdG)
levels according to two different algorithms as follows:
Algorithm 1 - defined evidence of luteal activity as a PdG
concentration being at least 3 times as high as the minimum 3-
concentration moving average during the past 28 days.
Algorithm 2 - same as Algorithm 1, with an additional requirement
that PdG concentration must be >0.5 mmol/mol creatinine.
N = total number of subjects; n = number of subjects in subset
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Two patients had ovarian cysts >3.5 cm during the treatment period: one patient on
placebo underwent surgical removal of a simple cyst and another patient treated with
lOmg asoprisnil had a complex cyst, which resolved spontaneously. Overall,
treatment with asoprisnil for 12 weeks prior to hysterectomy was well tolerated.
3.4. Discussion
The objectives of this study were to assess the clinical effects of treatment with
asoprisnil in women with uterine fibroids associated with symptoms severe enough
to pose an indication for surgical intervention. Simultaneously, safety and tolerability
were carefully evaluated. A rapid reduction in uterine bleeding, as evidenced by MP
scores, was demonstrated as well as an improvement of other fibroid-related
symptoms and quality of life measures. The effect of asoprisnil administered for
three months on uterine artery blood flow was also investigated through
ultrasonographic Doppler measurements of impedance (resistance and pulsatility
indices) as a possible mechanism of action. Asoprisnil treatment was shown to be
associated with a moderate decrease in uterine artery blood flow. Ovarian activity
during treatment was determined using urinary PdG and EiG levels. Whilst there was
an apparent dose-dependent suppression of luteal activity, follicular activity
continued or was only partially suppressed in most patients who were given
asoprisnil.
3.4.1. Clinical symptoms
The profound effect of asoprisnil on menstrual bleeding pattern and improvement of
fibroid-related symptoms demonstrated in this double-blind placebo-controlled
study, is consistent with previous reports142. These findings emphasize the potential
of asoprisnil for the medical management of uterine fibroids139 and as a possible
alternative to surgical intervention. The dramatic reduction in menstrual blood loss
with asoprisnil has previously been described in women with142 and without
fibroids137. Asoprisnil has consistently suppressed menstruation and frequently
achieved amenorrhoea in a dose-dependent manner.
In this study, the amount of blood loss was quantified with the aid of the menstrual
pictogram (MP) rather than assessed semi-quantitatively. Consistent use of
standardized sanitary products and the provision of visual analogues of the stained
products on the pictogram allowed for quantification over three four-week periods
i £n
during the study as well as the pre-treatment cycle, as previously described
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Statistically, menstrual blood loss during the third and final month of treatment was
compared to the pre-treatment cycle in all treatment groups. Whilst there was a slight
increase in the placebo group, the reductions in both asoprisnil groups were
substantial (-154ml and -215ml, respectively after lOmg and 25mg asoprisnil). This
represents a profound effect of asoprisnil on uterine bleeding, especially considering
that the definition of heavy menstrual bleeding (HMB) has traditionally been a blood
loss of over 80ml147, and the reduction by treatment with asoprisnil 25mg is more
than 2.5 times this amount. Even though statistically the final month of treatment was
compared to baseline, substantial reductions were already apparent after the first
month, highlighting not only a profound but also a rapid effect of asoprisnil on
uterine bleeding. Not just the MP but also the record of the number of days with
bleeding reflected a marked and dose-dependent reduction of bleeding by either dose
of asoprisnil. The percentage of patients experiencing complete suppression of
bleeding also appeared to be dose-related. Treatment with 25mg asoprisnil achieved
suppression of uterine bleeding in 91% of patients, which is substantial particularly
considering that some of these patients presented with menstrual blood loss of over
200ml according to their MP scores.
Managing HMB in the presence of uterine fibroids is often challenging and not
infrequently an indication for hysterectomy. Due to the distortion and enlargement of
the uterine cavity, management options such as the levonorgestrel-releasing
intrauterine system (LNG-IUS) or endometrial ablative techniques may not be
appropriate and have limited success rates152. In this and previous studies138'142,
asoprisnil suppressed menstrual bleeding independent of the size and location of
uterine fibroids. The high rates of amenorrhoea achieved with the 25mg dose of
asoprisnil highlight its potential role for the conservative management of women
with heavy bleeding and uterine fibroids.
In addition to the effect on uterine bleeding, the symptom of dysmenorrhoea was
significantly improved after treatment with either dose of asoprisnil compared to the
placebo group. Most likely this is due to the suppression of menstruation. Other
fibroid-related symptoms (bloating, pelvic pressure, urinary symptoms) did also
improve even though the difference to the placebo group was not statistically
significant. This trend suggests that treatment with asoprisnil is beneficial for a
variety of symptoms, which may be associated with uterine fibroids. The UFS-QOL
focussed specifically on the impact of these symptoms on quality of life. In this
study, treatment with asoprisnil achieved statistically significantly greater
improvements in most of the disease-specific UFS-QOL domains than placebo. As
previously described, responses to the UFS-QOL questionnaire were grouped into
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subscales of concern, activities, energy / mood, control, self-consciousness, sexual
function and symptom severity169. The improvement from baseline to final visit was
reported with both doses of asoprisnil and on all subscales. The difference to placebo
was statistically significant in the subscales of concern, activities, control and self-
consciousness and for the total UFS-QOL score. The difference in reduction of
symptom severity was only statistically significant after 25mg asoprisnil. In addition
to its effects on measurable parameters such as menstrual blood loss and fibroid
volumes, asoprisnil therefore appears to also have a significant impact on patients'
perception of their symptoms and on their quality of life. All patients in this study
had presented with symptoms, which were significant enough for them to consent to
major surgery for benign disease. In this cohort of patients with debilitating
symptoms, 12 weeks of treatment with 25mg asoprisnil resulted in amenorrhoea in
91% of cases and 100% improvement in dysmenorrhoea. Menstrual dysfunction is
the most common complaint associated with uterine fibroids and so not surprisingly,
asoprisnil also made a statistically significant difference to the quality of life of these
women whose only option for improvement was to resort to hysterectomy.
3.4.2. Uterine artery blood flow and size of fibroids
The results of previous clinical studies have suggested that uterine artery blood flow
is an important variable influencing the growth of uterine fibroids. Uterine artery
blood flow has been shown to increase in patients with uterine fibroids176.
Conversely, there is evidence that pharmacological agents such GnRH analogues177
and danazol178 reduce uterine artery blood flow as well as fibroid volumes. The same
combined effects have been demonstrated in a study with the progesterone antagonist
mifepristone156. Hence, in this study, the effect of asoprisnil on uterine artery blood
flow was assessed to investigate a possible mechanism of action in the presence of
uterine fibroids. With measurements of impedance in the uterine arteries via the
resistance and pulsatility indices (RI and PI), a statistically significant effect of both
doses of asoprisnil on PI was demonstrated compared to placebo. There was also a
trend towards increased RI. Together, these findings are suggestive of a moderate
inhibitory effect of asoprisnil on uterine artery blood flow.
The presumably causative association between reduced uterine artery blood flow and
decreasing volumes of uterine fibroids is the rationale behind treatment of
symptomatic fibroids by uterine artery occlusion techniques such as uterine artery
embolization (UAE)152'179. It has been demonstrated that UAE significantly reduces
the size of fibroids as well as the overall uterine volumes. This was associated with a
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substantial improvement of symptoms such as heavy menstrual bleeding,
dysmenorrhoea, pressure symptoms and also urinary symptoms and sciatica154. The
impact of UAE on quality of life has been shown to be comparable to surgical
intervention for uterine fibroids152. There is evidence that reduced uterine artery
blood flow may also be achieved pharmacologically, for example with GnRH
analogues177. GnRH analogues are the mainstay of current medical management of
uterine fibroids and are known to be effective in reducing volumes of the fibroid
uterus86'180. The finding of intravaginal misoprostol reducing uterine artery blood
flow has led to the suggestion it could be used in patients with fibroids even though
this effect may be secondary to uterotonic action181. Danazol therapy for six weeks,
whilst improving symptoms of dysfunctional bleeding, caused increased uterine
artery impedance resulting in reduced blood flow178. The present study shows that
the SPRM asoprisnil has similar properties even though it remains to be investigated
how exactly the effect on the uterine artery blood flow is exerted. It appears that the
effect of asoprisnil on decreasing fibroid volumes may be at least partially mediated
by reduced uterine artery blood flow.
Twelve weeks of treatment with either dose of asoprisnil resulted in a reduction of
the sonographically measured volume of the largest fibroid, whilst this increased in
the placebo group. This is consistent with previous reports168, although in this study,
the difference between groups was not statistically significant. The reduced size was
accompanied by decreased mitotic activity in leiomyoma tissue and a more common
appearance of degenerative changes in patients receiving asoprisnil135. There appear
to be a multitude of direct and indirect mechanisms involved in the asoprisnil-related
reduction of fibroid volumes. Decreased uterine artery blood flow is likely to
contribute, even though it is probably not the primary mechanism.
With the recognition that progesterone stimulates fibroid development and
growth84'85, a compound with partial antagonist effects on progesterone target tissues
would be expected to have antiproliferative properties. Evidence from in vitro studies
is growing regarding suppressed proliferation and induction of apoptosis in cultured
leiomyoma cells exposed to asoprisnil, whilst no such effect is seen in myometrial
1 RO 1 fil
cells ' . Treatment of cultured leiomyoma cells with asoprisnil has been shown to
result in down-regulation of growth factors (epidermal growth factor (EGF), insulin¬
like growth factor-I (IGF-1) and transforming growth factor P3 (TGF (13) and their
receptors (pEGF-R, IGF-1 Ra, pTGFP-RII). Asoprisnil also reduced the number of
viable leiomyoma cells, which is indicative of an antiproliferative effect. The same
treatment of myometrial cells did affect neither growth factor expression nor cell
proliferation184. In vitro studies have not only demonstrated the suppressive effect of
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asoprisnil on proliferation of leiomyoma cells but also a stimulating effect on
apoptosis. The tumour necrosis factor-related apoptosis-inducing (TRAIL)-mediated
signalling pathway was up-regulated by asoprisnil in leiomyoma cells, whilst the
inhibitor of apoptosis protein (Bcl-2) was down-regulated. These effects were
reversible by simultaneous treatment with progesterone and not observed at all in
myometrial cells182'185.
Overall, the results of these studies suggest that asoprisnil has selective
antiproliferative effects on leiomyoma cells via down-regulation of growth factors
and their receptors as well as induction of apoptosis183 mediated by the progesterone
receptor (PR). They indicate that asoprisnil targets uterine fibroids directly and
selectively, which is in contrast to the mode of action of GnRH analogues. GnRH
analogues down-regulate ovarian secretion of oestrogen and progesterone via the
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pituitary gland and achieve a reduction in total uterine volume , whilst asoprisnil
specifically decreases the size of fibroids.
3.4.3. Ovarian activity
In contrast to GnRH analogues, the present and previous studies have shown clinical
and antiproliferative effects of asoprisnil to occur in the presence of circulating
follicular phase oestrogen concentrations168. This implicates that side effects due to
hypo-oestrogenism would not be expected and have not been described. In this study,
follicular and luteal ovarian activity were investigated separately and in some detail
by assessing urinary PdG and EiG twice weekly throughout the treatment period.
Luteal activity was suppressed by treatment with asoprisnil, and this effect appeared
to be dose-dependent. Follicular activity was evaluated by comparing urinary EiG
levels during treatment to levels prior to dosing. Suppression of follicular activity by
asoprisnil was also dose-dependent but less consistent than the effect on luteal
activity. Most patients experienced continued or only partially suppressed follicular
activity whilst on treatment with asoprisnil. These findings indicate that asoprisnil
inhibits luteinization in the majority of women at the higher dose (25 mg), whilst
follicular activity and therefore ovarian oestrogen secretion is maintained. Previous
study have consistently reported asoprisnil to exert its clinical effects including
suppression of menstruation in the presence of follicular phase oestrogen
concentrations137'168. The fact that asoprisnil achieves its dramatic effects on
symptomatic uterine fibroids whilst physiological oestrogen concentrations are
maintained, emphasizes its clinical potential for this group of patients. The risk of
hypo-oestrogenism is the main limiting factor for the long-term use of GnRH
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analogues , and yet currently they are often the only medical management option
for control of symptoms due to uterine fibroids such as heavy bleeding and / or
pelvic pressure.
3.4.4. Safety parameters
In this study, treatment with asoprisnil was well tolerated. There were no premature
terminations during the treatment phase, and all patients completed the study with
good compliance. The majority of adverse events (AEs) were mild or moderate in
severity. The timing of AEs indicated that many were a result of the planned
hysterectomy or complications from that surgery. There were no clinically
meaningful changes from baseline in haematology, coagulation, general chemistry,
or urinalysis laboratory values. These findings are consistent with previous studies
showing asoprisnil to have a favourable safety and tolerability profile137'168.
There was no increase in the sonographically measured endometrial thickness and
indeed a decrease after 12 weeks of treatment with asoprisnil 25mg. This trend for
decreased endometrial thickness was also found, when histological sections of the
endometrium were measured by eyepiece micrometer135. These findings are
consistent with an antiproliferative effect of the SPRM asoprisnil on human
endometrium as previously observed in animal models139. This aspect will be further
explored in the next two chapters.
3.4.5. Limitations of the study
The effects of asoprisnil on clinical symptoms associated with uterine fibroids
appears to be profound and rapid, as they were apparent after only one month of
treatment. However, this study is not able to demonstrate whether this effect will be
maintained long term, as the study period of 12 weeks is relatively short. It also
appears that most of the symptom relief is related to the suppression of uterine
bleeding. As heavy menstrual bleeding was the predominant symptom in most
patients in this study, it is difficult to independently assess any effect of asoprisnil on
other fibroid-related complaints. It would have been interesting to specifically ask
every patient prior to hysterectomy, whether they would have chosen to avoid
surgery, had asoprisnil remained available as a management option. As it stands, the
responses to the UFS-QOL may suggest their views on this, but other factors not
included in the study may also influence patients' preference for a certain treatment
modality.
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This study suggests that asoprisnil reduces uterine artery blood flow, which may
represent a possible mechanism of action. It is important to bear in mind the possible
inter- and intra-observer variability of colour Doppler imaging. Every effort was
made in this study to limit the opportunites for error by specifying the menstrual
cycle phase for obtaining measurements prior to commencing the study drug and by
ensuring that the majority of investigations were carried out by one specialized
radiologist per study site. However, as there were four study sites for 33 patients, the
possibility of inter-observer errors needs to be considered.
The effects of asoprisnil on ovarian activity in this study were investigated by
measuring urinary PdG and EjG levels twice weekly, To assess the effect on
ovulation, serial ultrasound assessments of the dominant follicle and more frequent
measurements of the ovarian and pituitary hormone levels would be required.
Urinary PdG levels indicate the presence of progesterone as a result of either
ovulation or a luteinized unruptured follicle. In this study, it is not possible to
differentiate whether ovulation has occurred or not.
3.5. Conclusion
In patients with symptomatic uterine fibroids scheduled for hysterectomy, asoprisnil
taken for 12 weeks substantially reduced blood loss as evidenced semi-quantitatively
by menstrual pictogram evaluation. It also improved other symptoms and quality of
life measures, as indicated by responses to the LSAQ and the UFS-QOL. Asoprisnil
was shown to moderately reduce uterine artery blood flow demonstrated by altered
resistance and pulsatility indices. This effect may contribute to fibroid volume
reduction, as demonstrated in this study, even though it is unlikely to be the primary
mechanism. All these effects were seen without significant alterations of serum
oestrogen levels. 10 mg and 25 mg doses of asoprisnil were safe and effective when
administered daily for a 12-week period. Further studies are needed to determine the
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4.1. Introduction
Endometrial morphology is recognized to change considerably according to the
different phases of the menstrual cycle under the influence of the ovarian steroid
hormones. These changes are so distinct that the cycle phases are classified into
proliferative and secretory by the endometrial appearances. Follicular ovarian
activity results in increased secretion of oestrogen (E), which promotes endometrial
proliferation with frequent mitoses, particularly in the functional layer. Following
ovulation, luteal ovarian activity subsequently raises progesterone (P) levels
transforming the endometrium into a secretory state required for successful
implantation. Glandular as well as stromal compartments exhibit characteristic
changes dependent upon the exposure to ovarian steroid hormones. The typical
endometrial appearances have been correlated to the cycle stage and used to
determine the phase of the cycle during which an endometrial specimen was
obtained6'7.
Quite expectedly, endometrial morphology may be further modified by exogenous
steroid hormones or by conditions altering steroid activity in the endometrium.
Notably, exposure to unopposed E acts as a protracted proliferative stimulus and is
well known to result in endometrial hyperplasia with an increased risk of endometrial
cancer187"189. The mitogenic effect of E may be unopposed due to persistent
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anovulation (i.e. with polycystic ovarian syndrome or in the perimenopause) or with
hormone replacement therapy. Prolonged and continuous administration of
progestins is currently the basis for medical management of many benign
gynaecological conditions as well as most forms of hormonal contraception. The
highest endometrial levels of progestin are achieved with delivery via an intrauterine
system such as the levonorgestrel-releasing intrauterine system (LNG-IUS).
Endometrial appearances in LNG-IUS users have been studied and described as
glandular atrophy, extensive stromal decidualization with altered blood vessel
integrity190. These morphological changes appear to be related to the clinical effects
of suppressed uterine bleeding even though the common occurrence of breakthrough
bleeding has not been sufficiently explained.
Progesterone receptor modulators (PRMs) have mixed and partial progesterone
receptor (PR) agonist and antagonist properties. Mifepristone was the first developed
compound within this category and has mostly PR antagonistic activity. This may
raise the concern of causing endometrial changes as seen with exposure to
unopposed oestrogen. However, very soon after discovery of mifepristone, its
endometrial antiproliferative effect was described in non-human primates191. This
paradoxical observation was termed the functional non-competitive anti-oestrogenic
effect, as it occurred in the presence of physiological oestrogen levels and was
specific to the endometrium. The same phenomenon has since been observed with
other PRMs in non-human primates and women123. In cynomolgus macaques, the
endometrial antiproliferative effect was characterized by reduced mitotic activity,
decreased thickness and wet weight in conjunction with glandular apoptosis, stromal
atrophy and stromal compaction. Additionally, the spiral arteries showed hyalinizing
degeneration with a narrowed lumen123. Similarly in humans, the endometrial
appearances following administration of low dose (2-5mg) mifepristone have been
described as suppressed glandular proliferation with reduced mitotic indices and
increased stromal density124'192.
Other features seen in endometrium exposed to mifepristone and other PRMs have
previously been described as simple hyperplasia162. This diagnosis was made mainly
on the basis of prominent cystically dilated glands reminiscent of the appearances of
the disordered proliferative endometrium due to the effect of unopposed E. Further
detailed examination revealed however, that unlike the proliferative lining of the
glands seen with hyperplasia, the glands in endometrium after administration of
PRMs were only weakly mitotic and sometimes secretory. It was realized that PRMs
cause changes to the endometrial morphology, which are unique to this class of
compounds136'193. These appearances are not amenable to conventional assessment
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using the Noyes criteria6 and have since been characterized as non-physiologic
secretory effects137.
It has not been fully explained by which mechanism PRMs exert their effects on
endometrial morphology and on clinical symptoms. It has been hypothesized that the
endometrium is directly targeted, as most effects are evident irrespective of
continuing follicular and luteal ovarian activity. The specific endometrial changes,
particularly within the stroma and the vasculature, may mediate the clinical
suppression of uterine bleeding137. Hence, the detailed study of endometrial
morphology after administration of PRMs is most important for two reasons. It may
serve to further elucidate the exact mechanism of action of these compounds. It is
also vital in order to ensure the safety of long-term administration.
In this study, detailed histological assessment was carried out in full thickness
endometrial samples from hysterectomy specimen after administration of 10 or 25mg
asoprisnil for 12 weeks prior to surgery. Unlike samples obtained with a Pipelle, full
thickness specimens include the basal endometrial layer. These full thickness
endometrial samples retain their cellular architecture and thus provided the
opportunity to evaluate the effects of asoprisnil in all layers of the endometrium.
4.2. Materials & Methods
4.2.1. Tissue collection
Endometrial biopsies were collected from all patients with a Pipelle endometrial
sampler within 3 months prior to commencement of the study. It was an absolute
requirement for continuation in the study for this biopsy to be satisfactory for
assessment and normal.
Endometrial samples from the hysterectomy specimen were obtained as described in
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section 2.2.1 and a previous publication . For morphological assessment, three
blocks each were taken from the uterine fundus, mid-corpus and isthmus,
respectively. These were processed by routine methods. 3 pm haematoxylin-eosin
stained sections were prepared by microtomy and mounted on glass slides. A section
was considered unsuitable for assessment, if a fibroid was present within 10mm of
the endometrium.
Samples from myometrium and fibroids were also obtained from each patient. In
some cases, non-endometrial tissue (ovaries, Fallopian tubes, cervix) was collected at





Simple tubules - minimal undulation
Simple tubules - undulation as in normal proliferative phase
Tubules - undulation as in early secretory phase
Glands with morphology of mid or late secretory phase













Cell height Flattened - height < width
Cuboidal - height = width
Columnar - height > width
Secretory effects No cytoplasmic vacuolation
Sub- and/or supranuclear vacuolation







Present in 1 -2 glands
Present in >2 glands, up to 50%
Present in >50% of glands











Around vessels, extending into stroma (non confluent)
Confluent








Presence of abnormally muscularized arterial vessels0
Aggregations of vessels'1 None
1-2
>2
a Non-decidualized stroma only
b Atrophic defined as nucleus / cytoplasm ratio >1
c Abnormal arterial vessels similar to those seen in stroma of endometrial polyps
d Number of vessel aggregates per slide
Table 4.2. Morphological categories of endometrial stromal histology135
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4.2.2. Histological assessment
The Pipelle endometrial biopsies obtained prior to treatment were submitted to
routine pathological evaluation. The "Dictionary of Endometrial Biopsy Diagnoses
for Clinical Trials with SPRMs" was used to classify the endometrial appearances of
the hysterectomy samples in this study. This was developed by TAP Pharmaceuticals
Inc (Lake Forest, IL, USA), Diagnostic Cytology Laboratories (Indianapolis, IN,
USA) and a group of expert gynaecological pathologists, when it became evident that
the unique endometrial changes encountered following exposure to PRMs were not
assessable by the conventional criteria of endometrial dating6. This system is based
on the currently used criteria of the normal menstrual cycle as described by Noyes6
and in Blaustein's Pathology of the Female Genital Tract143, but includes further
categories, which are considered characteristic of the PRM effects.
A single expert gynaecological pathologist evaluated all sections whilst blinded to
treatment groups. The maximum single endometrial thickness on each section was
measured using an eyepiece micrometer. Overall endometrial appearances were
categorized according to the classification system as above. Individual histological
characteristics of glandular, stromal and vascular compartments were analysed using
further descriptive subcategories (Tables 4.1 & 4.2).
Any histological changes or abnormalities in the myometrium and any degenerative
effects within the fibroids were noted. The samples from outwith the uterus were
screened for any changes within their vascular beds to assess whether the altered
appearances in the endometrium were site-specific.
4.2.3. Assessment of mitotic activity
The number of unequivocal mitotic figures present per 10 high-power microscope
fields of endometrium (Olympus BX51, x40 objective, field diameter 0.55mm) were
counted separately in glandular and stromal compartments and expressed as mitoses
per unit area. First, the area with the greatest density of mitoses was identified by
microscopic assessment for counting to commence. Thereafter, a minimum of 10
non-overlapping fields was randomly selected for counting.
4.2.4. Data analysis
The numbers and percentages of patients in each diagnostic category were
summarized for each treatment group and for endometrial samples from each of the
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intrauterine locations (fundus, mid-corpus, isthmus). The same procedure was
performed for the more detailed evaluation of the morphological features in glands
and stroma. No statistical analysis was performed for these descriptive assessments.
For each treatment group and each of the three sampling locations, mean and
standard deviation were calculated for the endometrial thickness. The t-test was
applied to compare the thickness between placebo and combined asoprisnil groups
for each location separately. Hochberg's multiple comparison procedure was used to
adjust for the multiplicity resulting from the three sampling locations.
4.3. Results
4.3.1. Histological assessment
All Pipelle endometrial biopsies obtained at baseline were confirmed normal and
classified as inactive (10%), proliferative (28%), secretory (55%) or menstrual (7%).
Samples from all three sampling locations (fundus, mid-corpus, isthmus) were
available for histological assessment in 29 cases. Within the placebo group, normal
secretory appearances were seen in 71% of available samples from each of the three
locations. The majority of samples from either of the asoprisnil groups (50-73%)
were assigned to the non-physiologic secretory category reflecting the PRM-specific
endometrial effect. Administration of 25mg asoprisnil resulted in assignment to this
category in 73% of samples from both fundus and mid-corpus. Non-physiologic
secretory endometrial appearances were seen in only one placebo-treated case in the
samples from fundus and mid-corpus (Table 4.3.).
4.3.2. General endometrial morphology following exposure to asoprisnil
The non-physiologic secretory effect commonly seen in endometrium after
administration of asoprisnil, is characterized by a combination of morphological
features in glands, stroma and vasculature. All tissue compartments need to be
assessed in order to assign a sample to this category, as none of the individual
features on their own are specific for exposure to PRMs.
Generally, the endometrium from asoprisnil-treated patients tended to be too thin to
distinguish functional and basal layers (Figure 4.1.A). The morphological
appearances associated with exposure to asoprisnil were similar near the surface and























0(0) 1(14) 5(71) 1 (14) 0(0)
Corpus
n = 7
0(0) 1(14) 5(71) 1(14) 0(0)
Isthmus
n = 7





0(0) 2(20) 1 (10) 7(70) 0(0)
Corpus
n= 10
1 (10) 2(20) 2(20) 5(50) 0(0)
Isthmus
n= 10





1(9) 1(9) 1(9) 8(73) 0(0)
Corpus
n= 11
1(9) 0(0) 1(9) 8(73) 1 (9)
Isthmus
n= 10
3 (30) 1(10) 0(0) 5(50) 1(10)
Table 4.3. Overall diagnostic category assigned to endometrial specimens135
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Figure 4.1. Endometrial vascular morphology following exposure to
asoprisnil
A Thin endometrium with dilated thin-walled vessels
(arrows)
B Clusters of thick-walled muscularized spiral arterioles
within the endometrial stroma
(Reproduced with permission from Dr Alistair Williams,
Department of Pathology, University of Edinburgh)
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Figure 4.2. Endometrial glandular morphology following exposure to
asoprisnil
A Non-physiologic secretory appearance of endometrial
glands with tortuous or serpentine profiles similar to
the normal mid-secretory phase
B Cystic glandular dilatation is commonly seen with
asoprisnil (arrows)
(Reproduced with permission from Dr Alistair Williams,
Department of Pathology, University of Edinburgh)
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Most striking and most consistently identified after asoprisnil administration were
the features of the endometrial vasculature. The endometrial stroma commonly
displayed clusters of thick-walled muscularized vessels similar to the vascular
appearances in benign endometrial polyps (Figure 4.l.B). Thin-walled vessel
aggregates were also frequently identified throughout the endometrium (Figure
4.1.A). Whilst none of the clusters of thick-walled muscularized vessels were found
in endometrial samples from placebo-treated patients, dilated thin-walled vessels did
occur occasionally but much less commonly than in the asoprisnil-treated groups.
The glandular pattern was reminiscent of secretory differentiation with serpentine or
tortuous profiles and columnar epithelium showing few or no mitotic figures (Figure
4.2.A). Despite the secretory appearances, evidence of active secretion such as
cytoplasmic vacuolation was very rarely observed. Cystic glandular dilatation was
common but without any abnormal folding patterns and without increasing the gland-
stroma ratio above normal (Figure 4.2.B). There was a tendency for increased
stromal compactness but no evidence of decidualization.
4.3.3. Endometrial thickness
The measurements of the single layer endometrial thickness as obtained with the
eyepiece micrometer from the histological sections of the hysterectomy specimen are
shown in Table 4.4. The ranges over the different intrauterine locations were 3.1 -
4.1mm single layer thickness in the placebo group, 2.1 - 2.6mm with lOmg
asoprisnil and 1.3 - 2.8mm with 25mg asoprisnil. Even though there appeared to be a
trend for asoprisnil to decrease endometrial thickness, the differences between
placebo and the combined asoprisnil groups were not statistically significant.
4.3.4. Mitotic activity
The numbers of endometrial sections from uterine fundus, mid-corpus and isthmus
showing 0, 1, 2-5 or >5 mitotic figures per 10 high-power fields (HPFs) within the
glands or stroma are shown in Table 4.5. The use of samples from placebo-treated
patients for comparison is limited due to the variable cycle phases. Most patients in
the placebo group underwent hysterectomy during the secretory phase of their
menstmal cycle, when mitoses would be expected to be infrequent or absent.
However, it is notable that following administration of 25mg asoprisnil, no mitotic




































Table 4.4. Mean endometrial thickness
Measurements of single layer endometrial thickness are taken on the
histological sections from the hysterectomy specimen with the
eyepiece micrometer;
the apparent trend of reduced endometrial thickness with asoprisnil
treatment is not statistically significant at 0.05 level
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0 0 0 0 9
(100)
0 0 0 0
Table 4.5. Mitotic activity135
Number of samples with 0, 1, 2-5 or >5 mitotic figures per 10 high-
power fields (HPFs);






































Table 4.6. Endometrial stromal vessels
Number of endometrial samples showing aggregates of thin-walled
vessels and thick-walled muscularized vessels
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In the stroma, mitotic figures were found in three samples, whilst they were absent
from 73%, 82% and 100% of specimens from fundus, mid-corpus and isthmus,
respectively. Treatment with lOmg asoprisnil resulted in one mitosis or less per 10
HPFs in at least 70% of samples from both glands and stroma.
4.3.5. Specific morphology of different tissue compartments
4.3.5.1. Endometrial glands
The gland architecture in samples from the asoprisnil-treated groups varied from
simple tubules with minimal undulation to tortuous appearances reminiscent of the
normal mid- or late secretory phase. Following the higher asoprisnil dose of 25mg,
the simple tubular pattern was more commonly observed in samples from the uterine
isthmus (40%) than in fundus or mid-corpus (9%). Despite the architecture mostly
resembling the secretory phase, cytoplasmic secretory vacuolation was absent from
the glands in all patients taking 25mg asoprisnil and infrequent (up to 30%) with the
lower lOmg dose. The predominant epithelial cell type in endometrial glands from all
samples consisted of tall columnar cells with a degree of nuclear stratification that
did not vary significantly between treatment groups.
Some degree of cystic gland dilatation was evident in all uterine locations after
exposure to 25mg asoprisnil but particularly in the isthmus (80% compared to 29%
in the placebo group). No cytological atypia in epithelial cell nuclei was identified in
any patient. There was no difference in the frequency of glandular morphological
abnormalities other than cystic dilatation between placebo- and asoprisnil-treated
patients. Even though not systematically assessed, there was also no apparent
difference in the numbers of apoptotic glandular cells.
4.3.5.2. Endometrial stroma
In specimens from patients treated with either dose of asoprisnil, no decidual changes
were identified except in one sample from the uterine fundus. In contrast, decidual
changes were evident in 43% of sections from the placebo-treated group. Asoprisnil
appeared to induce increased stromal compactness when compared to placebo. The
stroma was assessed as compact in 0-14% of samples from the placebo group,
30-60% after lOmg asoprisnil and 45-70% after treatment with 25mg asoprisnil.
4.3.5.3. Vasculature
Two different vascular morphological features were observed with increased
frequency in the endometrial stroma of asoprisnil-treated patients. These consisted of
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leashes of thin-walled vessels and clusters of thick-walled muscularized vessels,
similar to those seen in the stroma of endometrial polyps.
In the placebo group, aggregates of thin-walled vessels occurred in 14-29% of
samples from uterine fundus and mid-corpus but not in the isthmus. At least one such
aggregate was found in 30-50% of specimen from fundus or mid-corpus after
treatment with asoprisnil and in 20-40% of samples from the isthmus. Clusters of
thick-walled vessels were not identified in any samples from the placebo group.
Assessing the specimen from uterine fundus and mid-corpus, this vascular
morphological feature was found in 20-30% after administration of lOmg asoprisnil
and in 45% with 25mg asoprisnil. In the uterine isthmus, these clusters were seen in
10 and 30% of samples following treatment with lOmg and 25mg asoprisnil (Table
4.6.). Although these thick-walled vessels are reminiscent of the appearances in
endometrial polyps, there are distinct differences. In endometrial polyps, these
clusters typically occur within a rounded, projecting polypoid mass with gland
crowding and collagenous changes to the stroma. Administration of asoprisnil for 12
weeks does not lead to gland crowding and the stroma is not notably collagenized.
On the contrary, the endometrium remains flat and often thinned.
Non-endometrial tissue was available for assessment of vascular beds in this study.
12 ovaries from 8 patients, 15 Fallopian tubes from 10 patients and 10 cervices were
removed at the time of hysterectomy and were examined. No specific histological
abnormalities were observed, and particularly no similar vascular changes as
described above occurred in non-endometrial tissues.
4.4. Discussion
The profound clinical effects of asoprisnil on menstrual bleeding pattern are
accompanied by distinctive changes to endometrial morphology. This phenomenon
has previously been appreciated137 and prompted the development of a list of
diagnostic criteria for classification of morphological changes induced by PRMs. The
criteria were defined by a group of expert gynaecological pathologists, as the
endometrial features encountered did not comply with the categories within the
existing compendium of pathological diagnoses. Previous studies into the effects of
asoprisnil on endometrial morphology relied on biopsies obtained by Pipelle
aspiration after treatment for 28 days137. For this study, full thickness endometrial
samples with underlying myometrium were available following administration of
asoprisnil for 12 weeks. The biopsies were mostly well oriented and undisrupted by
the sampling procedure facilitating detailed morphological assessment.
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The findings in this study were consistent with previous descriptions of PRM effects
on endometrium. The majority of endometrial samples from asoprisnil-treated
patients showed a non-physiologic secretory effect. This category is specific for the
PRM effect and was assigned to only one placebo-treated sample. These particular
morphological appearances were evident to a similar extent in all three uterine
locations (fundus, mid-corpus and isthmus) but were more common after exposure to
the higher dose of 25mg asoprisnil. They are not usually seen in normal cycling
endometrium or any described condition and have been hypothesized to reflect the
partial PR agonist/antagonist effect of asoprisnil129.
Histological features in both endometrial glands and stroma define the non-
physiologic secretory effect. The glandular architecture was similar to the tortuosity
seen in the normal secretory phase, but secretory activity or cytoplasmic vacuolation
was rare. Notably, the glands were often cystically dilated, but even though there was
nuclear stratification, mitotic activity was very rare and even absent in the samples
exposed to the higher dose of 25mg asoprisnil. Cystic glandular dilatation is
commonly associated in the minds of histopathologists with simple endometrial
hyperplasia. However, as part of the features of the non-physiologic secretory effect,
the dilated glands not only showed a paucity of mitotic activity but also absence of
glandular crowding. The cystic changes often involved a focus of one or two glands
in a field of non-dilated glands. Appearances of glandular dilatation may also
commonly be found in inactive endometrium in the peri- or postmenopause. In such
cases, cystic dilatation is not considered indicative of secretory activity and may
indeed be a consequence of a lack of secretory activity leading to occlusion of the
gland opening to the surface.
Total endometrial thickness after treatment with asoprisnil for 12 weeks was not
increased, and the trend (even though not statistically significant) was for the mean
endometrial thickness to be less than in the placebo group. Overall, no histological
changes were found to give cause for concern about the development of malignant or
premalignant disease. Each sample was specifically assessed for features of glandular
cytological atypia, but none were identified. In some cases, there was a superficial
resemblance to simple cystic hyperplasia due to the occurrence of dilated glands.
Notably, any other features of simple hyperplasia were lacking and the glandular
architecture certainly did not suggest complex hyperplasia. Comparison of mitotic
activity in this study is limited as most patients in the placebo group were in the
secretory phase of their cycle at the time of hysterectomy, when mitoses are not
expected to be present. However, the level of mitotic activity in the asoprisnil-treated
groups was notably low, which is consistent with previous findings in non-human
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primates describing an endometrial antiproliferative effect123. It is important that this
is recognized amongst histopathologists so that endometrial samples from patients
treated with asoprisnil are not misdiagnosed as hyperplastic on the basis of cystically
dilated glands.
Cystic glandular dilatation has also been found in previous studies with mifepristone,
when a significant proportion of samples were classified as hyperplastic105'162. These
early findings were subsequently reviewed with the conclusion that many cases had
been inappropriately assigned to the category of simple hyperplasia, as no other
features consistent with this definition could be identified108. Cystically dilated
glands with inactive epithelial appearances are a morphological feature commonly
occurring with administration of both mifepristone and asoprisnil. Similarly, the
endometrial antiproliferative effect has been consistently described with both
compounds124'194'195. However, there are also significant differences in the
morphology of endometrium after exposure to different PRMs. With mifepristone,
the glands appear less tortuous and more tubular suggesting absent agonist activity
on the PR with a pronounced antagonist effect. The glandular tortuosity seen in
asoprisnil-treated endometrium likely reflects the partial PR agonist effect in addition
to the antagonist action.
The most characteristic stromal effect in this study involved the endometrial
vasculature. Additionally, there was increased compactness without any decidual
changes. It has been hypothesized that the mechanism of action of asoprisnil may be
related to the vascular morphological changes. Notably, no specific effect on
endometrial vasculature has been identified after treatment with mifepristone.
Administration of asoprisnil caused a more frequent occurrence ofboth aggregates of
thin-walled vessels as well as clusters of vessels with thickened muscularized walls
compared to controls. No similar changes were found in the limited range of non-
endometrial tissues examined in this study. This specific effect on the endometrial
vasculature may be mediated via the perivascular cells, which are known to express
PR and have been described to be pivotal in the control of menstruation9.
Perivascular cells are intimately apposed to the endothelial cells of the spiral
arterioles and are thought to initiate vasoconstriction-vasodilatation cycles in
response to the falling progesterone levels in the late secretory phase.
The clusters of thick-walled vessels are reminiscent of those found in the stroma of
endometrial polyps. In asoprisnil-treated endometrium, the aggregates of thin-walled
vessels are probably a precursor of these clusters of muscularized arterioles. It is
possible that an effect of asoprisnil on the perivascular cells mediates an active
process of angiogenesis. Alternatively, the development of these vascular aggregates
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may be analogues to the stromal vessels in endometrial polyps. These are thought to
represent focal areas of endometrium, which are not shed at the time of menstruation
and therefore persist for several cycles to form polyps. Similarly, asoprisnil treatment
suppresses menstrual bleeding, and hence endometrium is not shed, which may cause
these morphologically abnormal vessels to develop. However, there are no other
similarities between polyps and asoprisnil-treated endometrium, which remains flat
and mostly thin with absent gland crowding and no prominent stromal collagen.
Notably, polyps developed very infrequently following administration of asoprisnil,
and in this study only one small polyp was found in one patient who had been taking
asoprisnil lOmg.
4.4.1. Limitations of the study
Similar to the findings in the clinical study, the effect of asoprisnil on endometrial
morphology appears profound and notable after administration for 12 weeks. This
study does not allow any conclusions, whether these morphological changes will be
maintained or further modified with prolonged exposure to asoprisnil. Of particular
interest would be the assessment of glandular morphology, endometrial thickness and
mitotic activity to provide assurance regarding the safety of long term administration
of asoprisnil.
The applicability of the results in this study may be limited by the presence of benign
gynaecological pathology in all patients. All patients in this study had at least one
uterine fibroid and had initially presented with symptoms associated with fibroids
such as heavy menstrual bleeding. Therefore, the endometrium cannot be considered
functionally normal and the results should be interpreted with caution. Every effort
was made to sample the endometrium with at least 10mm distance to the nearest
fibroid. However, vascular changes are known to occur within the endometrium in
the presence of uterine fibroids, even though in this study, all endometrial biopsies
obtained at screening were reported as histologically normal.
The results in this part of the study are all descriptive and based on the findings of a
single expert pathologist. As this is the first study assessing full thickness
endometrial specimen following administration of asoprisnil, it may be regarded as a
pilot study. Further studies including statistical inferences regarding the effects of
asoprisnil on endometrial morphology are indicated, in particular for measurements
of endometrial thickness. The numbers in this study were too small to compare each
asoprisnil group individually to placebo, and it would be interesting to assess
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whether the trend for asoprisnil to reduce endometrial thickness may be significant in
a larger sample group.
The effect of asoprisnil on vasculature has only been described in endometrium and
appears to be tissue-specific. None of the non-endometrial tissue specimen in this
study demonstrated any similar changes or other histological abnormalities.
However, these specimen were obtained incidentally and not specifically for the
purpose of assessing asoprisnil-related morphological changes.
4.5. Conclusion
Unique changes in endometrial morphology have been demonstrated following
administration of 10 or 25mg asoprisnil once daily for 12 weeks. For the first time, a
detailed assessment of endometrium exposed to asoprisnil has been carried out on
full-thickness samples obtained at hysterectomy. Most notable were the effects on
glandular appearances as well as the vascular changes in the stroma, which appeared
to be specific to the endometrium. It is important for histopathologists to be aware of
these unique effects of PRMs when examining endometrial samples from patients
treated with such compounds to avoid misclassification. In particular, some
appearances are reminiscent of simple hyperplasia or polyps but other concomitant
features are clearly inconsistent with these entities. The mechanism of action of
asoprisnil and particularly its effect on the suppression of menstrual bleeding is still






The data presented in this chapter have previously been peer-reviewed and published
in the manuscript:
Wilkens J, Williams ARW, Chwalisz K, Han C, Cameron IT and Critchley HOD
Effect of asoprisnil on uterine proliferation markers and endometrial expression of
the tumour suppressor gene, PTEN
Human Reproduction 2009; 24(5): 1036-44
5.1. Introduction
The endometrial antiproliferative effect of progesterone receptor modulators (PRMs)
as described in the previous chapter was discovered soon after their first
development and initially with mifepristone191. With the progesterone receptor (PR)
antagonistic properties of PRMs, this was quite an unexpected finding, as it may
have been hypothesized that unopposed oestrogenic effects potentially induce
endometrial proliferation. Since then, the antiproliferative effect has been
consistently described with mifepristone and other PRMs in humans and non-human
primates123'196. Even with administration of pure PR antagonists such as ZK 137 316,
the endometrium appeared atrophic197. This phenomenon has alternatively been
termed functional non-competitive anti-oestrogenic effect, but the exact mechanism
of action has still not been fully elucidated123. Until this is understood, endometrial
safety remains a potential concern, particularly when long-term administration is
considered, even though studies of endometrial morphology have been reassuring.
Occasionally occurring features such as cystic glandular dilatation, which are
partially reminiscent of hyperplasia, have actually been associated with low mitotic
indices in both endometrial glands and stroma135. In particular, there have been no
reports of premalignant or malignant morphological changes following
administration of PRMs136.
In addition to morphological studies, proliferation may be further assessed by
evaluating the expression of proliferation markers such as Ki-67 and anti-phospho-
histone H3 (PH3). The nuclear antigen Ki-67 is a marker, which may be detected in
all phases of the replicating cell (Gl, S, G2 and M) representing the growth fraction
of a cell population198'199. More recently, it has been described to play a role in
ribosomal RNA synthesis as well as mitosis and may therefore also be expressed in
non-proliferating cells200. The Ki-67 index is less specific than the mitosis-specific
marker PH3, which is only expressed during the actual phase of mitosis (M). When
proliferation of normal endometrium in different phases of the menstrual cycle is
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assessed using various proliferation markers, they all show a high proliferation index
during the proliferative phase with a significant decrease in the secretory phase.
There is a high correlation between the direct mitotic count and the PH3 count whilst
the Ki-67 index shows the same trend but is less specific14.
Further to the effect of PRMs on endometrial proliferation, it is of particular interest
whether there is any potential to increase the risk of carcinogenesis. PTEN
(phosphatase and tensin homologue) is a tumour suppressor gene product, which has
been described as a gatekeeper for initiation of carcinogenesis in the endometrium15.
Loss of PTEN function has been demonstrated to occur as an early event in
endometrial carcinogenesis and has therefore been suggested as a biomarker for
premalignant disease even in histologically normal endometrium16'17. Progesterone
has previously been shown to play an important role in eliminating PTEN-deficient
endometrial cells18, and hence the effect of partial progesterone antagonists such as
the PRMs on PTEN expression is important to evaluate.
A previous study with asoprisnil in cynomolgus monkeys described profound
endometrial atrophy and also a decrease in the endometrial expression of the
proliferation markers Ki-67 and anti-phospho-histone H3 (PH3)195. The objective of
this study was to enhance the morphological studies described in the previous
chapter and investigate in more detail the effects of asoprisnil on endometrial
proliferation markers in humans. Ki-67 and PH3 immunohistochemistry was carried
out in full thickness endometrial biopsies. Additionally, endometrial PTEN
expression was evaluated to assess the carcinogenic potential of asoprisnil.
5.2. Materials & Methods
5.2.1. Immunohistochemistry
5 pm paraffin sections were de-waxed, rehydrated, pressure-cooked for antigen
retrieval and cooled as described in section 2.2.2.1. PTEN immunohistochemistry
was carried out using the Bond-X Immunohistochemistry Staining System as
outlined in section 2.2.2.2.
For Ki-67 and PH3 immunohistochemistry, tissue sections were washed in 0.01M
phosphate buffered saline (PBS) before blocking endogenous peroxidase activity by
immersion in 3% hydrogen peroxide for 10 minutes at room temperature. After a
further wash in PBS, the appropriate protocols were followed for the two
proliferation markers as described below.
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After the final wash with PBST, the protocols for both proliferation markers Ki-67
and PH3 were followed by the addition of the chromagen 3, 3'-diaminobenzidine
(DAB). The reaction was stopped with distilled water when nuclear staining was
detected by inspection under the microscope. Harris's haematoxylin was used for
counterstaining. The sections were then dehydrated and finally mounted with Pertex.
5.2.1.1. Ki-67
Slides were incubated in non-immune horse serum (NHS) in PBS for 20 minutes at
room temperature in order to block non specific binding of the primary antibody. The
primary antibody Ki-67 (1:100 dilution in NHS/PBS) was added and sections
incubated for 30 minutes at 37°C. For the negative controls, the primary antibody
was replaced with non-immune mouse IgGl antibody at a matched antibody
concentration (1:1000). Subsequently, slides were washed in PBS with added
Tween 20 (PBST) before incubating in biotinylated horse anti-mouse antibody for
30 minutes at room temperature. Following another wash in PBST, an avidin-biotin-
peroxidase complex (ABC-HRP) was applied for 30 minutes at room temperature
before the final wash with PBST.
5.2.1.2. PH3
At room temperature, sections were incubated in avidin for 15 minutes, rinsed in
PBS and then incubated in biotin for a further 15 minutes. To block non-specific
binding of the primary antibody, slides were incubated in non-immune goat serum
(NGS) in PBS with 5% bovine serum albumin (BSA) for 20 minutes at room
temperature. The primary antibody anti-phospho-histone H3 (1:1000 dilution in
NGS/PBS/BSA) was added and the slides incubated overnight at room temperature.
For the negative controls, the primary antibody was replaced with non-immune
rabbit antibody IgG at a matched antibody concentration (1:1000). Sections were
washed in PBST before incubating in anti-rabbit envision kit for 30 minutes at room
temperature and washing again with PBST.
5.2.2. Scoring
For assessment of PTEN immunostaining, a histoscore was applied as described in
section 2.2.2.3. A separate histoscore was applied to surface epithelium, glandular
epithelium, stroma, perivascular cells and endothelium, respectively.
Stereological methods were applied and varied for assessment of Ki-67 and PH3,
respectively, as described below.
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5.2.2.1. Ki-67
When the endometrial tissue sections were inspected after immunostaining for Ki-67,
there was an impression of scanty staining in the majority of sections. It therefore
appeared inappropriate to apply any histoscores, and in order to quantify the level of
immunoreactivity, stereological methods were used as previously described201.
The program used was Image-Pro plus 4.5.1 with Stereology-Pro 5.0 plug-in
software in combination with an Olympus BH-2 microscope fitted with a Prior
automatic stage. With the aid of the software, random fields were selected for
counting and grids were placed over the fields at x200 magnification. All 432
intersections of a grid were defined as points, and all points falling over tissue were
counted as one of the following categories: (a) - unstained epithelial cell, (b) -
stained epithelial cell, (c) - unstained stromal cell, (d) - stained stromal cell, (e) -
lumen (i.e. the empty space within glands or vessels). The proportion of tissue
occupied by each of these categories was expressed as a percentage of total points
counted (Figure 5.1.).
A percentage standard error (SE) value of less than 10% was aimed at to determine
the number of fields to be counted. For all but four tissue sections, 10 fields (i.e.
4320 points) were sufficient to obtain a percentage SE of less than 10% for the
categories of unstained cells and lumen. For three of the remaining tissue sections, 50
fields (i.e. 21600 points) and in one case 20 fields (i.e. 8640 points) were counted.
The number of points occupied by stained epithelial or stromal cells was counted in a
total of 50 fields for all tissue sections. According to the statistical formula for
sample size calculations, 50 fields (or 21600 points) are sufficient to detect a
proportion of 0.01% of stained cells assuming a null hypothesis of 0.00001%.
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Therefore, the point count was limited to 50 fields for all tissue sections .
5.2.2.2. PH3
The amount of PH3 immunostaining appeared very scanty indeed on first inspection
of the slides. Therefore, the total number of stained epithelial and stromal cells in all
sections was counted respectively, in order to quantify the positive immunoreactivity
in endometrium. Stereological methods were used to determine and measure the area
of endometrium in each section. The same program as for evaluation of Ki-67
immunostaining was used (Image-Pro plus 4.5.1 with Stereology-Pro 5.0 plug-in
software) in combination with an Olympus BH-2 microscope fitted with a Prior
automatic stage. The cell count was expressed as the number of stained cells per mm2
endometrium.
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Figure 5.1. Method of Ki-67 scoring
Stepwise illustration of the method of point count following
immunostaining of the endometrium for Ki-67 antigen:
A Randomly selected field of microscopic view of
immunostained endometrium at x200 magnification
B Application of a grid with 154 intersections
C Count of all stained epithelial cells overlying an
intersection of the grid (6 yellow points = 3.9%)
D Count of all stained stromal cells overlying an
intersection of the grid (12 green points = 7.8%)
E Count of all unstained epithelial cells overlying an
intersection of the grid (44 dark blue points = 28.6%)
F Count of intersections of the grid overlying glandular
lumen (8 light blue points = 5.2%)
All remaining points are counted as unstained stromal tissue




Each group of asoprisnil treated subjects (10 and 25mg) was compared to a subgroup
of placebo treated subjects who had undergone hysterectomy in the secretory phase
of their menstrual cycle. The Wilcoxon's rank sum test was used for this analysis and
significance was determined at 0.05 level using Hochberg's multiple comparison
procedure.
5.3. Results
Endometrial expression of proliferation markers was low in all asoprisnil treated
subjects as well as in placebo treated subjects in the secretory phase of the menstrual
cycle.
There was high proliferation marker expression in the endometrium of the two
placebo treated subjects who had undergone their hysterectomy in the proliferative
phase.
5.3.1. Proliferation markers Ki-67 and PH3
The trend of the effect of asoprisnil on endometrial proliferation marker expression
was suppressive. When Ki-67 immunostaining was quantified as described above,
the median of grid points occupied by stained cells in endometrial epithelium and
stroma was less than 2% in specimen from both asoprisnil- and placebo-treated
subjects. Administration of asoprisnil led to a statistically significant and dose-
dependent decrease in Ki-67 expression in endometrial stroma (Fig. 5.2.A) compared
to the placebo treated subjects in the secretory phase of their menstrual cycle. The
95% confidence intervals indicated that according to this study, lOmg asoprisnil
reduces the percentage of stromal cells expressing Ki-67 by at least -1.51 and 25mg
asoprisnil by at least -0.83 (Table 5.1.). Ki-67 expression was not statistically
significant different between treatment groups in glandular epithelium (Fig. 5.2.B).
Immunostaining for PH3 showed generally a very low count of stained endometrial
cells in epithelium and stroma of both asoprisnil- and secretory phase placebo-treated
subjects (< 3/mm2). There was no statistically significant difference between














Ki-67 % Total points occupied by stained stromal cells
Mean +/- SD 1.83+/-0.94 0.71 +/-0.44 0.36 +/- 0.36
Minimum - Maximum 0.61 -3.14 0.17-1.35 0.07-1.16
95% Confidence intervals
Mean difference to placebo
N/A -1.73 to-1.51 -2.11 to -0.83
P-valuea N/A 0.012$ <0.01$
PH3 Stained stromal cells per mm2 endometrium
Mean +/- SD 5.77 +/- 8.56 1.58 +/- 0.98 2.32+/- 1.51
Minimum - Maximum 0.97-26.65 0.13-3.35 0.5-4.93
95% Confidence intervals
Mean difference to placebo
N/A -9.12 to +0.76 -8.91 to+2.01
P-valuea N/A 0.057 0.351
Table 5.1. Proliferation marker expression in endometrial stroma
Ki-67 expression is quantified by defining the percentage of total grid
points occupied by stained stromal cells
PH3 expression is determined by counting all stained cells divided by
the area of endometrium
a Each asoprisnil group is compared to placebo using Wilcoxon's rank
sum test
(T
Denotes statistical significance at 0.05 level using Hochberg's
multiple comparison procedure
N/A = not applicable
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Figure 5.2. Ki-67 expression in endometrial stroma and glands
following administration of asoprisnil
A Ki-67 expression in endometrial stroma
B Ki-67 expression in endometrial glands
Ki-67 expression is quantified by percentage of grid
points overlying stained glandular or stromal cells
respectively, following the stereological projection of a
grid over several views of a tissue section;
in the box plots, the box spans between lower and upper
quartiles with the horizontal line within it representing the
median; the whiskers extend to the minimum and
maximum observations; the cross represents the mean;
each asoprisnil group is compared to placebo (secretory
phase) using Wilcoxon's rank sum test;
in stroma, both asoprisnil groups have a statistically
significantly lower expression of Ki-67 than placebo using
Hochberg's multiple comparison procedure at 0.05 level;
in glands, neither difference between an asoprisnil group
and placebo is statistically significant
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Figure 5.3. PH3 expression in endometrial stroma and glands
following administration of asoprisnil
A PH3 expression in endometrial stroma
B PH3 expression in endometrial glands
PH3 expression is quantified as stained glandular or stromal
cells per mm2 endometrium respectively following a count of
all stained cells in the available tissue section and
stereological measurement of the endometrial area;
each asoprisnil group is compared to placebo (secretory
phase) using Wilcoxon's rank sum test;
none of the differences between asoprisnil and placebo
groups is statistically significant
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Figure 5.4. PTEN expression in endometrial stroma and glands
following administration of asoprisnil
A PTEN expression in endometrial stroma
B PTEN expression in endometrial glandular epithelium
PTEN expression is quantified by a histoscore (0 - 300);
each asoprisnil group is compared to placebo (secretory
phase) using Wilcoxon's rank sum test;
none of the differences between asoprisnil and placebo
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Figure 5.5. PTEN immunolocalisation in endometrium
A PTEN immunostaining in endometrium from placebo
group in secretory phase of menstrual cycle
Inset - Negative control
B PTEN immunostaining in endometrium from
treatment group (asoprisnil 25mg)
Scale bar 100pm
(Previously published in:




PTEN immunohistochemistry resulted in a nuclear staining pattern with similar
intensity in glandular epithelium and stroma (Fig. 5.4.). The difference in PTEN
expression between treatment groups was not statistically significantly different in
any of the tissue compartments assessed. The staining intensity was strongest in the
surface epithelium (median histoscores of 125-180) and only weak in endothelium
and perivascular cells (median histoscores of 25-32.5 for perivascular cells and 30-45
for endothelium). In asoprisnil and placebo groups, there were inter-individual
variations independent of the treatment received with some subjects showing very
weak and others quite strong staining. However, there was no significant difference
between treatment groups (Fig. 5.5.).
5.4. Discussion
The results of this study demonstrate that asoprisnil does not induce endometrial
proliferation when administered daily for 12 weeks. A statistically significant
difference in proliferation marker expression indicates an inhibitory effect in the
endometrial stroma. This appears to be independent of ovarian oestrogen production,
which is maintained at early proliferative phase levels in pre-menopausal women
treated with asoprisnil137'142.
Most patients in the placebo group of this study underwent hysterectomy in the
secretory phase of their menstrual cycle. In these patients, endometrial proliferation
marker expression was low in both glandular epithelium and stroma, whilst it was
high in the two cases in which samples had been obtained in the proliferative phase.
This is consistent with previous reports14. The low levels of proliferation marker
expression in endometrium after 12 weeks of treatment with asoprisnil were
comparable to samples from a secretory cycle phase. There was no statistically
significant difference in PH3 expression between treatment groups, which is a likely
reflection of the overall very scanty immunostaining. Expression of the less specific
marker Ki-67 in endometrial epithelium was also not significantly different in the
asoprisnil treated groups compared to the placebo treated group in the secretory
phase. However, the finding of significantly decreased Ki-67 expression in the
stroma of asoprisnil treated patients indicated a dose-dependent inhibitory effect on
proliferation. There was no evidence of altered endometrial PTEN expression and
specifically no suppression by administration of asoprisnil.
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The effect of suppressed or unchanged proliferation marker expression after
treatment with asoprisnil is consistent with the morphological findings described in
the previous chapter and in previous trials. Endometrial hyperplasia or other
appearances suggestive of an unopposed oestrogen effect have not been described
with asoprisnil. Various doses of asoprisnil (5mg once daily to 50mg twice daily)
have been administered to healthy premenopausal women for 28 days in one trial137
and doses of 5, 10 or 25mg to women with uterine fibroids for 12 weeks in another
study142. In both studies, Pipelle® endometrial biopsies were obtained following
treatment with no findings of endometrial hyperplasia or cytological atypia. Distinct
and unique morphological changes were noted reflecting the mixed progesterone
agonistic/antagonistic properties of asoprisnil in the human endometrium but no
overtly suspicious features. In this study, full thickness endometrial samples were
obtained and examined with similar findings as previously described.
The effect of asoprisnil on proliferation marker expression has previously been
studied in adult cynomolgus monkeys195. In a 39-week toxicity study in cynomolgus
monkeys, the endometrium appeared morphologically atrophic with suppressed
gland proliferation and stromal compaction. Some glands appeared dilated and cystic
in the absence of any hyperplastic features129. However, contrary to the findings in
the human, this study neither showed secretory changes in endometrial glands nor
thickening of the wall of spiral arterioles. Studies in non-human primate models have
been crucial in the discovery and development of SPRMs and have provided
valuable insight into their possible mechanisms of action132. A distinct morphological
response consistent with an antiproliferative effect has been seen in endometrium
from monkeys as well as humans following exposure to SPRMs191. However,
important differences between monkeys and humans have been highlighted
indicating the need for caution when extrapolating results from non-human primate
studies to the human. A different steroid receptor pharmacology of monkey and
human endometrium may account for these discrepancies132. The balance between
agonist and antagonist effect of asoprisnil may possibly be in favour of the agonist
side in humans due to species differences in metabolic end products or due to
species-specific cellular environments creating a different balance of co-activator and
co-repressor expressions203. Specifically the findings of secretory endometrial gland
changes and formation of thick-walled endometrial spiral arteries following
treatment with asoprisnil in the human were unique and have not been observed in
the monkeys. However, suppression of proliferation marker expression following
asoprisnil exposure has been demonstrated in both human and non-human
endometrium. Endometrial Ki-67 and PH3 expression was suppressed in cynomolgus
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monkeys treated with 10, 30 or 90mg/kg asoprisnil for 90 days. The suppression was
significant when compared to samples from the placebo group in the proliferative
cycle phase195. Concordant with the findings in this study, there was no significant
difference between asoprisnil treated monkeys and monkeys in the secretory cycle
phase. In the monkey studies, there was no differentiation into separate tissue
compartments (stroma and epithelium), whilst this study showed human Ki-67
expression to be significantly suppressed in endometrial stroma but not in the
epithelium after 3 months asoprisnil treatment.
Ultimately, to assure safety of long-term administration of asoprisnil and other
SPRMs, evidence is required that they do not induce endometrial carcinogenesis. The
most common form of endometrial cancer is the endometrioid endometrial
adenocarcinoma, which is specifically associated with the risk factor of exposure to
unopposed oestrogen. In this type of cancer, the PTEN tumour suppressor gene is
inactivated in up to 83%15. Both PTEN mutations and deletions are frequently found
and have also been identified in precancerous endometrial tissue with endometrial
intraepithelial neoplasia16. Decreased endometrial PTEN expression may indicate
carcinogenic potential even in the absence of any histological changes. PTEN
expression may be altered by exogenous hormones. This was demonstrated, when a
group of peri- or postmenopausal women with endometrial hyperplasia, as seen in an
endometrial biopsy, were treated with a progestin-impregnated intrauterine system
(IUS), cyclic oral progestins or kept under surveillance only. Endometrial biopsies
were repeated after three months, and the proportion of samples with absence of
PTEN expression significantly declined in the group treated with the IUS. Hence,
high doses of locally administered progestins appear to ablate latent endometrial
precancers18. Systemic administration of progestins has also been shown to increase
PTEN expression and induce the involution of precancerous endometrial lesions204.
Consequently, a compound with partial progesterone antagonist activity may raise
the concern of an unfavourable effect on PTEN expression and therefore on the
potential to influence the predisposition to latent endometrial precancerous lesions.
This was the reason to investigate the effect of asoprisnil on endometrial PTEN
expression in this study, which found that PTEN expression remained unaltered after
12 weeks of treatment. This finding further supports the conclusion that the effect of
asoprisnil on endometrium is antiproliferative and does not increase the risk of
carcinogenesis. Morphologically, the endometrial glands may occasionally become
cystically dilated in response to administration of asoprisnil. Low mitotic indices
within these glands have already indicated that they are not associated with
endometrial hyperplasia. This is further affirmed by the findings of low Ki-67 and
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PH3 expression. In addition, maintained PTEN expression assures that the distinct
morphological changes seen with SPRMs are not a feature to raise concerns about
carcinogenic potential and are not pre-malignant.
It still has not been fully elucidated how the endometrial antiproliferative effect of
SPRMs is mediated. The endometrial vasculature has been suggested as a principal
target and particularly the spiral arteries131. The perivascular cells may have a pivotal
role in mediating the effects on these vessels132. This hypothesis appears to be
supported by the striking effect of asoprisnil on the formation of thick-walled spiral
arterioles in humans. However, the absence of similar morphological vascular
changes in non-human primate models suggests there may be another pathway. More
recently the role of the endometrial androgen receptor (AR) has been emphasized as
a potential mechanism of the endometrial antiproliferative effect123'205.
5.4.1. Limitations of the study
Due to the overall very low prolilferation marker expression, all endometrial samples
had to be assessed in some detail for quantification. Endometrial PH3 expression was
particularly scanty, and the sample size in this study was possibly too small to
demonstrate a significant effect as indicated by the wide confidence interval (Table
5.1.) Sample size was determined by the power calculation for the primary endpoint
of the clinical study and therefore fixed for any further variables of investigation.
The study into proliferation marker expression described in this chapter may be
particularly limited by a lack of power as the expected differences would be very
small. Even though the findings in this study appear reassuring regarding
endometrial safety with administration of asoprisnil, no conclusions may be drawn
regarding the effects of prolonged exposure beyond the duration of 12 weeks.
5.5. Conclusion
The results of this study have demonstrated that the endometrial antiproliferative
effect of asoprisnil, which has previously been described morphologically, is
accompanied by low proliferation marker expression. Expression of Ki-67 in
endometrial stroma was significantly suppressed compared to placebo controls in the
secretory menstrual cycle phase. Furthermore, this study showed that endometrial
PTEN expression remains unchanged during asoprisnil treatment. Asoprisnil







Sex steroids (oestrogen (E), progesterone (P), androgens and glucocorticoids)
regulate reproductive functions, such as implantation and, in the absence of
pregnancy, menstruation and endometrial repair. The effects of these steroid
hormones are mediated via their respective nuclear receptors, and the role of various
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co-regulators has also been highlighted . In human endometrium, it is well
recognized that the spatio-temporal distribution of steroid receptors varies depending
on the stage of the menstrual cycle19.
Two forms of ligand-specific oestrogen receptors (ER) have been identified, ERa
and ERp. ERa appears to be the dominant isoform and is essential for normal uterine
function89. ERa is also responsible for mediating the proliferative effect of E on
endometrium49. Immunohistochemical studies in endometrium have demonstrated
the expression of ERa within the nuclei of both glandular and stromal cells in the
proliferative phase of the menstrual cycle. In the secretory phase, ERa declines in
the functional layer of the endometrium but expression persists in the basal layer206.
The second ER isoform, ERp, has been discovered more recently207. Unlike ERa,
ERp is also expressed in the endometrial vascular endothelium, even though both
isoforms are expressed in perivascular cells29. ERP appears overall less abundant
than ERa but is present throughout the menstrual cycle with a decline in only the
glandular epithelium of the functional layer during the late secretory phase29. Whilst
the exact role of ERp still remains to be elucidated and may well involve some
antagonistic action to ERa, its presence within the vasculature suggests it may
mediate the effects of sex steroids on vascular remodelling30.
The progesterone receptor (PR) has also been differentiated into subtypes. The two
main isoforms, PR-A and PR-B, arise from a single gene. PR-A is the shorter
subtype, which is devoid of 164 amino acids present at the N-terminus of PR-B. It is
otherwise identical to PR-B but functionally distinct19. Studies in PR-A and PR-B
knockout mice (PRAKO and PRBKO) have suggested PR-A to play a crucial role in
decidualization. It is the dominant isoform in endometrial stroma and is required to
oppose E-induced proliferation89. Immunohistochemical studies using antibodies,
which recognize both subtypes, have demonstrated a peak in expression of PR in the
late proliferative and early secretory cycle with a subsequent decline within the
glandular epithelium, whilst stromal expression remains constant56. When a specific
antibody to PR-B is used to differentiate the subtype expression, it appears that in the
secretory phase, both subtypes are dramatically reduced in the glands and only PR-A
is expressed in the stroma64.
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The endometrium is also a target tissue for androgens, which suppress E-dependent
proliferation. In normal, cycling endometrium, the androgen receptor (AR) is only
very weakly expressed in the glandular cells and is mainly localized in the stroma. It
appears to be most abundant in the early proliferative phase with a subsequent
decrease, particularly in the basal layer24. The expression of the glucocorticoid
receptor (GR) in the endometrium has not been as widely studied, and the exact role
remains to be determined. However, whilst it appears to be absent from glandular
epithelium, strong GR expression has been demonstrated in the stroma and also in
the endothelium. GR is present in those tissue compartments throughout the
menstrual cycle and particularly in the proliferative phase22.
The last three decades have seen the development of synthetic PR ligands, which do
not have purely agonistic activity. First developed was mifepristone in 198 1 99'101'104
followed by several other progesterone antagonists (PAs)208. More recently, a new
class of PR ligands has been discovered exerting clinically relevant tissue-selective
progesterone agonist, antagonist, partial or mixed agonist/antagonist effects on
various target tissues depending on the biological action studied139. Within this class
of selective progesterone receptor modulators (SPRMs), asoprisnil is the compound,
which has undergone most pre-clinical and clinical evaluation. Its effects have been
studied in women with symptomatic uterine fibroids141 and endometriosis139 as well
as in healthy menstruating women137. The clinical effects of profound suppression of
uterine bleeding in the presence of follicular phase E concentrations141 and the
distinct histomorphological changes of the endometrium with aggregations of
unusually thick-walled spiral arterioles135 have been described in previous chapters.
Clinical evaluation was preceded by studies in Old World monkeys. The first
evidence of the direct endometrial antiproliferative effects of asoprisnil was derived
from studies in cynomolgus monkeys131. Further assessments during the
developments of asoprisnil and other SPRMs have been performed in cynomolgus
and rhesus macaques due to their similarities to humans with respect to hormonal
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regulation and morphological changes during the menstrual cycle . Studies in these
non-human primates have played a key role in the discovery and evaluation of
SPRMs132, even though important differences between non-human primate and
human endometrial responses have also been observed, possibly due to variances in
steroid receptor pharmacology and a different balance of co-activator and co-
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repressor expressions .
The effect of PAs on endometrial steroid receptor expression has been studied in
rhesus macaques, where a striking up-regulation in ER, PR and AR in glands and
stroma has been demonstrated209. Notable was the increase in ER, whilst
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morphologically there was a clear inhibition of endometrial cell proliferation and
growth. The glandular AR signal, usually only very weak in endometrial glands, was
significantly enhanced by treatment with mifepristone, and stromal AR expression
was also increased. This phenomenon has been confirmed in human endometrium
with administration of the PA mifepristone210. The up-regulation of AR in
endometrium exposed to mifepristone appears consistent in non-human primates and
humans. A clinical study with daily low-dose mifepristone for 120 d showed a
significant down-regulation of PR in both glandular epithelium and stroma after 60
and 120 d. ER expression was unchanged in surface epithelium and stroma and
decreased in glands after 120 d, even though not significantly194. Low-dose
mifepristone has also been shown to significantly up-regulate glandular GR
expression in humans, when GR is usually localized specifically in endometrial
stroma21'. The aim of this study was to examine how asoprisnil modulates sex steroid
receptor expression in human endometrium.
6.2. Materials & Methods
The methods of tissue collection, immunohistochemistry, quantitative reverse
transcription-polymerase chain reaction (RT-PCR) and statistical analysis are all as
described in chapter 2. Specifically examined were the endometrial expression of
ERa, PR, AR, ERp and GR. For the analysis of immunoexpression, a histoscore was
applied as described in section 2.2.2.3144. In addition to the mRNA expression of the
steroid receptors, the sex steroid co-regulators N-CoR, SRC-1, SRC-2 and SRC-3






Table 6.1. Primer and probes of sex steroid receptor co-regulators for




6.3.1. Immunoexpression of ERa, PR, AR, ER{3 and GR
Endometrial ERa expression was significantly increased in both stroma and
epithelium (Figures 6.1.A and 6.2.).
Endometrial PR expression was significantly down-regulated in the stroma following
administration of 25mg asoprisnil with a lower 95% confidence limit of -27.7
compared to placebo/secretory. It was also suppressed in the perivascular cells by
both doses of the drug compared to placebo. Conversely, PR expression was
significantly up-regulated in both surface and glandular epithelium (CI 100-263 for
lOmg asoprisnil and 100-269 for 25mg asoprisnil compared to placebo) (Figures
6.1.B and 6.3. / Table 6.2.).
There was significant up-regulation of AR expression in endometrial stroma, whilst
the increase in the surface epithelium was only significant after 25mg asoprisnil. AR
expression was not significantly altered in glandular epithelium (Figures 6.1.C and
6.4.).
Endometrial perivascular cells did not express ERa or AR, and endothelial cells did
not express ERa, PR or AR. This pattern of sex steroid receptor expression did not
change following exposure to asoprisnil. ERp expression was significantly
suppressed in the stroma by lOmg asoprisnil, whilst unaffected in other tissue
compartments (Figures 6.1.D and 6.5.). The only effect of asoprisnil on GR
expression was seen in endothelium with slight elevation after lOmg asoprisnil
(Figure 6.6.).
6.3.2. Expression of nuclear steroid receptor and co-regulator mRNA
There was a statistically significant up-regulation of endometrial PR mRNA
expression in both asoprisnil groups compared to placebo / secretory phase. The
amount of PR mRNA normalized to the endogenous reference and relative to the
placebo/secretory phase was 8.1 for the asoprisnil 10 mg group and 16.2 for the
asoprisnil 25 mg group. There was also a trend for up-regulation of ERa and AR
mRNA, although the differences between the placebo/secretory and asoprisnil groups
only approached statistical significance. A statistically significant up-regulation in
GR mRNA was seen only in the asoprisnil 25 mg group compared to
placebo/secretory subjects. No statistically significant difference was observed for
















Mean +/- SD 36.3 +/- 75.25 218.2+/- 95.4 0.36 +/- 0.36








P-valuea N/A <0.001$ <0.001$
STROMA
Mean +/- SD 104.4+/-55.45 62.1 +/-49.56 31.8+/-38.55




N/A -89.4 to +5.1 -117.5 to
-27.7
P-valuea N/A 0.085 0.002$
Table 6.2. Endometrial progesterone receptor expression
Progesterone receptor expression is quantified by applying a
histoscore
a Each asoprisnil group is compared to placebo using Wilcoxon's rank
sum test
<r
Denotes statistical significance at 0.05 level using Hochberg's
multiple comparison procedure
N/A = not applicable
153
Figure 6.1. Endometrial expression of sex steroid receptors
Endometrial expression of sex steroid receptors following
administration of asoprisnil compared to placebo / secretory
phase as assessed by applying a histoscore to surface
epithelium, glands and stroma respectively;
the three treatment groups were compared by performing the
Wilcoxon's rank sum test and significance determined at
0.05 level using Hochberg's multiple comparison procedure;
significance is indicated by * = P<0.05, ** = PO.Ol and
*** = p<0 ooi
A Endometrial ERa expression
B Endometrial PR expression
C Endometrial AR expression
D Endometrial ERJ3 expression
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Endometrial ERu expression
□ Placebo/Secretory * = P <0.05
■ Asoprisnal 10mg " = P <0.01





































Figure 6.2. Immunohistochemical expression of ERa
A Strong immunohistochemical expression of ERa in
endometrial surface epithelium, glands and stroma
following administration of asoprisnil 25mg
B Endometrial immunohistochemical expression of




Figure 6.3. Immunohistochemical expression of PR
A Strong immunohistochemical expression of PR in
endometrial glandular epithelium but only scarce
expression in the stroma and notably in the
perivascular cells (arrows) following administration
of asoprisnil 25mg
B Endometrial immunohistochemical expression of PR
predominantly in the stroma and present in
perivascular cells (arrows) following administration
of placebo (secretory phase)
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Figure 6.4. Immunohistochemical expression of AR
A Strong immunohistochemical expression of AR in
endometrial stroma following administration of
asoprisnil 25mg
B Endometrial immunohistochemical expression of AR
following administration of placebo (secretory phase)
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Figure 6.5. Immunohistochemical expression of ERP
A Endometrial immunohistochemical expression of
ERP following administration of asoprisnil 25mg
B Endometrial immunohistochemical expression of




Figure 6.6. Immunohistochemical expression of GR
A Endometrial immunohistochemical expression of GR
following administration of asoprisnil 25mg
B Endometrial immunohistochemical expression of GR
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Administration of asoprisnil significantly modulates human endometrial sex steroid
receptor expression in both epithelium and stroma. In this study, there was clearly a
differential effect on endometrial epithelium and stroma following administration of
asoprisnil for 12 weeks. Whilst ERa expression was up-regulated in both epithelial
and stromal compartments, PR expression was increased in the glands but suppressed
in the stroma. Notably, there was also a down-regulation of PR in the perivascular
cells. AR expression was considerably elevated in the stroma with a slight increase in
surface epithelium, but no significant effect was observed in the epithelial glands.
The effect of asoprisnil on endometrial sex steroid receptor expression has previously
been studied in cycling cynomolgus monkeys195. They were administered either
saline or vehicle as controls or one of three doses of asoprisnil (10, 30 or 90mg/kg
orally) daily for 90 days. Endometrial immunoexpression of ERa, PR and AR was
assessed in full thickness samples. Whilst no significant effect on glandular
epithelium could be demonstrated, there was significant down-regulation of PR and
up-regulation of AR in the stroma. Stromal ERa expression was suppressed.
As in the studies with PAs194'209, there are notable differences between the responses
of human and non-human primate endometrium to administration of asoprisnil. Both
species show a differential effect on epithelium and stroma. Stromal down-regulation
of PR and up-regulation of AR is consistently found in both species. However, whilst
ERa stromal expression is suppressed in the cynomolgus monkey, it is increased in
the human. Epithelial expression of any sex steroid receptors was not significantly
altered in the non-human primate, but both glandular ERa and PR were up-regulated
in this study.
Non-human primate models have provided valuable insight into the possible
mechanism of action of SPRMs132, but variances in the responses between the non-
human primate and the human endometrium have previously been highlighted. It is
possible that the balance between agonist and antagonist properties of asoprisnil,
influenced by the species-specific expression of co-regulators, is in favour of an
agonist effect in humans203. This may account for the discrepancies between the
human and cynomolgus monkeys.
The response in sex steroid receptor expression to the SPRM asoprisnil is different
from the response to PAs in both human and non-human primate endometrium. A
study in rhesus macaques showed a striking up-regulation in ER, PR and AR in
glands and stroma by PAs209. In contrast, both ER and PR were down-regulated in
the endometrial stroma by asoprisnil in the monkey. In humans, daily low-dose
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mifepristone (5mg) administered continuously for 120 d has been demonstrated to
down-regulate PR expression in both glandular epithelium and stroma, whilst ERa
remains essentially unaltered except for a slight decrease in glandular epithelial
expression194. Interestingly, the effect of a single higher dose of mifepristone
(200 - 400mg) given in the luteal phase has been shown to have a different effect
with up-regulation of both ER and PR in stroma as well as epithelium, similar to the
findings in the rhesus macaque212. These observations highlight the importance of the
duration of the exposure and the dose of administered compounds when evaluating
effects on sex steroid receptor expression. The acute effect may differ from the
observed changes following administration over a longer period. The endometrial
response to asoprisnil administered for 12 weeks, however, did not resemble the
response to either acute or chronic exposure to mifepristone. As shown in this study,
asoprisnil suppressed stromal PR expression but significantly increased PR in the
glands. As opposed to the equivocal effect of low-dose mifepristone on ERa,
asoprisnil has been demonstrated to significantly up-regulate its expression in both
stroma and epithelium.
The effect of mifepristone on sex steroid receptor expression appears to be similar in
endometrial stroma and epithelium in both non-human primates and humans. This
study has demonstrated that the endometrial response to asoprisnil is differentially
modulated in various tissue compartments. This is particularly notable regarding the
effect on PR expression in human endometrium, where both down-regulation in the
stroma by 25mg asoprisnil and up-regulation in the epithelium are statistically
significant compared to placebo following administration of the drug for 12 weeks.
This differential effect on steroid receptor expression highlights the novel effect of
asoprisnil on endometrium. Similar to the changes in endometrial morphology
following administration of asoprisnil, which had not previously been described135,
the effect on sex steroid receptor and particularly PR expression appears to be unique
to this SPRM. The exact significance of these modulations of sex steroid receptor
expressions and the mechanism of action remain to be elucidated.
Consistently in non-human primates and in humans, both PAs and asoprisnil have
been shown to up-regulate endometrial AR expression. This up-regulation is
particularly striking in the stroma but notably also seen in the epithelium, where AR
is usually only very weakly expressed. As the initially unexpected suppressive effect
of PAs and SPRMs on endometrial proliferation resembles the atrophic effect
induced by androgens, a role for the AR in the mechanism of action of PAs and
SPRMs has previously been suggested205. The finding that treatment with the anti-
androgen flutamide counteracts the antiproliferative effect of PAs in the primate
168
endometrium has confounded this hypothesis123'213. There is evidence that
E-dependent growth factors essential for glandular mitosis and arterial growth are
produced in the stroma214, which may be suppressed by the increased AR expression.
PAs have been proposed to block glandular cell mitosis by modulating E-dependent
stromal-epithelial interactions via up-regulation of AR. A similar pathway may
mediate suppression of vascular growth causing arterial degeneration and
consequently atrophy and reduced endometrial blood flow. Whilst in normal
endometrium, the effect of androgens on glands or vascular structures would be
mediated indirectly through stromal AR, it is also possible that administration of PAs
or SPRMs allows a direct effect through the up-regulation of epithelial AR
205
expression .
There is some evidence that the primary targets, mediating the effects of PAs and
131SPRMs on primate endometrium, are the spiral arteries . Indeed, morphological
studies have found striking changes in the endometrial vasculature following
administration of asoprisnil. Prominent aggregations of unusually thick-walled
muscular spiral arterioles have been described, which do not feature in untreated
endometrium135. In this context, it is notable that asoprisnil appears to suppress PR
expression not only in the endometrial stroma but specifically in the perivascular
cells. Previous studies in PR null mice have demonstrated evidence for a direct role
of the PR in the regulation of the response to vascular injury and vascular smooth
muscle cell proliferation. In vivo studies in the mice have suggested that the PR
exerts an antiproliferative effect in vascular smooth muscle cells215. Modulation of
PR expression in the perivascular cells by asoprisnil may mediate the effect on the
vasculature and consequently its antiproliferative effect on endometrium. The
findings of down-regulated PR expression in perivascular cells in this study and the
previously described thickened spiral arterioles135 appear consistent with the findings
91 S
of the studies in the mice and may provide insight into the role of PR in
endometrial vascular remodelling and the mechanism of action of asoprisnil.
6.4.1. Limitations of the study
Despite the relatively small sample size, the confidence intervals for the mean
differences of PR expression in glands after administration of asoprisnil compared to
placebo, indicate a good reliability. Nevertheless, it would be appropriate to further
confound these results with a study in a larger group of patients receiving asoprisnil
for an extended period. Sex steroid receptor expression appears to be influenced
significantly by the type, the dose and the duration of the compound administered,
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and previous studies with mifepristone have yielded conflicting results depending on
the study design. Prior to drawing firm conclusions, the reproducibility of the
findings in this study would therefore need to be demonstrated. It is also possible that
the response of the endometrial sex steroiod receptors to asoprisnil is modified by the
presence of uterine fibroids in this cohort of patients.
6.5. Conclusion
We have demonstrated that asoprisnil has a significant effect on sex steroid receptor
expression in human endometrium. Notably, asoprisnil exerts a differential effect in
endometrial stroma and epithelium. This is most significant for the expression of PR,
which is up-regulated in the glands by asoprisnil and down-regulated in the stroma.
Interestingly, we have also shown a suppression of PR in the perivascular cells,
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The data on microarray analysis described within this chapter have previously been
summarized in the Final Report for TAP Pharmaceutical Products Inc entitled "A
pharmacogenomic study on endometrium from subjects with uterine leiomyomata
scheduled for hysterectomy following three month treatment with asoprisnil or
placebo control" prepared by Mr Thorsten Forster, Mr Petter Storm, Mr Gary Rubin,
Mr Tom Freeman and Professor Peter Ghazal from the Division of Pathway
Medicine at the University of Edinburgh in October 2007. Figures 7.1. and 7.2. as
well as Table 7.2. have been derived from this report.
The author was personally involved in the extraction of high quality RNA from
endometrial samples collected at the time of hysterectomy from women in the
clinical trial. With technical assistance from Ms Pamela Comes, RNA was extracted
and quality checks carried out until a sample of sufficient quantity and quality was
available from each patient. This material was then passed onto the team in the
Division of Pathway Medicine for microarray analysis.
7.1. Introduction
The most striking clinical effect of PRMs has been a profound suppression of uterine
bleeding. The associated antiproliferative effect on the endometrium has been quite
unexpected in a class of compounds with P antagonistic properties, and the
mechanism of action still remains to be elucidated. A possible role for the AR has
been described ' , but it has also been hypothesized that clinical and
morphological effects of PRMs are mediated via the endometrial vasculature103'131.
As outlined in chapter 4, asoprisnil leads to a characteristic morphological pattern in
the endometrium, which has been termed "non-physiologic secretory effect". This
unique pattern is defined in part by distinct vascular changes consisting of increased
aggregates of thin-walled vessels but even more notably clusters of unusually thick-
walled muscularized spiral arterioles. These prominent aggregations of thickened
arterioles appear to occur exclusively in the endometrium. PR, the receptor asoprisnil
ligates to, is normally abundantly expressed in endometrial stroma and notably in the
29 30
perivascular cells ' . If asoprisnil exerts its effects primarily via the endometrial
vasculature, these characteristic vascular clusters may be a morphological indicator
of this mechanism of action.
Over the last decade, microarray technology has been developed216 and used to study
endometrial function on a genomic level. A wide range of microarrays are
commercially available and may be divided into the two categories of cDNA arrays
917
and high-density oligonucleotide microarrays with the latter providing a higher
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degree of hybridisation specificity. This technology has enabled the analysis of
expression of thousands of different genes at the same time, even though results
should be validated using a different technique such as Q-RT-PCR or in situ
hybridization. Microarray analysis has been applied to evaluate the normal function
and cyclicity of endometrium, in particular with regards to endometrial receptivity
during the window of implantation218. By studying the genetic events underlying the
function of the normal endometrium, it has been envisaged that further insight might
be gained into the processes leading to malfunction, and hence strategies for
managing pathological conditions may be developed219. With this technology,
endometrial tissue has been analysed in the different phases of the natural menstrual
cycle220 but also in response to hormones221 and in pathological conditions such as
endometriosis, uterine fibroids222 and endometrial cancer. Specific efforts have been
made to define the determinants of the receptive endometrium in order to facilitate
infertility treatments. It has been in this context that the genetic response to the PA
mifepristone, known to render the endometrium unreceptive, has previously been
assessed223'224.
The objective of this present study was to evaluate the effects of asoprisnil compared
to placebo in patients with uterine fibroids in order to provide further insight into the
potential mechanism of action. In particular, the hypothesis of asoprisnil exerting its
effects via the endometrial vasculature was to be further explored. For the purpose of
elucidating the mechanism of action, microarray technology using an Affymetrix
high-density oligonucleotide microarray was applied to study the endometrial gene
expression profiles of asoprisnil-treated versus placebo-treated patients. Further to
the results of the microarray analysis, Q-RT-PCR and immunohistochemistry were
also performed for validation of relevant targets.
7.2. Material & Methods
7.2.1. RNA extraction & quality assessment
Endometrial RNA was extracted as described in section 2.2.3. Prior to microarray
hybridisation, the quality and integrity of each RNA sample was checked with the
Agilent 2100 Bioanalyser. Approximately 500ng of total RNA was added to an RNA
Nano 6000 Biochip and run according to manufacturer's instructions. This analyser
provides a very sensitive qualitative analysis using a fluorescent assay, which
involves electrophoretic separation for qualitative evaluation of RNA samples. As
the RNA is pulsed through a microchannel over time, the amount of fluorescence is
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measured and an electropherogram created by the Bioanalyser software. An RNA
quality score is generated (RNA Integrity Number (RIN)). Usually, the 5s, 18s and
28s ribosomal RNA species generate three peaks in an electropherogram. With RNA
degradation, these peaks become lower and background peaks appear in between.
The RIN software algorithm classifies eukaryotic total RNA and determines a RIN
between 1 and 10, with 1 labelling the most degraded profile (Figure 7.1.) Only
samples with a RIN > 8.5 were accepted for further analysis. Prior to full array
analysis, the RNA was further subjected to the Affymetrix Test3 Array, in order to
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Figure 7.1. Electropherograms of RNA in different stages of degradation
High quality RNA with a high RIN of 10 generates three clear peaks
in the electropherogram (5s, 18S, 28S), whilst these peaks become
gradually less distinct and eventually absent depending on the stage of
RNA degradation
(Derived from:
Final Report for TAP Pharmaceutical Products Inc by Forster et al,
University of Edinburgh 2007)
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The array platform employed was Affymetrix Human Genome U133 plus 2.0,
fhttp:/7vvww.affvmctrix.com/suDnort/technical/datasheets/hunianl. a whole human
genome expression array. This GeneChip Hybridization Array covers over 47,000
transcripts and variants, including 38,500 well-characterised human genes. It
therefore offers comprehensive analysis of the transcribed human genome on a single
array. It contains over 54,000 probes sets and 1,300,000 distinct oligonucleotide
features, and multiple independent measurements were taken for each transcript.
7.2.3. Data processing
A standard Robust-Multiarray-Average (RMA) model was applied for between-array
normalisation of microarray data. The resulting expression values were processed
according to the following approaches:
7.2.3.1. Non-specific filtering
All genes were removed which never exceeded the detection threshold or never
varied in expression across all samples.
7.2.3.2. Statistical hypothesis testing
For statistical analysis, a basic cell means model was applied for each gene probe
signal to extract contrasts between either dose of asoprisnil (10 or 25mg) and
placebo. The model was enhanced by empirical Bayes shrinkage of standard errors of
genes, and significance estimates were corrected for multiple testing by the
Benjamini & Yekutieli method. The genes with a high differential expression
(>5-fold) between placebo and asoprisnil lOmg and / or 25mg were identified.
7.2.3.3. Pathway analysis
Differentially expressed genes with an absolute fold change of >5 and a significant
corrected p-value <0.05 were subjected to Gene Ontology Enrichment analysis to
determine associations with biological functions and/or diseases. DAVID
(www.david.abcc.ncifcrf.gov), KEGG (www.genome.jp/kegg/pathway) and 1PA
(Ingenuity Inc, USA) knowledge databases and software tools were employed
applying hyper-geometric test of significance for pathway membership. The genes
were mapped to networks connecting different genes and proteins based on a range
of interactions described in the literature. Additionally, Pearson correlation network
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analysis of co-regulated genes explored how differentially regulated genes were
correlated and how their concerted alteration may have an impact on biological
functions.
7.2.3.4. Network clustering
Novel 3D network visualisation tools (Biolayout) enable the construction of large
networks with co-expressed genes forming highly connected cliques. Hierarchical
and network-based clustering algorithms are used to cluster the genes according to
their expression profiles. Cohorts of genes are then identified with potentially related
functionality.
7.2.4. Validation of gene targets
The effects of asoprisnil on certain gene targets, as indicated by analysis of the
microarray data, were validated by taq-man Q-RT-PCR and immunohistochemistry.
The genes investigated were IL-15 and CD56. As decribed below, asoprisnil
appeared to have a significant effect on the expression of genes within the network
associated with endometrial immune cell function. The NK cell recruiter IL-15 is
central to this network and closely related to the regulation ofNK cell marker CD56.
7.2.4.1. Q-RT-PCR
As described in section 2.2.3, taq-man Q-RT-PCR was applied for assessment of
endometrial IL-15 and CD56 expression after administration of asoprisnil compared
to placebo. For statistical analysis, ACT values were calculated as outlined in section
2.3.3. These were subsequently analysed by one-way ANOVA with Kruskal-Wallis
testing and Dunn's multiple comparisons.
7.2.4.2. Immunohistochemistry
Immunohistochemistry was carried out for CD56, as described in section 2.2.2. Data




28 endometrial RNA samples were of suitably high quality (RIN >8.5; Mean RIN
9.35) to be forwarded for microarray studies. Of these, six were from placebo-treated
patients, whilst 11 and 10 were from the asoprisnil lOmg and 25mg groups,
respectively.
The step of non-specific filtering resulted in 26111 of 54675 probes on the chip to
remain in the analysis set. Further analysis showed that 245 genes were significantly
(p<0.05 after multiple testing correction) up- or down-regulated 5-fold or greater in
either or both treatment groups compared to placebo. Twice as many genes were
down-regulated (166 genes) than up-regulated (79 genes). Notably down-regulated
were genes associated with immune cell function including IL-15, IL-2R and
granulysin, a uterine NK cell marker. The down-regulation of many genes including
IL-15, IL-2R and granulysin was dose-dependent. 25mg asoprisnil had a more
significant effect than the lower dose of lOmg (Table 7.1.).
Asoprisnil lOmg Asoprisnil 25mg Significant
for both doses
5+ fold up from 30 68 19
placebo
5+ fold down from 88 162 84
placebo
Total number of genes 118 230 103
up- or down-regulated
Table 7.1. Differential endometrial gene expression following treatment
with asoprisnil
Number of endometrial genes with statistically significant 5-fold up-
or down-regulation compared to placebo using a p-value level of 0.05;
twice as many genes are down-regulated as were up-regulated; the
alteration in gene expression appears dose-dependent with a higher
number of genes up- or down-regulated after the higher dose of 25mg
asoprisnil
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The analysis of differentially expressed genes for association with biological
functions generated 8 significant networks (Table 7.2). Of all possible effects on the
human genome, asoprisnil appeared to particularly alter the gene expression of
networks associated with immune cell function. Most notable was the down-
regulation of IL-15, a well-known NK-cell recruiter central to the combined
networks 1 and 3 with a significant function related to the immune system (Figure
7.2.). 3D network-base clustering of the data identified several clusters of co-
expressed genes, which were all down-regulated by asoprisnil. Within these clusters
was a significant over-representation of genes involved in immune response, cell
death and apoptosis.
7.3.2. Q-RT-PCR
Subsequent to the results of the microarray analysis, Q-RT-PCR was performed on
endometrial tissue samples to evaluate the effects of asoprisnil on IL-15 and the uNK
cell marker CD56. IL-15 mRNA expression was statistically significantly down-
regulated by 25mg asoprisnil compared to placebo / secretory samples (Figure 7.3.).
No significant difference in endometrial mRNA expression of CD56 was
demonstrated between asoprisnil- and placebo-treated samples.
7.3.3. Immunohistochemistry
Immunohistochemistry demonstrated that endometrial expression of CD56 was
statistically significantly down-regulated by 10 and 25mg of asoprisnil in the stromal
compartment compared to placebo / secretory samples with confidence limits of-90
to -32 for lOmg asoprisnil and -94 to -33 for 25mg asoprisnil (Table 7.3.). CD56
positive cells are normally detected in the stroma of secretory endometrium, but
immunoexpression was absent following treatment with asoprisnil (Figure 7.4.).
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Table 7.2. Network analysis
Using network analysis, eight different networks were
created, within which genes were significantly altered by
asoprisnil; mostly affected are genes related to immune cell
function;
most genes were down-regulated (green) and some were up-
regulated (red); notably down-regulated were the uterine NK
cell recruiter IL-15, IL-2R and the uterine NK cell marker
granulysin (GNLY)
(Derived from:
Final Report for TAP Pharmaceutical Products Inc
by Forster et al, University of Edinburgh 2007)
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Molecules in the Network Focus
Genes
Main functions
1 ADFP, APOD, BEX1, CLIC6, CRABP2, CTNNB1,
DKK1, DK.K.3+, DVL3, FGF19 (incl EG:9965),
GOS2, HSD17B2, ID4, IGFBP2, LAMB3, LIPE,
LRP5, LRP6, LRRC17, MSX2, MYF5, PAX3,
PPARG, RBP4, SERPINAL1, SFN+, SFRP4, SGK,
TCF4, TNC, VNN1, WNT10B, WNT3A, WNT5A,
XDH
17 Organismal, Cellular and
Skeletal & Muscular
Development
2 B2M, CLEC4E, CP, CXCL14+, EDNRB+, F3,
FGF2, FLOT1, GOS2, GNLY+, H2-Q1, H2-Q4,
HLA-E, IL13, INDO, KLRC1, KLRC2, KLRC3,
KLRD1, MAOA+, MMP17, MN1, MT1X+,
MUC5AC, PDCD8, PLA2G7, PTGES, QDM, RLN2,




3 AQP3, CCL18, CDKN1A, CLDN2, CTSW,
CX3CRI, CXCR3, DPP4+, GZMB, HNRPA2B1,
IFNG, ELl|, IL32, IL15RB, IL18RAP, IL1RL1,
IL2RB, KIR2DL3, KLRB1C, MAP3K5+, MT1G,
MT1H, PAEP, PDE4B, PLEK, PRF1, PRG1 (incl
EG:5552), RARRES1+, S100A11, SERPINB9,




4 CARD 10, GZMA, GZMB, IHH, IKBKG, IL2, IL25,
IL17RB, KCNQ1, KLF11 (incl EG:8462), LAMA1,
LAMA2+, LAMA3, LAMB1, LAMB3, LAMB 1-2,
LAMC1, LAMC2, LAMC3, LIF, MALT1, MAPK1,
MET, MGC45438, NEFH, PDE4B, POMC, PPP2CB,






Molecules in the Network Focus
Genes
Main functions
5 ACP5, CCNG2, CD36+, CITED2, COMP, CPB2,
DAPK1, FKBP5+, FOXG1B, F0X01A+, HNRPU,
HOXA9, HOXD3, HTRA1, IGFBP2, ITGB6, JAGI,
LPA, LTBP1+, MMP11, MT2A, NLK, PDZK1IP1,
ROCK1, SERPINA1, SGK, SPP1, STARD10,
TAF4B, TBX21, TBXA2R, TCN1, TGFB1, TGM2,
TNFRSF1 IB




6 ACSL5, AGRP, ANK2, CART, CD247, CD40LG,
DLG3, DUSP5, G0S2, GDA, IFITM1, INDO,
INHBA, ITPR1, KCNK3, KIR3DL1, LEFTY1, LEP,
MT1E, MTHFD2, NODAL, PKMYT1, PRKCA,
SCN3A, SLC15A1, SLC1A1+, SLC8A1, SNAP25,
SNAPAP, STXBP6 (incl EG:29091), TNF, TRA@+,
TRAT1,TRD@, TRH




7 ACSL4, ACTA2, ACTB, AGC1, BCL2L11, BIRC5,
CCNB1, CD9, CDC25A, CDH1, CDK6, DPP4+,
DPT, E2F1, ERBB2, FBLN2, HMGB2, IGSF4 (incl
EG:23705), ILK, KRT7, MAP3K14, MUC1, NDRG1,
NFYB, NOPE, PLCL1, PVRL3, RRM1, RRM2,





8 ALDH1A3, ANPEP, AOX1, BASP1, BTBD11,
CD83, CHAT, CHGB, CLEC4E, CYP3A5+, E2F5,
EFEMP1, ID2, IL6, IL15RA, KRAS, MYOP1,
NFIL3, NGFB, NR1I2, NTRK2, PAX8, PDIA3,
POSTN+, RGS20, SNX10, STMN2+, TCF12, TCF23,






Figure 7.2. Gene Network Analysis with differentially expressed genes
Alterations of gene expressions by administration of asoprisnil within
biological networks associated with immune cell function and
apoptosis (networks 1 and 3); most genes within these networks are
significantly down-regulated (green), only few are up-regulated (red);
central to the network and notably down-regulated is the uNK cell
recruiter IL-15 (circled)
(Derived from:
Final Report for TAP Pharmaceutical Products Inc by Forster et al,
University of Edinburgh 2007)
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0.00
Placebo (n=8) Asoprisnil 10mg (n=12) Asoprisnii 25mg (n=9)
Figure 7.3. IL-15 mRNA expression
IL-15 mRNA expression is statistically significantly down-regulated
by 25mg asoprisnil (* = P<0.05) compared to placebo / secretory
samples;
in the box plots, the box spans between lower and upper quartiles with
the horizontal line within it representing the median; the whiskers
extend to the minimum and maximum observations; each asoprisnil



















Mean +/- SD 40 +/- 0 69.4 +/- 48.36 8.3 +/- 12.31 5.9 +/- 9.7
Minimum -
Maximum 40 0-135 0-35 0-30




to placebo N/A N/A
-90 to -32.2 -94.4 to
-32.5
P-valuea N/A N/A 0.004$ 0.004s
PERIVASCULAR CELLS
Mean +/- SD 7.5+/- 10.61 41.9+/-38.7 1.3+/- 4.33 4.1 +/- 8.31
Minimum -
Maximum 0-15 0-90 0-15 0-25
Median 7.5 27.5 0 0
P-valuea N/A N/A o oo 0.011s
Table 7.3. CD56 immunohistochemistry
Histoscores of endometrial CD56 expression comparing placebo-
treated samples (secretory phase) to asoprisnil-treated samples with
highly significant p-values; CD56 expression is completely absent
after treatment with asoprisnil
a Each asoprisnil group is compared to placebo / secretory using
Wilcoxon's rank sum test
(T
Denotes statistical significance at 0.05 level using Hochberg's
multiple comparison procedure
N/A = not applicable
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Figure 7.4. CD56 immunohistochemistry
A Endometrial CD56 immunoexpression in placebo-
treated samples (secretory phase)
B Endometrial CD56 immunoexpression is absent




Analysis of whole human genome expression array data and endometrial gene
expression profiles following treatment with asoprisnil showed a down-regulation of
genes associated with local immune cell function and apoptosis. The microarray data
specifically revealed a dose-dependent down-regulation of the uterine natural killer
(uNK) cell recruiter IL-15 and the uNK cell marker granulysin by asoprisnil.
Consistent with these findings, subsequent Q-RT-PCR also showed a down-
regulation of IL-15. Immunohistochemistry demonstrated an absence of CD56 (uNK
cell marker) positive cells in endometrial stroma of women administered 10 or 25mg
asoprisnil daily for 12 weeks. These results indicate that asoprisnil exerts a
significant effect on local immune responses, which may play a role in remodelling
the endometrial vasculature.
Endometrial mRNA expression of CD56 appeared unaltered by administration of
asoprisnil. This discrepancy may be explained by the relatively short sequence of the
primer used in the Q-RT-PCR analysis. Whilst the whole genome is analysed in the
microarray, the Q-RT-PCR focuses on a short sequence of the relevant gene only and
may not always detect alterations, which are not reflected in that particular sequence.
A role for immune cells in spiral arteriole remodelling has previously been
demonstrated in the early stages of human pregnancy225. IL-15 is known to influence
the process of endometrial vascular remodelling via its role in post-ovulatory
recruitment, differentiation and proliferation of uNK cells226'227. In the secretory
phase, 70-80% of endometrial lymphocytes are uNK cells, which display a unique
phenotype (CD56bnght, CD16dim, CD3dim) and differ from peripheral blood NK cells
(CD56dim, CD16dim, CD3"). Across the menstrual cycle, endometrial uNK cell
numbers vary in parallel with IL-15 expression43. Endometrial uNK cells appear to
influence the development of decidual spiral arteries, as they produce interferon
(IFNy) and other angiogenic factors, which possibly regulate the gene a.2-
macroglobulin (a2M)228.
IL-15 has been demonstrated to have a central role in attracting peripheral blood NK
cells into the endometrium during the secretory cycle phase"26. Endometrial IL-15
expression is up-regulated in the luteal phase in endometrial stroma and notably in
the perivascular cells surrounding the spiral arteries42'43. The complex process of IL-
• 229
15 regulation in human endometrial cells has also been studied in vitro"" . IL-15
could be stimulated by prostaglandin E2 (PGE2) and 8-Bromo cAMP in the presence
of interferon-y (IFN-y) in human endometrial stromal cell cultures. The addition of
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progestins appeared to enhance these responses230. It has been suggested that ovarian
steroids regulate IL-15 expression, but this control may be indirect and also
influenced by other cytokines with immune regulatory functions such as tumour
necrosis factor (TNF)-a and transforming growth factor (TGF)-P'31.
The variance in endometrial IL-15 expression corresponds to the fluctuation of uNK
cells43. Experiments with IL-15 knockout mice substantiate the hypothesis of a close
link between IL-15 and uNK cell differentiation, proliferation and function227'232.
Mice lacking a functional IL-15 are deficient in uNK cells with a complete absence
in their implantation sites. Morphologically, these IL-15 -/- mice show decidual
pathologies with thick-walled arteries with narrowed lumen and swollen endothelial
cells and acellular, oedematous decidua227. Another study equally demonstrated that
spiral artery modification was absent, and there was a lack of decidual integrity
compared to normal mice232.
The functions of uNK cells have been studied in mouse models and particularly in
early pregnancy228'233. uNK cells produce cytokines and angiogenic growth factors
affecting the decidual vasculature234. uNK cell-derived IFN-y is essential in
triggering spiral artery modification in early pregnancy233. IFN-y induces gene
transcriptional alterations and has been demonstrated to up-regulate the a2M gene
family228. Both experiments with mice deficient in uNK cells and mice deficient in
members of the a2M family show a significant effect on the vasculature in
implantation sites228'235. The decidual vessels in immunodeficient mice lacking uNK
cells are characterized by an unusual morphology with elevated wall to lumen ratios
and endothelial hypertrophy236. The larger spiral arterioles appear thick-walled with a
deficit in elongation and coiling. Interestingly, the morphology of these spiral arteries
in uNK cell deficient mice is reminiscent of the spiral artery morphology observed in
asoprisnil-treated human endometrium227.
The precise role of the uNK cell in human endometrium is still to be clearly defined,
and most studies have been done in the context of the development of decidua in
early pregnancy. uNK cells are the predominant leucocytes in the early pregnancy
decidua, and studies in women with recurrent early pregnancy loss implicated an
association between alterations in uNK cell populations and early pregnancy
failure237. Very little is known about the significance of uNK cells outwith the
context of implantation and early pregnancy. It has been suggested that endometrial
NK cells have no significant role prior to conception238. However, it has also been
recognised that the menstrual process is influenced and regulated by inflammatory
mediators33. A large influx of leukocytes and particularly an increase in uNK cells
has been demonstrated in the human endometrium in the late secretory phase19, and
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the role of the perivascular cell in this inflammatory response has been highlighted9.
A study of endometrium from women with irregular bleeding in the context of
hormone replacement therapy (HRT) found uNK cell numbers and endometrial
IL-15 expression to be increased during bleeding episodes compared to HRT users
with no bleeding239. Similarly, endometrial immunoexpression of IL-15 has been
found elevated in women with irregular bleeding whilst using levonorgestrel
implants compared to those with regular cycles or amenorrhoea240. These data
suggest an association and, considering the known link between uNK cells and
endometrial vascular remodelling, possibly a causative relation between uNK cells
and uterine bleeding pattern.
In this study, a whole human genome expression array was used. This approach had
the advantage of being completely unbiased and allowing major alterations on a
genome wide level to be detected. Analysis of the effect of asoprisnil on endometrial
gene expression profiles has resulted in the observation that the main genes altered
by asoprisnil treatment compared to placebo are related to immune response. The
results indicate a down-regulation of several key factors within the network affecting
the local immune system, central to which is IL-15. Down-regulation of IL-15 was
confirmed on mRNA level. Local effects of IL-15 are thought to be mediated via
activation of uNK cells. uNK cells have been demonstrated to be absent in
endometrium with asoprisnil treatment (as indicated by their marker CD56). These
observations support the previously formulated hypothesis that the clinical effects
seen with asoprisnil are mediated by a directly modulating effect on endometrial
vasculature, possibly via the suppression of local immune responses, IL-15 and
subsequently uNK cells.
7.4.1. Limitations of the study
The results of the microarray studies have prompted the development of a whole new
concept of the mechanism of action of asoprisnil. It appears to comply with previous
suggestions that asoprisnil may exert a direct effect on the endometrial vasculature.
However, the indicated modulation of local immune cell function represents a novel
approach to understanding the effects of asoprisnil on endometrium.
This concept needs to be consolidated by specifically analysing multiple relevant
genes and proteins. In this study, the effects on IL-15 mRNA and CD56 protein have
been investigated. Difficulties with obtaining IL-15 antibodies for
immunohistochemistry have prevented analysis of the effects on IL-15 on protein
level. The striking suppression of CD56 protein could not be confirmed on mRNA
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level, possibly due to the limited sequence of the primer used for Q-RT-PCR
analysis. In order to further develop and confound the concept of asoprisnil
modulating endometrial immune cell function, a wider variety of target genes and
proteins will need to be studied.
7.5. Conclusion
Asoprisnil down-regulates endometrial genes known to be involved in local immune
cell function and apoptosis, in particular IL-15. Asoprisnil also down-regulates the
uNK cell marker protein CD56 in endometrial stroma and perivascular cells. The
effects of asoprisnil on local immune responses may play an important role in
morphological and functional changes in endometrial vasculature. These may





8.1. Synopsis of results
This thesis has evaluated the effects of the PRM asoprisnil in women with
symptomatic uterine fibroids. Primarily, clinical efficacy and tolerability were
established. Particular emphasis of further studies was placed on assessment of
endometrial safety and on the investigation of the mechanism of action.
As consistently demonstrated with PRMs in humans and non-human primates, this
study consolidated the finding of a remarkable effect of asoprisnil on menstrual
bleeding pattern with profound suppression and minimal breakthrough bleeding.
Even in this group of women who had mostly presented with very heavy menstrual
bleeding, including some with blood loss of over 200ml per period, the higher dose
of 25mg asoprisnil caused amenorrhoea in over 90%. There was also a favourable
influence of asoprisnil on the quality of life of these women, who had consented to
major abdominal surgery due to the impact of their symptoms on their quality of life.
Clinically, in this study asoprisnil appeared highly effective and also had a
favourable safety and tolerability profile. In keeping with previous studies, these
significant clinical effects were achieved with mostly continued follicular ovarian
activity and therefore maintained serum E levels. Doppler sonographic assessments
of uterine artery blood flow demonstrated a moderate reduction indicating that a
vascular effect may be an important contributor to the mechanism of action of
asoprisnil.
Thorough assessment of endometrial morphology following administration of
asoprisnil demonstrated a unique pattern, which was inconsistent with previously
known histological classifications. Particularly notable were changes in glandular
and vascular appearances. Cystic glandular dilatation, a feature previously found
following administration of mifepristone, was demonstrated in the asoprisnil treated
samples. However, this was not associated with any hyperplastic changes, and
specifically the mitotic counts were very low. Further investigations of proliferation
marker expression revealed no evidence of asoprisnil inducing endometrial
proliferation. On the contrary, there was significant suppression of proliferation
marker expression in the stroma. The results of this study indicate that administration
of asoprisnil for 12 weeks does not increase the risk of endometrial hyperplasia or
cytological atypia. This conclusion was further supported, when the expression of the
tumour suppressor gene PTEN was assessed and found to be unaltered by asoprisnil.
Morphologically prominent were the changes of the endometrial vasculature in the
asoprisnil treated samples. These were specific to the endometrium and consisted of
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an increased occurrence of both aggregates of thin-walled vessels and clusters of
thick-walled muscularized spiral arterioles compared to controls. These distinct
features further indicated that vascular remodelling might play an important role in
mediating the effects of asoprisnil.
As asoprisnil ligates to a sex steroid receptor, the response of endometrial sex steroid
receptor expression to asoprisnil was studied on both mRNA and protein levels.
Expression of ERa, PR and AR were significantly altered. Notably there was a
differential effect in endometrial stroma and epithelium. In particular, PR was up-
regulated in the epithelium but down-regulated in the stroma. Expression of PR was
specifically decreased in perivascular cells. This may be significant for the
modulation of endometrial vascular function by asoprisnil. There was also significant
up-regulation of ERa and AR. AR expression was specifically increased in the
stroma. Similar effects of PRMs on AR have previously been demonstrated and
hypothesized as significant for the endometrial antiproliferative effect.
To elucidate the mechanism of action of asoprisnil further, endometrial RNA
samples were submitted for microarray analysis and evaluation of endometrial gene
expression profiles following administration of asoprisnil compared to controls. With
the unbiased approach of using a whole human genome expression array, the results
indicated a notable down-regulation of genes related to the local immune system.
Specifically, IL-15 expression was suppressed, which was confirmed at the mRNA
level. Due to previous evidence that local effects of IL-15 are mediated via activation
of uNK cells, the expression of uNK cell marker CD56 was further investigated and
found to be absent in asoprisnil treated endometrial stroma and perivascular cells.
These findings strongly support the previously formulated hypothesis that asoprisnil
exerts its effects by direct modulation of the endometrial vasculature, possibly via
suppression of local immune responses.
8.2. PRMs in clinical practice
Since the first discovery of mifepristone in 1981, many studies have been conducted
to evaluate the clinical applicability of various PR ligands. Two compounds have
been licensed in the context of fertility control but in addition, their usefulness has
been proposed predominantly for management of benign gynaecological conditions.
The main property rendering PRMs such suitable agents is the endometrial
antiproliferative effect with associated suppression of menstrual bleeding. This study
confirmed that administration of asoprisnil for 12 weeks appears clinically effective
with profound reduction of uterine blood loss. With further improvements in quality
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of life and the favourable tolerability profile, it may be concluded that PRMs, and in
particular asoprisnil, offer themselves as an alternative for the medical management
of gynaecological entities associated specifically with heavy uterine bleeding.
8.3. PRMs and endometrial safety
The property of PRMs and specifically their PR antagonistic effect may and did give
rise to concerns regarding the exposure of the endometrium to unopposed oestrogens
and hence endometrial safety. Early clinical studies with mifepristone fuelled these
concerns as cases of endometrial hyperplasia were reported. Subsequent detailed
morphological studies have however indicated that the main feature previously
leading to the classification of hyperplasia was cystic glandular dilatation and did
actually occur in isolation without any other hyperplastic changes. It has since been
appreciated that PRMs induce a unique class effect in the endometrium. The
"Dictionary of Endometrial Biopsy Diagnoses for Clinical Trials with SPRMs" was
developed by a group of expert gynaecological pathologists in cooperation with TAP
Pharmaceuticals Inc. and Diagnostic Cytology Laboratories in the USA to classify
these characteristic endometrial appearances. No cases of hyperplasia or cytological
atypia have been described with asoprisnil. The results of this study supported the
conclusion that administration of asoprisnil for 12 weeks is safe, as there was no
evidence of increased proliferation and indeed significant suppression of
proliferation marker expression in the stroma. Maintained PTEN expression provided
further reassurance that asoprisnil does not induce endometrial carcinogenesis.
8.4. The mechanism of action of asoprisnil
The endometrial antiproliferative effect of PRMs and PAs became apparent early in
the course of their discovery and was unexpected. The mechanism of action has still
not been fully elucidated. As it occurs with maintained serum E levels and with
administration of compounds with predominantly P antagonistic properties, it is not
immediately obvious how this antiproliferative effect may be achieved. The up-
regulation of stromal AR expression demonstrated in this study has previously been
highlighted as potentially significant in this context. It has also been hypothesized
that suppression of endometrial proliferation may be mediated via a direct effect on
the endometrial vasculature. This hypothesis was supported by several findings in
this study. Uterine artery blood flow was found to be moderately reduced by
asoprisnil compared to controls. Morphologically, there were striking changes to the
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endometrial vessels and specifically the spiral arterioles. Most significant were the
results of the whole human genome expression array analysis. Of all possible effects
on endometrial gene expression, the genes related to local immune cell function were
significantly down-regulated by asoprisnil. Specifically IL-15 expression was
altered, which is known to affect endometrial vascular remodeling via regulation of
uNK cells. These findings were a strong indication that asoprisnil modulates the local
immune response system, which may alter the function of the endometrial
vasculature. It appeared that these effects of asoprisnil might be pivotal in the
understanding of its mechanism of action.
8.5. Suggestions for future studies
With evidence for clinical efficacy and endometrial safety of asoprisnil administered
at doses of 10 or 25mg for 12 weeks, future studies will be required to establish that
long-term administration will fulfill the same criteria. It will be of particular interest
to investigate how endometrial morphology develops with continued exposure to
asoprisnil. Specific features to observe would be the glandular architecture and the
endometrial vasculature. It will be important to establish whether the cystically
dilated glands found in asoprisnil-treated samples after 12 weeks, remain at a similar
appearance, dilate further or become atrophic. It may also be an objective to study
whether the addition of another PR ligand or potentially a small dose of progesterone
alters or even abolishes the occurrence of these dilated glands. Of specific interest
will be the development of the endometrial vessels and the observed aggregates of
thick-walled muscularized spiral arterioles over time, particularly in view of their
proposed implications for the mechanism of action of this class of compound.
The most profound clinical effect of asoprisnil is the suppression of uterine bleeding.
Currently, the most efficient non-surgical management option for heavy menstrual
bleeding (HMB) is the levonorgestrel containing intrauterine system (LNG-IUS
Mirena®). In a phase III trial, the effects of asoprisnil on HMB may be compared to
the effects of the LNG-IUS. It would be interesting to assess and compare the
suppression of menstrual bleeding, but also the occurrence of unscheduled break¬
through bleeding. The latter is a common reason for discontinuing treatment with the
LNG-IUS but has not been reported with asoprisnil. A phase III trial could be
conducted with oral administration of 25mg asoprisnil, which has been demonstrated
to have a more profound effect than lOmg without increase in side effects in this
study. Alternatively, an intrauterine system containing asoprisnil may be developed
for a trial comparing its effect to the LNG-IUS. It will be important to gather
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evidence for endometrial safety with any future clinical trial and particularly with
prolonged periods of treatment. It may be proposed that an endometrial biopsy is
obtained at 3-6 monthly intervals for this purpopse.
The findings of the microarray studies have unveiled new insights into potential
pathways of the effects of sex steroid receptor ligands. The relevance of the local
immune system for endometrial vascular remodeling and the evidence for its
modulation by asoprisnil enables a whole new approach into the study of these
compounds and the study of endometrial function in general. Further studies will
need to elucidate the exact components of these pathways and will then allow to
determine ways of modulation for therapeutic purposes. The role of the endometrial
immune response may be significant not only for fertility treatment but also for the
management of common symptoms such as heavy menstrual bleeding and
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Ethics Submission No.: 386/02/w
Patient Information Sheet
Full Title: Study C02-003: "A Phase II, 12-Week, Double-Blind, Placebo
Controlled Study to Evaluate the Effects of J867 on Uterine
Artery Blood Flow and the Morphology of the Endometrium,
Myometrium and Uterine Leiomyomata in Subjects with Uterine
Leiomyomata Scheduled for Hysterectomy"
Short Title: "J867 in women with uterine fibroids"
You are being invited to take part in a research study. Before you decide it is
important for you to understand why the research is being done and what it will
involve. Please take time to read the following information carefully and discuss it
with others if you wish. Ask the research doctor or nurse if there is anything that is
not clear or if you would like more information. Take time to decide whether or not
you wish to take part.
Thank you for reading this.
What is the purpose of the study?
Clinical research is performed in patients to see whether or not a new treatment
works and is safe to use.
The purpose of this study is to determine the effect of two doses of the investigational
medication asoprisnil on the uterus (womb) compared to placebo (dummy treatment)
when given daily for 12 weeks to patients with uterine fibroids. The effects of
asoprisnil on blood flow in the uterus and on the layers of the uterine wall will be
studied. Your participation in this study will include a screening period of up to six
weeks, medication period for 12*weeks, followed by your scheduled hysterectomy,
and a 6-week follow-up period after hysterectomy. The study will involve at least 5
visits to the clinic prior to hysterectomy and 1 visit to the clinic following hysterectomy
(a minimum of 7 visits, including surgery).
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Why have I been chosen?
You have been chosen to take part in the study because you have been diagnosed
with uterine fibroids and the doctor has decided that you require a hysterectomy.
There will be approximately 45 patients enrolled in this study at 4-5 centres in the
UK.
Do I have to take part?
It is up to you to decide whether or not to take part. If you decide to take part, you will
be given this information sheet to keep and be asked to sign a consent form.
However, you are still free to withdraw at any time and without giving a reason. A
decision to withdraw at any time, or a decision not to take part, will not affect the
standard of care you receive.
What will happen to me if I take part?
In order to take part in the study, you must be scheduled for a hysterectomy at the
end of the study treatment period due to symptoms associated with uterine fibroids.
Participation in the study involves 4-5 visits over a 3-month period prior to your
hysterectomy plus a follow-up visit 6 weeks after surgery.
Study Procedures:
1s' Visit - Screening (performed within 45 days of starting the study medication)
The research doctor or staff will ask you questions to determine if you are eligible to
participate in this study. You will be asked about any medication you have taken in
the last month.
You will also be asked to have:
• Complete physical, breast and pelvic examinations.
• Vital signs (measurement of heart rate, blood pressure, and body
temperature) and measurements of height and weight.
• Cervical smear.
• Endometrial biopsy - The endometrial biopsy is a test that involves inserting a
small tube into the neck of the womb to obtain small pieces of tissue. If
difficulty is encountered in passing this tube into the uterine opening, another
small tube may also need to be inserted to help widen the opening. This is a
routine procedure conducted in the outpatient setting to investigate menstrual
problems.
• Electrocardiogram (ECG) - measures the electrical activity of your heart
• Blood and urine sample collection for routine laboratory tests (chemistry,
haematology, coagulation, lipids, hormones, and urinalysis), and pregnancy
testing.
• Contraception counselling.
• Transvaginal ultrasound (TVU) procedure(s) - The TVU is a pelvic ultrasound
examination involving the insertion of a probe instrument into the vagina to
produce a picture of the pelvic area using sound waves and is done to
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determine the thickness of the lining of the uterus and the size of the uterus
and fibroids.
• Interview by the research staff regarding your medical, fibroid, gynaecologic,
menstrual, medication (including other hormonal preparations), and social
(smoking, caffeine and alcohol consumption) histories will be conducted and
recorded.
• Bleeding Diary - you will receive a diary to record daily uterine bleeding for a
minimum of one full menstrual cycle prior to your first tablet (Day 1) as well as
any non-steroidal anti-inflammatory (NSAIDs) medications and transexamic
acids taken. You will be given sanitary protection products for use in order to
maintain consistency across the study.
• Urine Collections - you will be asked to collect urine samples twice a week
(Monday and Thursday or Tuesday and Friday) starting on one of the first 5
days of your next menstrual cycle. The first urine sample of the day should
be collected. The samples will be used to measure your ovarian hormone
levels throughout the pre-treatment and treatment periods. Specific collection
containers will be provided. The date of collection should be marked on the
containers and the samples should be stored at -20 ° C in the freezer until
you bring them to the clinic at your next visit.
2nd Visit - Pre-dose (day 20-23 of menstrual cycle prior to dosing)
The following procedure will be performed during days 20 to 23 of your menstrual
cycle immediately prior to dosing:
• Transvaginal ultrasound (TVU) including measurement of blood flow in the
uterus
3rd Visit - Pre-dose (Day -1)
The following procedures may be performed at the 2nd Visit or on the day before your
first dose of the study drug:
• Complete physical andbreastexaminations
• Vital sign and weight measurements
• Blood and urine sample collection for routine laboratory tests (chemistry
haematology, coagulation, lipids, hormones, and urinalysis)
The following procedures will be performed the day before your first dose of the study
medication:
• Blood and urine sample collection for pregnancy testing
• Contraception counselling
• Symptom assessment - your symptoms since the last clinic visit will be
assessed
• Uterine fibroid symptom and health-related quality life questionnaire (UFS-
QOL)
• Review of the bleeding diary from the screening period
• Return of urine collection samples
• Interview regarding use of other medications
• Dispensing of new diaries, sanitary protection products, urine collection tubes,
and study drug (8-week supplies)
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Study Treatment
The study is "blinded" which means that neither you nor your doctor will know what
treatment you receive until after the study is completed. Sometimes, because we do
not know which way of treating patients is best, we need to make comparisons.
Patients in this study will therefore be put into groups and then compared. The
groups are selected by a computer list, which has no information about the individual
- i.e. by random chance (like the flip of a coin) and will determine which of the three
treatments you will receive. In an emergency situation we are able to find out which
treatment you are on. There is an equal chance of receiving any one of the 3
treatments. If you qualify to take part in this study, you will receive one of the
following treatments:
• 10 mg asoprisnil or
• 25 mg asoprisnil or
• Placebo for asoprisnil
A placebo is a dummy treatment, which looks like the real thing but contains no
active ingredients.
During the treatment phase you will be required to keep a daily record of any vaginal
bleeding and medication use in the diary provided to you. The diary should be
completed before going to bed each night so that information for the entire day may
be captured.
At each visit you will be supplied with new diaries, sanitary protection products (in
order to ensure consistency throughout the study), urine collection tubes, and study
medication supplies.
A member of the study staff will call you at Week 4 to discuss the study medication
and other medications you may have taken since the Day -1 visit and any side
effects you may have experienced during that period. You will also be counselled on
the use of contraception.
4th Visit
At the Week 8 Visit, the following procedures will be performed: brief physical
examination; vital sign and weight measurements; blood and urine sample collection
for routine laboratory tests and pregnancy testing; contraception counselling;
symptoms assessment; review of the bleeding diary from the previous visit; and an
interview regarding use of other medications and any medical problems. You will be
asked to return the urine samples that you collected during the previous 8 weeks at
this visit. A new diary, sanitary protection products, urine collection tubes, and a 4-
week supply of study medication will be dispensed.
5th Visit
At the Week 12/Final Treatment Visit, the following procedures will be performed:
vital signs and weight measurements; complete physical, breast, and pelvic
examinations; cervical smear; electrocardiogram (ECG); transvaginal ultrasound
(TVU) including measurement of blood flow in the uterus; blood and urine sample
collection for routine laboratory tests and pregnancy testing; contraception
counselling; symptom assessment; Uterine fibroid symptom and health-related
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quality of life questionnaire (UFS-QOL) review of the bleeding diary from the previous
visit; and an interview regarding use of other medications and any medical problems.
Your pelvic examination and Pap smear may be performed at the Hysterectomy Visit
instead of this visit. You will be asked to return the urine samples that you collected
during the previous 4 weeks at this visit.
At the 4th (week 8) and 5th (week 12) visits, a member of the study staff will evaluate
how well you are taking your study medication by counting the number of tablets in
the blister card that you will bring back at each clinic visit.
You will be asked to have urine and blood collected at all study visits for laboratory
testing including a urine pregnancy test. If at any time you have a positive pregnancy
test, you will be withdrawn from the study. Approximately 2 to 3 tablespoons of blood
will be collected at each clinic visit. At week 8, an additional !4 to 1 tablespoon of
blood will be drawn for extra hormone tests.
In addition, some procedures may be performed at other times during the study if
medically necessary (for example, if the cervical smear or endometrial biopsy sample
was not adequate).
Some of these procedures might be done anyway as part of your standard care even
if you do not take part in this research study. The study doctor or a member of the
study staff can answer any questions you may have about the procedures that are
not part of your standard care.
Hysterectomy Visit:
Hysterectomy will be performed within 24 hours after the Week 12 Visit (4th - 5"1
visit). Prior to hysterectomy, blood will be taken for the measurement of hormone
concentrations. If you did not have your pelvic examination and Pap Smear at the
previous visit (5th visit), they will be performed at this visit prior to the hysterectomy.
After your uterus has been removed, biopsies (a small section is cut away) of all
layers of the uterine wall will be taken.
If your surgery is delayed by more than 24 hours, you will have enough medication to
continue treatment for up to 4 additional weeks. In that case, the Week 12
ultrasound scan will be performed within 24 hours prior to your rescheduled
hysterectomy. Blood will be taken for the measurement of hormones on the day of
the rescheduled hysterectomy.
You will be asked to give permission for storage of the hysterectomy sample for use
in future research studies on uterine function. The precise nature of some of these
studies will depend upon future scientific advances. Some of the potential future
projects may be carried out by researchers other than your own study physician.
Tissue taken for study assessments will be stored at the University of Edinburgh.
6-Week Follow-Up Visit:
You will be asked to return to the clinic 6 weeks after your hysterectomy for complete
physical, breast, and pelvic examinations and an interview regarding any medical
problems. In addition, if you did not have your ovaries removed during hysterectomy,
you will have an examination of the ovaries by transvaginal ultrasound.
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If you decide to take part in this research study, you will be asked to complete the
study visits and other procedures and to follow the instructions of the study doctor
and study staff. If you decide to stop participating in the study or if you do not follow
instructions, it is important that you notify the study doctor or study staff to help you
make these decisions safely. If you stop participating, you will also be asked to see
your study doctor to have the appropriate procedures done at your final study visit. It
will be important for you to agree to an endometrial biopsy, as an outpatient
procedure (as described earlier on page 2) for a safety assessment in the event of
early discontinuation from the study.
Your participation in this study may also be discontinued without your consent by the
doctor conducting the study or by the sponsoring agency at any time for reasons
such as: if it appears that participation in the study may be medically harmful to you,
if you fail to follow directions for participating in the study, if it is discovered that you
do not meet the study requirements, or if the study is cancelled. You will be made
aware of any significant new findings that may affect your decision to remain in the
study.
What do I have to do?
Unless you have been sterilised or your partner has had a vasectomy, you must
agree to use a medically proven double-barrier method of birth control (condoms with
spermicide, sponge with spermicide, or diaphragm with spermicide) during the study
and until you have had your hysterectomy or until your first menses after treatment if
you decline surgery.
If you think you may be pregnant, you should immediately stop taking the study
medication and contact your study doctor. If you become pregnant you will be
withdrawn from the study, and the study doctor will track your pregnancy and report
the outcome to the sponsor and the Ethics Committee at the hospital.
Hormonal products (including oral birth control pills or DepoProvera®) plus some
other medications (prescription medications, over-the-counter medications, and
nutritional supplements) that you may be taking at the present time must be
discussed with your research doctor who will have a list of excluded medications.
You will be asked to stop these medications before starting the study medication.
This is called a washout period where the effects of your current medications leave
your body. The length of the washout period depends upon which medications you
are using.
Because of the possible interactions of asoprisnil with other medications or foods,
you will be asked to tell your study doctor all the medications (prescription
medications, over-the-counter medications, and nutritional supplements) that you
may be taking, and you will need to receive approval for their use during the study.
Grapefruit may not be eaten and grapefruit juice may not be consumed during the
medication period of the study since it may affect how your body uses the study
medication. There are no other dietary restrictions imposed on you. Your general
practitioner will also be notified of these restrictions and your participation in the
study.
If you have any questions please discuss them with your research doctor.
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What is the medication or procedure that is being tested?
Asoprisnil is a research medication that modifies the effects of the female hormone
progesterone. It is currently underdevelopment by TAP Pharmaceutical Products
inc. for the treatment of patients with gynaecological disorders such as endometriosis
and fibroids. More than 300 healthy females have received asoprisriil in clinical
studies performed to date. If you are entered into the study, you will be given an
emergency card, which contains brief details regarding your treatment. Your research
doctor will provide you with the card. This card should be carried around with you at
all times and shown to anyone who treats you e.g. doctor, nurse, dentist or
pharmacist. For this study, you are required to take one tablet (study medication)
orally (by mouth) at the same time every morning for 12 weeks.
What are the alternatives for diagnosis or treatment?
Participation in this study is not a substitute for your usual ongoing medical care by
your regular doctor or specialist. You do not have to participate in this study to
receive treatment for your fibroids. Alternatives to participating in this study include
other medications or no treatment prior to surgery. Your study doctor will be able to
explain these and other alternatives that are currently available to you to treat your
fibroids. In addition, your study doctor will advise you whether or not you will need
additional treatment.
The study doctor will tell you more about the risks and benefits of participating in this
study as compared to the risks and benefits of alternative treatments. You are
strongly encouraged to ask the study doctor or a member of the study staff if you
have questions about the results of your laboratory tests and other diagnostic
procedures.
What are the side effects of any treatment received when taking part?
The most commonly reported side effects in studies where pre-menopausal subjects
were given several doses of asoprisnil for up to 6 months, were: headache, upper
respiratory infection, nausea, vomiting, abdominal pain, breast tenderness, and
muscle and back pain.
Ovarian cysts (abnormal sacs filled with liquid) were observed more frequently in
subjects receiving asoprisnil compared with placebo. In most subjects, the ovarian
cysts resolved or decreased in size while the subjects were still on asoprisnil and the
subjects did not experience any physical symptoms. However, one subject that
received asoprisnil and had a medical history of symptomatic ovarian cysts, did
experience physical symptoms and was diagnosed with a hemorrhagic (bleeding)
ovarian cyst. The cyst was surgically removed without complications.
One subject participating in a uterine fibroids clinical study developed a prolapsed
fibroid (a fibroid that has moved from the uterus into the vagina). This condition may
cause a sudden increase in vaginal bleeding over that which you may be
experiencing. The subject underwent an uncomplicated removal of the fibroid with
complete resolution of her bleeding. The study treatment group (placebo or
asoprisnil) was not revealed and the subject remains in the study.
One subject in a uterine fibroids clinical study was found to have cancer in her uterus
after receiving asoprisnil for approximately 9 months. MRI pictures of her uterus
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taken prior to starting treatment with asoprisni! appear to show the growth in which
cancer was found after surgery. However, it is not known whether the cancer was
present prior to the subject taking asoprisnil. The subject has undergone a
hysterectomy without complications, and examination of surrounding fluid and tissue
indicate that the cancer cells have not spread. Other notable events reported in
subjects treated with asoprisnil include 1 case each of pancreatitis and pulmonary
embolism (post-hysterectomy) that have resolved, and 1 case of seizure disorder.
Some patients experienced temporary alterations in hormone levels. This included a
small to moderate increase in testosterone concentrations (male sex hormone) that
was not associated with the development of masculine characteristics such as oily
skin, acne or facial hair. While receiving asoprisnil, the normal cyclic changes within
the endometrium (lining of the uterus) seen during the menstrual cycle may be
suppressed.
There may be mild discomfort or pain associated with the gynaecologic examinations
and TVU. The endometrial biopsy may cause pelvic discomfort during the procedure
and for a few minutes afterwards, and/or uterine bleeding. Rarely, the procedure
may result in perforation (tearing) of the uterus or infection, which could require
hospitalisation for treatment. If a sedative is used during the biopsy, the study doctor
will describe its risks to you but usually these include dizziness and feeling very tired
afterwards.
Some women experience discomfort from the pressure applied when the speculum is
inserted into the vagina or when the cervix is scraped to take a Pap smear. There
may be temporary spotting or bleeding afterwards. You may experience discomfort
from the pressure applied during a manual pelvic examination.
During the collection of blood samples, you may experience some pain and/or
bruising on your arm where the blood is taken. In rare instances, a localised blood
clot may form or an infection may occur. Some patients experience faintness during
or shortly after having blood drawn.
Since the study medication is investigational, there may be other risks that are
currently unknown or unforeseen. There is also the possibility of an allergic reaction
to the study medication.
If you suffer from any of these or any other symptoms you should report them next
time you meet the research doctor. If you have any worries at any time during the
study you should contactyour research doctor.
This information is provided, not to alarm you, but to help you in deciding whether or
not to participate in the study. Your research doctor is aware of the possible risks and
has determined that the potential benefits outweigh the possible risks. If you decide
to take part, you will be insured for any study-induced injury.
What are the possible disadvantages and risks of taking part?
Women of Childbearing Potential:
Even though you may stop having menstrual periods during the study or you may
have a delay in the start of your menstrual periods after stopping the study
medication, you could still become pregnant if you do not use birth control. To date,
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several pregnancies have been reported during treatment or follow-up periods in
short and long term asoprisnil studies.
The risk of asoprisnil to children born to mothers exposed during pregnancy to the
medication is unknown at this time. With respect to the unborn baby, exposure
during pregnancy may affect fetal survival. Furthermore, the possibility of
malformations in the surviving fetus cannot be excluded. In laboratory animal
studies, severe birth defects were seen in fetuses exposed to asoprisnil through the
mothers.
As a result, women should not participate in this study if they are pregnant, breast¬
feeding, or actively trying to become pregnant. You will be required to have one or
more pregnancy tests during the study and unless you have been sterilised or your
partner has had a vasectomy, you must agree to use a medically proven double-
barrier method of birth control (condoms with spermicide, sponge with spermicide, or
diaphragm with spermicide) until the day of your hysterectomy. It is possible that you
may not have menstrual periods during the time you are taking study medication or
that your menstrual periods may be lighter, but even if this is the case, you must still
use contraception until the date of your hysterectomy.
What are the possible benefits of taking part?
You may receive no or few benefits from this study. However, your symptoms of
fibroids may be relieved by asoprisnil.
Study procedures such as physical examinations, electrocardiograms, transvaginal
ultrasounds, biopsies, and laboratory tests are performed at no cost to you. Study
medication is provided at no cost as well. We hope that the treatment will help you.
However, this cannot be guaranteed. Information gained from this study may help
develop new treatments for patients in the future.
What if new information becomes available?
Sometimes during the course of a research project, new information becomes
available about the medication being studied. If this happens, your research doctor
will tell you about it and discuss with you whether you want to continue in the study. If
you decide to withdraw, your research doctor will make arrangements for your care to
continue. If you decide to continue in the study you will asked to sign an updated
consent form.
What happens when the research study stops?
The treatment is only available to you whilst on the study. Occasionally, the
company making the medications will stop the research. If this happens you may
have to withdraw from the study, but the research doctor will continue to care for you.
What If something goes wrong?
If you have any complaints during the study as to your treatment by the members of
staff e.g. doctors, nurses etc you can report this through the NHS complaints
procedure. The hospital can advise on this.
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Compensation for any injury caused by taking part in this study will be in accordance
with the guidelines of the Association of the British Pharmaceutical Industry (ABPI).
Broadly speaking the ABPI guidelines recommend that 'the sponsor', without legal
commitment, should compensate you without you having to prove that it is at fault.
This applies in cases where it is likely that such injury results from giving any new
medication or any other procedure carried out in accordance with the protocol for the
study. The sponsor* will not compensate you where such injury results from any
procedure carried out which is not in accordance with the protocol for the study. Your
right at law to claim compensation for injury where you can prove negligence is not
affected.
Should you require further information, contact your research doctor (phone
number and address can be found on page 11 of this document).
Will my taking part in this study be kept confidential?
If you consent to take part in the research, any of your medical records may be
inspected by the company sponsoring and/or the company organising the research
(Harrison Clinical Research) for purposes of analysing the results. People from
regulatory authorities and the ethics committee may also look at your medical
records to check that the study is being carried out correctly. Your name and
address, however, will not be disclosed outside the hospital.
With your permission, your GP will be notified, by letter, of your participation in the
study. In addition, other medical practitioners not involved in the study may also need
to be notified. We will ask for your permission that these parties can be informed.
Data will be collected by the research doctor or a member of the research team in
accordance with the Data Protection Act 1998. Data will be analysed and controlled
by TAP Pharmaceutical Products Inc., and various government health agencies, in
the USA and UK, which approve the use of new medications. The data collected from
you for this study will be stored by the research doctor and TAP Pharmaceutical
Products Inc. sponsoring the study. The data collected from you for this study will be
stored on paper and electronically. The data will not be destroyed before the end of
the study.
Your information may be passed onto researchers or regulatory authorities in
countries that do not provide the same protection as the UK.
What will happen to the results of the research study?
When the study has been completed, a report will be prepared showing the results of
the study. A copy of the report will be provided to the Ethics Committee.
Information contained in the report will be coded to protect identity. Your name and
all other personal data, as well as that from other patients in this study will be kept
confidential and, to the extent permitted by the applicable laws and/or regulations,
will not be made publicly available. If the results of the study are published, your
identity will always remain confidential.
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Who is organising and funding the research?
A US pharmaceutical company called TAP Pharmaceutical Products Inc. is funding
this research study. This company is referred to as the 'sponsor'.
The Hospital NHS Trust is being paid to identify you as a suitable patient for
participation in this study. This includes payments to cover the necessary
expenses and laboratory tests and the salaries of the research staff involved.
You will not be paid for taking part in the study. However, you will be able to claim for
travel expenses (see your research nurse or doctor for more details).
Who has reviewed the study?
To ensure the study is being conducted safely and ethically, the Local Research
Ethics Committee has reviewed the study. This committee is a panel comprising
medically qualified people and laypersons from the local community and is
independent from the study doctor and the sponsor company (the company paying
for the research to be done).
Contact for Further Information
Should you require it, further information can be obtained from Professor Critchley or
other members of the research team at:
Tel: 0131 242 6441
Fax: 0131 242 6440
Address: Obstetrics and Gynaecology
Reproductive and Development Sciences
Centre for Reproductive Biology
University of Edinburgh
49 Little France Crescent
Old Dalkeith Road
Edinburgh EH16 4SB
We thank you for taking the time to read this information sheet, and (if you decide to
do so) for taking part in this study.
Consumers for Ethics in Research (CERES) publish a leaflet entitled 'Medical
Research and You'. This leaflet gives more information about medical research and
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Title of Project: Study C02-003: A Phase II, 12-Week, Randomised, Double-
Blind, Placebo Controlled Study to Evaluate the Effects of
J867 on Uterine Artery Blood Flow and the Morphology of
the Endometrium, Myometrium and Uterine Leiomyomata in
Patients with Uterine Leiomyomata Scheduled for
Hysterectomy.
Short Title of Project: J867 in women with uterine fibroids.
Name of Researcher:
(Please initial box)
1. I confirm that I have read and understand the information sheet dated
21 June 2004 (Version 4.3) for the above study and have had the
opportunity to ask questions. I understand that I will receive apopy
of this information sheet and a signed and dated consent form for my
records.
□
Deleted: signed and dated
2. I understand that my participation is voluntary and that I am free to
withdraw at any time, without giving any reason, without my medical
care or legal rights being affected.
□
' Formatted: Bullets and
I Numbering
Patient Consent Form (Version 4.3, dated: 21 June 2004) - Critchley
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3. I understand that sections of any of my medical notes may be looked
at by responsible individuals from TAP Pharmaceutical Products Inc.
(and/or their representatives) or from regulatory authorities where it is
relevant to my taking part in research. I give permission for these
individuals to have access to my records.
4. I agree that my GP and other medically qualified people who assist in
my care can be notified of my participation in the thai.
5. I agree that data about me relating to this study may be sent to
countries that do not have data protection laws that are similar to
those in the UK. I understand that my data will be made anonymous
before the information leaves the hospital or research centre.
6. I give permission for the sample of tissue collected to be stored for
possible use in future studies. The precise nature of these studies will
depend upon future scientific advances. I understand that some of
these projects may be carried out by researchers other than the study
researcher at the hospital, or members of the study team.
7. I understand that if I withdraw from the study while on medication I will
give my consent to collection of an endometrial biopsy as an
outpatient.
8. I agree to take part in the above study.
Name of Patient Date Signature
Name of Person taking consent Date Signature
(if different from researcher)
Researcher Date Signature
Patient Consent Form (Version 4.3, dated: 21 June 2004) - Critchley
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Room SU 304 NEW ROYAL INF
Univ of Edinburgh Med Sch
49 Little France Cres EDINBURGH
Date 06 November 2002
Your Ref
OurRef LREC/2002/6/17
Enquiries to Joyce Clearie
Extension 89022
Direct Line 0131 536 9022
Email @lhb.scot.nhs.uk
US IRB No.: IRB00001462
Dear Prof Critchley,
A PHASE II 12-WEEK DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO
EVALUATED THE EFFECTS OF J867 ON UTERINE ARTERY BLOOD FLOW AND THE
MORPHOLOGY OF THE ENDOMETRIUM MYOMETRIUM AND UTERINE
LEIOMYOMATA IN SUBJECTS WITH UTERINE LEIOMYOMATA SCHEDULED FOR
HYSTERECTOMY.
Thank you for submitting the above research proposal for ethical review. The
Paediatrics/Reproductive Medicine Research Ethics Committee of the Lothian Research
Ethics Committee has reviewed this proposed research and has given it a favourable
ethical opinion. Please note however that the committee felt that the patient information
sheet should be clearer with regard to dosages i.e. page 1, What is the purpose of the
study? section, paragraph 2 and page 6, What is the drug or procedure that is being
tested? section, paragraph 3. An official Certificate of Ethical Opinion outlining the
conditions of this opinion is enclosed together with a list of members present at the
meeting. Please note that the LREC reference number LREC/2002/6/17 must be quoted
on all correspondence. Correspondence received without the LREC reference number will
be returned.
Under the terms of the Scottish Executive Health Department Research Governance
Framework for Health and Community Care this opinion has been notified to the Research
& Development Office of the relevant NHS Trust(s) where the research is intended to take
place. It is the NHS Trust(s) from whom you must obtain management approval before any
work on the proposed research can proceed.
Headquarters
Deaconess House 148 Pleasance Edinburgh EH8 9RS
Chair Brian Cavanagh





LOTHIAN RESEARCH ETHICS COMMITTEE
CERTIFICATE OF ETHICAL OPINION
LREC Reference Number: LREC/2002/6/17
Title: A Phase II 12-Week Double-blind Placebo-Controlled Study to Evaluated the Effects of
J867 on Uterine Artery Blood Flow and the Morphology of the Endometrium Myometrium and
Uterine Leiomvomata in Subjects with Uterine Leiomvomata Scheduled for Hysterectomy.
Researcher: Prof Hilary Critchley
The Paediatrics/Reproductive Medicine Research Ethics Committee of the Lothian Research
Ethics Committee (the Committee) reviewed this proposed research and is of the opinion that it
is ethical and appropriate to be carried out in the Lothian Area. This opinion encompasses all
aspects of the application including the Patient/Subject Information Sheet and all other
accompanying documentation provided.
The LREC application form, protocol, subject information sheet, information on compensation
arrangements, payments to researchers and the provision of expenses to subjects (where
appropriate) were reviewed and approved and the members of the Committee present at the
meeting are shown on the attached Membership List.
This opinion is issued subject to the following conditions and is invalid if they are not followed:
• You must obtain appropriate management approval from the relevant NHS Trust(s)
before starting the proposed research. It is the NHS Trust(s) that ultimately decide
whether or not this research should go ahead taking account of the advice of the Local
Research Ethics Committee.
• You must notify the Sub-Committee and the relevant NHS Trust(s), in advance, of any
significant proposed deviation from the original protocol or application form and obtain
approval for any such amendments using the Amendment Approval Request Form.
• You must submit reports to the Sub-Committee and the NHS Trust(s) once the study is
underway if there are any unusual or unexpected results which raise questions about
the safety of the research.
• You must report annually on successes, or difficulties, in recruiting subjects in order to
provide useful feedback on perceptions of the study among patients and volunteers
using the Progress Report Form.
• Where the study is terminated prematurely you must report within fifteen days indicating
the reasons for early termination.
• You must submit a final report within three months of the completion of the study using
the Progress Report Form.
Peter Reith
Secretary











Liquid based cytology ThinPrep® Pap Test, Cytyc Corp
Pipelle suction curette Unimar Pipelle® Endometrial Suction
Curette, Medscand
4% neutral buffered formalin (NBF) See appendix II
Tissue-tek TEC Embedding Station Sakura Finetek USA, Inc.
Thermo Shandon Gill 1 Hematoxylin Anatomical Pathology International,
Runcom, Cheshire, UK
EA-50 (Eosin) Cellpath Ltd, Newtown, Powys, UK
Olympus BX51 microscope Olympus UK Ltd, Southend-on-Sea,
Essex, UK
IMMUNOHISTOCHEMISTRY SUPPLIER
Histoclear National Diagnostics, Atlanta, Georgia,
USA
Phosphate buffered saline (PBS) Sigma tablets (see appendix II)
PBS + Tween 20 (PBST) Sigma tablets (see appendix II)
Sodium citrate See appendix II
Pressure cooker Model: CLIPSO, Tefal, Nottingham, UK
Bond-X Immunohistochemistry Staining Vision BioSystems, Newcastle Upon
System Tyne, UK
Bond detection system reagents: Vision BioSystems, Newcastle Upon
- 3% hydrogen peroxide Tyne, UK
- post primary polymer penetration
enhancer





Hydrogen peroxide solution (30%) BDH Laboratory supplies, Poole, UK
Non-immune horse serum Vector laboratories, Peterborough, UK
Biotinylated horse anti-mouse antibody Vector laboratories, Peterborough, UK
Avidin-biotin-peroxidase complex Vector laboratories, Peterborough, UK
(ABC-HRP)
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Avidin/Biotin blocking kit Vector laboratories, Peterborough, UK
Non-immune goat serum Autogen Bioclear
Bovine serum albumin Sigma, Poole, Dorset, UK
Anti-rabbit envision kit
(EnVision+ System-HRP)
DAKO Cytomation, Cambridge, UK
3, 3'-diaminobenzidine (DAB) DAKO, Cambridge, UK
Harris's haematoxylin Pioneer Research Chemicals Ltd,
Colchester, UK
Xylene BDH Laboratory supplies, Poole, UK
Pertex Cellpath pic, Hemel Hempstead, UK
Axioskop 2 / Cell Imaging System Carl Zeiss Ltd
Stereology software (Image-Pro plus
4.5.1 with Stereology-Pro 5.0)
Media Cybernetics UK, Wokingham,
Berkshire, UK
Olympus BH-2 microscope Prior Scientific Instruments Ltd,
Cambridge, UK
PRIMARY ANTIBODIES SUPPLIER
Mouse anti-Ki-67 / NCL-Ki67-MM1 Novocastra, Newcastle-upon-Tyne, UK
Rabbit Anti-phospho-histone H3 Upstate Biotechnology, Buckingham,
UK
Mouse anti-PTEN (NCL-PTEN) Novocastra, Newcastle-upon-Tyne, UK
Mouse anti-CD56 Zymed Laboratories, Cambridge, UK
Mouse anti-ERcc: Clone 1D5 DAKO, Cambridge, UK
Mouse anti-ER31 Serotec, Oxford, UK
Mouse anti-PR: Novocastra, Newcastle upon Tyne, UK
specific to both PR isoforms
Mouse anti-GCR Novocastra, Newcastle upon Tyne, UK
Rabbit anti-AR (F-39) Novocastra, Newcastle upon Tyne, UK
Non-immune mouse IgG Vector Laboratories, Peterborough, UK
Non-immune mouse IgG 1 Sigma, Poole, Dorset, UK
Non-immune mouse IgGl kappa Sigma, Poole, Dorset, UK
Non-immune rabbit IgG Vector Laboratories, Peterborough, UK




RNAlater® Solution (RNA stabilization) Ambion Inc, Austin, Texas, USA
Trizol RNA isolation reagent Invitrogen, Paisley, UK
Hand held homogeniser (Polytron PT Kinematica, Switzerland
1200B)
Phase lock gel tubes Eppendorf, Hamburg, Germany
Chloroform Sigma, Poole, Dorset, UK
Isopropanol Sigma, Poole, Dorset, UK
Ethanol (molecular biology grade) BDH Laboratory supplies, Poole, UK
RNA storage solution Ambion Inc, Austin, Texas, USA
Qiagen RNeasy mini kit columns Qiagen Sciences, Maryland, USA
REAL TIME Q-RT-PCR SUPPLIER
DNAse 1, Amplification grade kit Invitrogen Life technologies, Paisley,
(includes DNAse buffer and EDTA) UK
Agilent RNA 6000 Nano Kit Agilent Technologies, Waldbronn,
Germany
Taqman reverse transcription reagents Applied Biosystems, Cheshire, UK
Taqman universal PCR mastermix Applied Biosystems, Cheshire, UK
Ribosomal RNA control reagents Applied Biosystems, Cheshire, UK
Primer/probe sets for sequences of Applied Biosystems, Cheshire, UK or
interest Biosource International Ltd, UK
Primer/probe set for IL-15 Universal Probe Library, Roche
Diagnostics, Germany






Weight / Volume Chemical name Supplier
6.5 g Na2HP04 BDH
4.5 g Na2P04.2H20 BDH
100 ml 40% formaldehyde BDH
900 ml Distilled water
0.01M PBS pH 7.4
Weight / Volume Chemical name Supplier
5 tablets PBS Sigma
1 1 Distilled water
0.1M Sodium citrate
Weight / Volume Chemical name Supplier
29.41 g Tri-sodium citrate BDH
0.1 g Sodium azide Sigma
700 ml Distilled water
pH to 6 and make up to 1 1 with distilled water
Dilute 1:10 for working 0.01M solution
0.01M PBST pH 7.4
Weight / Volume Chemical name Supplier
5 tablets PBS Sigma
1 1 Distilled water
8g NaCl BDH
100 pi Tween 20 Sigma
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Supplier of all reagents: Vision BioSystems
Temperature throughout staining process: Ambient
Step 1 Reagent - Peroxide Block 5 minutes
Step 2 Bond Wash solution
Step 3 Bond Wash solution
Step 4 Bond Wash solution
Step 5 Reagent - Primary antibody 180 minute
Step 6 Bond Wash solution
Step 7 Bond Wash solution
Step 8 Bond Wash solution
Step 9 Reagent - Post primary 8 minutes
Step 10 Bond Wash solution 2 minutes
Step 11 Bond Wash solution 2 minutes
Step 12 Bond Wash solution 2 minutes
Step 13 Reagent - Polymer 8 minutes
Step 14 Bond Wash solution 2 minutes
Step 15 Bond Wash solution 2 minutes
Step 16 Deionized water
Step 17 Reagent - Mixed DAB Define
Step 18 Reagent - Mixed DAB Define 10 minutes
Step 19 Deionized water
Step 20 Deionized water
Step 21 Deionized water
Step 22 Reagent - Hematoxylin 5 minutes
Step 23 Deionized water
Step 24 Bond wash solution
Step 25 Deionized water
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Supplier of all reagents: Vision BioSystems
Temperature throughout staining process: Ambient
Step 1 Reagent - Peroxide Block 5 minutes
Step 2 Bond Wash solution
Step 3 Bond Wash solution
Step 4 Bond Wash solution
Step 5 Reagent - Primary antibody 180 minutes
Step 6 Bond Wash solution
Step 7 Bond Wash solution
Step 8 Bond Wash solution
Step 9 Reagent - Post primary 8 minutes
Step 10 Bond Wash solution 2 minutes
Step 11 Bond Wash solution 2 minutes
Step 12 Bond Wash solution 2 minutes
Step 13 Reagent - Polymer 8 minutes
Step 14 Bond Wash solution 2 minutes
Step 15 Bond Wash solution 2 minutes
Step 16 Deionized water
Step 17 Reagent - Mixed DAB Refine
Step 18 Reagent - Mixed DAB Refine 10 minutes
Step 19 Deionized water
Step 20 Deionized water
Step 21 Deionized water
Step 22 Reagent - Hematoxylin 5 minutes
Step 23 Deionized water
Step 24 Bond wash solution
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Effect of asoprisnil on uterine proliferation markers and endometrial
expression of the tumour suppressor gene, PTEN
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Effects of the selective progesterone receptor modulator asoprisnil on uterine
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Progesterone receptor modulators in gynaecological
practice
Julia Wilkens, Hilary Critchley
Introduction
The sex steroid progesterone plays a major role in the
regulation of female reproductive activity. Circulating levels
of progesterone are maximal in the secretory phase of the
menstrua] cycle, its main source being the corpus luteum.
The effects of progesterone are mediated via the
progesterone receptor (PR), which is essential not only for
the co-ordination of ovulation, implantation and the
maintenance of pregnancy but also for breast development
and sexual behaviour. Within the uterus, progesterone
predominantly contributes to the regulation of endometrial
function. Progesterone is crucial in preparation for
implantation by decidualisation, during pregnancy and
during the process of menstruation, which occurs when
progesterone levels fall in the absence of a conceptus. Since
the discovery of natural progesterone in the mid-1930s,1
many synthetic progestogens have been developed and
introduced into clinical practice. As contraceptive agents,
these compounds have revolutionised fertility control.
Progestogens also have an established role in the
management of benign gynaecological conditions such as
menstrual disturbances and endometriosis, as well as in
hormone replacement therapy and assisted reproductive
technology.
The discovery of the progesterone receptor2'3 enabled
the development of synthetic compounds binding to the PR
with agonistic but also with antagonistic properties. The
first of these to be described in 1981 was mifepristone (RU
486), a PR and glucocorticoid receptor (GR) antagonist.4
Reports soon followed on its effect on menstruation,5
highlighting its potential for cycle regulation and birth
control.6 It was established that mifepristone could induce
menstruation by interrupting the luteal phase of the
menstrual cycle. Its potency to disrupt early pregnancy was
then recognised, leading to its clinical application in the
termination of pregnancy.7 Various related compounds
exerting their effect via the PR have subsequently been
developed and are reviewed here.
Development of PRMs
The initial aim in developing progesterone receptor
modulators (PRMs) was to find compounds with more
profound P antagonistic potency but less antiglucocorticoid
activity than mifepristone. The applications envisaged in
the early stages were fertility control and the treatment of
breast cancer.8-9 The major therapeutic potential of PRMs
for the management of benign gynaecological conditions
became apparent when their endometrial antiproliferative
effect inducing endometrial atrophy and amenorrhoea was
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demonstrated, initially in non-human primates and
rabbits.10'11 Unfortunately, the significant abortifacient
activity of progesterone receptor antagonists (PAs) led to
the delay and obstruction of development of mifepristone
and similar compounds with progesterone antagonistic
properties for other clinical applications. Large
pharmaceutical companies distanced themselves from the
perceived negative image of a drug that was capable of
terminating a pregnancy. Further introduction of PRMs into
clinical practice was also precluded by concerns regarding
safety of the endometrium, as it may potentially be exposed
to the effects of unopposed estrogens, and concerns
regarding their antiglucocorticoid activity at higher doses.
A drug discovery programme was initiated to develop
a compound with partial PR agonistic and antagonistic
properties on the assumption that this would eliminate the
concerns regarding PRMs.12 A number of compounds with
varying degrees of PR agonist and antagonist properties
were synthesised (Figure 1) and those with partial and
mixed agonist/antagonist activity were classified as
selective progesterone receptor modulators (SPRMs).
These demonstrated high PR binding affinity and PR
specificity with much reduced antiglucocorticoid activity
compared to mifepristone. Their more favourable effect on
the endometrium was attributed to their partial PR
agonistic activity.13-14 The SPRM, asoprisnil (J867), was
selected for further clinical development as it
demonstrated particularly pronounced PR agonistic
properties and absence of labour-inducing or abortifacient
activity.12
Many potential indications for PRMs in benign
gynaecology have been proposed including the
management of menstrual disturbances, uterine fibroids
and endometriosis.15-16 Most clinical experience to date
has been with asoprisnil and mifepristone. Randomised
double-blind placebo-controlled trials have also been
conducted with ulipristal (CDB-2914) and proellex (CDB-
4124).17 For many years, mifepristone was the only
compound licensed for clinical use. Recently, ulipristal has
received a licence for emergency contraception.18-19
A number of other PRMs have been developed
including onapristone, Org 31710, Org 33628,ZK 137 316,
ZK 230 211 among others. Preclinical20-23 and clinical24
studies have been published with findings of dose-
dependent suppression of menstrual and ovarian
cyclicity.21-23 Profound reduction of menstrual blood loss
has been demonstrated consistently. Studies in macaques
have been conducted with ZK 230 211 administered via an
intrauterine system (IUS) with similar results.22 The use of
ZK230 211 administered via an IUS in humans with a view
to its potential in contraception and in the management of
benign gynaecological conditions has been evaluated in
one pilot study.24 This study demonstrated that intrauterine
delivery of ZK 230 211 is feasible, as significant
endometrial levels of the drug were detected.
This review focuses on the evidence for the use of the
PRMs that have been administered in clinical trials to date.
Endometrial effects of PRMs
The discovery of the endometrial antiproliferative effect of
PRMs was an important milestone in their
development.11-25 It was also unexpected, as compounds
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Figure 1 Examples of selective
progesterone receptor modulators
(SPRMs) exhibiting varying degrees of
progesterone receptor (PR) agonist and
antagonist properties, including those
with partial and mixed agonist/antagonist
activity. ONA, onapristone; RU486,
mifepristone; J867, asoprisnil. Figure
reproduced, with permission, from
Schubert G, Elger W, Kaufmann G,
Schneider B, Reddersen G, Chwalisz K,
Discovery, chemistry, and reproductive
pharmacology of asoprisnil and related
11beta-benzaldoxime substituted
selective progesterone receptor
modulators (SPRMs). Semin Reprod
















































with PR antagonistic activity had been anticipated to result
in unopposed estrogenic effects on the endometrium. A
number of studies had described a significant proportion of
women developing endometrial hyperplasia when
mifepristone was used for the management of uterine
fibroids at doses of 5-50 mg daily for 3-6 months.26-28 A
report was also published of significant endometrial
hyperplasia following 6 months courses of mifepristone at
400 mg per day.29 On further histological examination,
however, in most cases the changes described as
hyperplastic consist of cystically dilated glands,30 which
contrary to the glands in endometrial hyperplasia, do not
exhibit increased mitotic indices. There have been no
reports of cytological atypia. Administration of
mifepristone in low doses (2-5 mg) for 120 days has been
reported to reduce endometrial proliferation markers.31
Asoprisnil has not been found to cause endometrial
hyperplasia after administration for up to 12 weeks. A
study into the effects of 10 or 25 mg asoprisnil given for 12
weeks on endometrial proliferation markers demonstrated
that asoprisnil does not induce proliferation, and indeed the
stromal expression of the proliferation marker Ki-67 was
significantly decreased. In addition, the expression of the
tumour suppressor gene PTEN, previously described as a
gatekeeper of endometrial carcinogenesis,32 was
unaffected and specifically not suppressed.33
It has now been recognised that the endometrial
morphological features described with PRMs are a unique
class effect and are not consistent with the previously
recognised histological changes through the normal
cycle.34-35 New diagnostic criteria to describe the features
observed with PRM administration have been developed
with the intention of raising the awareness of pathologists
when assessing endometrial morphology after exposure to
this class of compound.36 To date, no pre-malignant lesions
have been described.
Potential clinical applications for PRMs
Heavy menstrual bleeding
Menstrual disturbances have an impact on the quality of
life of many women. The prevalence of menstrual
complaints has increased over the last century with earlier
menarche, increased life expectancy, advances in fertility
control and shorter episodes of lactational amenorrhoea.
With the current trend for women to postpone plans for a
family to their fourth or even fifth decade, surgical
intervention is often not an option. Hence, there is an
increasing requirement for an acceptable form of medical
management.37-38 Suppression of menstruation may be
desirable not only for women suffering from excessive
menstrual blood loss but also as a personal option for any
woman between menarche and menopause. The perceived
benefits of amenorrhoea include the abolition of heavy
blood loss and painful periods and a reduced risk of
anaemia. A questionnaire survey of 1001 women attending
a family planning clinic showed that the reduction of
periods associated with certain forms of contraception was
highly acceptable.39 It has even been argued that
menstruation should be optional for all women .40~43 PRMs
may offer this option once it has been established that long-
term administration is safe.
The medical management options for heavy menstrual
bleeding (HMB) have been reviewed previously.44
Currently, most involve the administration of progestogens,
either orally, parenterally or via an IUS. The side effect most
commonly responsible for discontinuation of such therapy is
unscheduled bleeding. Most studies assessing the effect of
PRMs on bleeding pattern have been carried out in patients
with benign uterine pathology such as uterine fibroids,
which are known to contribute to the symptom of HMB.
However, the effect of asoprisnil was also evaluated in 60
women with regular menstrual cycles and no uterine
pathology in a Phase I double-blind dose-escalation study.
They were administered doses of asoprisnil varying from 5
mg once daily to 50 mg twice daily for 28 days commencing
during the first 4 days of their cycle. As a result, cycle
lengths were increased, and the onset of menstruation was
significantly delayed with doses at or above 10 mg once
daily.45 Suppression of menstruation with asoprisnil has
been found to be reversible and not associated with the
adverse systemic side effects of estrogen deprivation as seen
with gonadotropin-releasing hormone (GnRH)
analogues.12-46 The prolongation of the menstrual cycle in
this Phase I study occurred even in the presence of a normal
luteal phase and luteolysis, indicating that the endometrium
is a direct target.45 Asoprisnil may have clinical advantages
over continuous progestogen treatment, as reports of
unscheduled bleeding with PRMs have been rare.
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Uterine fibroids
Current options of medical management for symptoms
associated with uterine fibroids are very limited due to
unfavourable success rates and side effect profiles. HMB is
the commonest symptom requiring intervention and is
often refractory to administration of progestogens,
particularly if the uterine cavity is enlarged and distorted.
Any symptoms due to the mass of the fibroids such as
pelvic pressure or discomfort are even less amenable to
pharmacological intervention. GnRH analogues may only
be administered on a temporary basis due to their hypo-
estrogenic side effects. Uterine artery embolisation (UAE)
is a potentially fertility-conserving and non-surgical
management option and has recently been compared to
hysterectomy with favourable results.47 Longer-term
follow-up studies of UAE, particularly regarding its effect
on subsequent pregnancies, are awaited.
PRMs may prove to be an important advance in the
medical management of symptomatic uterine fibroids as
the clinical effects of this class of compounds are
dramatic.48-49 In addition to their beneficial effect on
bleeding patterns, PRMs reduce the size of the fibroids and
therefore have the potential to alleviate symptoms due to
fibroid mass. Favourable results have been reported in
studies that included assessments of the impact on patients'
leiomyoma-specific quality of life.50'51
Mifepristone has been described to significantly
improve bleeding patterns in women with uterine fibroids.
Reports of amenorrhoea vary and appear to be dose
dependent, but range from 60-100% with doses of 5-50
mg daily.26-28'52 A recent study using a low dose of 5 mg
mifepristone for 6 months found an amenorrhoea rate of
41%.51 Other fibroid-related symptoms such as
dysmenorrhoea and pelvic pressure have also been seen to
respond favourably to the administration of mifepristone.27
Reduction in the size of fibroids by 26-74% has been
described with administration of 5-50 mg mifepristone
once daily for 3-6 months.27 The evidence regarding the
dose dependency of this effect is currently inconclusive.
Whilst no consistent correlation between dose and response
could be found in one review,27 a study specifically
investigating the dose-response effect concluded that only
doses of at least 25 mg daily achieved a clinically
significant decrease in fibroid volume.53 The reduction in
the size of fibroids may also be related to the duration of
exposure to mifepristone.27 Recent randomised placebo-
controlled trials in women with symptomatic fibroids have
reproduced the findings of decreased fibroid volumes and a
significant reduction in menstrual blood loss, resulting in
increased haemoglobin levels after treatment with 5-50 mg
mifepristone once daily for 3-6 months 28'30'51
Phase II studies with asoprisnil in women with uterine
fibroids reaffirmed the observation that this compound
induces reversible amenorrhoea. In a double-blind,
placebo-controlled study, doses of 5, 10 or 25 mg of
asoprisnil were administered orally to women with uterine
fibroids for 12 weeks.54 Duration and intensity of uterine
bleeding were significantly reduced in a dose-dependent
manner, and no episodes of unscheduled bleeding were
reported. Amenorrhoea was achieved in over 83% of
patients with the highest dose of 25 mg. In addition to the
suppression of both normal and heavy menstrual bleeding,
a reduction in the volume of the largest fibroid (by 36%
after 12 weeks with 25 mg asoprisnil) was demonstrated,
resulting in a dose-dependent improvement of pressure
symptoms such as bloating and pelvic pressure.48-50 In a
subsequent and similar double-blind, placebo-controlled
study with 10 or 25 mg of asoprisnil for 12 weeks, these
findings were reproduced with a particularly impressive
reduction in menstrual blood loss, a decrease in fibroid size
and a significant improvement in quality of life.50 In this
study, the menstrual blood loss was semi-quantitatively
assessed with a menstrual pictogram, which showed that
between the pre-treatment cycle and the final month of
treatment there was a difference in blood loss of-154 and
-215 ml in the 10 and 25 mg asoprisnil groups,
respectively. Considering the traditional definition of HMB
as menstrual loss over 80 ml,55 this was a dramatic
improvement. Even in this cohort of women presenting
with excessive menstrual bleeding, amenorrhoea was
achieved in 91% of patients with a daily dose of 25 mg
asoprisnil.
The effect of CDB-2914 administered for 3 months in
doses of 10 and 20 mg to women with symptomatic
fibroids has been evaluated in a randomised, placebo-
controlled trial. The higher dose of 20 mg achieved
amenorrhoea in all patients. As well as suppression of
menstruation and ovulation, CDB-2914 was found to
significantly reduce fibroid volumes by 21-36% and to
improve quality of life, comparable to the results of studies
with other PRMs.56
The mechanism of the effect of PRMs on fibroid size
has not yet been fully elucidated. Reduced uterine artery
blood flow in women with symptomatic uterine fibroids
has been described with both mifepristone57 and
asoprisnil50 and may contribute to the decrease in tumour
size. Asoprisnil also appears to target uterine leiomyoma
cells directly, resulting in restriction of proliferation and
induction of apoptosis, whilst leaving normal myometrial
cells unaffected.58
Endometriosis
As with other benign gynaecological conditions, medical
management of endometriosis is currently largely
dependent upon administration of progestogens. Estrogen
deficiency restricts long-term use of GnRH analogues. Not
only is satisfaction with medical management often limited
by the side effects, but symptom control may also remain
suboptimal.
The results of studies of PRMs in women with
endometriosis are promising.13-59 Mifepristone has been
shown to have a significant beneficial effect on symptoms
and extent of disease with administration of 50 mg daily
for 6 months.59 The rationale for the use of asoprisnil in
the management of endometriosis is based on the
presumed effects of tissue-selective inhibition of
endometrial proliferation and suppression of endometrial
bleeding by targeting the endometrial vasculature
directly.13-49 The finding of tissue-specific suppression of
endometrial prostaglandin production in preclinical
studies also appeared promising with regard to the
potential of asoprisnil to ameliorate endometriosis-
associated pain.10-60 Phase II studies with asoprisnil have
been conducted in women with pelvic pain due to
endometriosis. In a randomised, placebo-controlled study,
doses of 5, 10 or 25 mg asoprisnil were administered for
12 weeks to women with a laparoscopic diagnosis of
endometriosis who suffered moderate or severe pain. All
three doses significantly reduced non-menstrual pelvic
pain and dysmenorrhoea compared to placebo 49
Contraception
Mifepristone strongly antagonises all effects of
progesterone, including endometrial preparation for
implantation and maintenance of pregnancy. Hence, not
surprisingly, its first clinical application was for
termination of pregnancy, which remains its only licensed
indication.61-62 Mifepristone has also been demonstrated to
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act as a highly effective postcoital contraceptive
agent.63-65 The potential of ulipristal for use in emergency
contraception was also explored, and it was found to be at
least as effective as the progestogen, levonorgestrel
(LNG).66 Ulipristil has received a product licence for this
indication and is therefore the second PRM to become
available for clinical use.
The concept of administering mifepristone as an
estrogen-free contraceptive pill has also been
evaluated.67-68 Clinical trials have been conducted
administering 2 or 5 mg of mifepristone daily for 4-6
months, demonstrating it to be an effective oral
contraceptive agent, inhibiting ovulation and inducing
amenorrhoea in the majority of cases.69 When compared to
progestogen-only pills, the effect on the bleeding pattern
was significantly more favourable, with more cases of
amenorrhoea and a lower incidence of spotting.70 There is
a potential for PRMs to be developed for use in fertility
control, if their advantages can be more widely appreciated
and if they can be divorced from their image as
abortifacients.
PRMs have been administered as a therapeutic
intervention for the management of unscheduled bleeding
with progestogen-only contraception (POC).71-73
Breakthrough bleeding is a frequent reason for
discontinuing POC.74-75 In one study, the discontinuation
rate of new users of the LNG-releasing intrauterine system
(LNG-IUS) due to bleeding problems was found to be
16.7% over 5 years. As is well known, this side effect is
most prevalent during the first months post-insertion and
most patients who stop using the LNG-IUS due to
unscheduled bleeding do so during the first year
(10.5%).76 PRMs have been proposed to ameliorate this
effect.77 Even a single dose of mifepristone (200 mg) has
been shown to reduce bleeding episodes in users of a
LNG-releasing subdermal contraceptive implant73 Org
31710 also appeared to regularise the bleeding pattern
when administered monthly in addition to a desogestrel-
only contraceptive pill.78 However, suppression of
unscheduled bleeding has not been consistently
demonstrated, and the implications for contraceptive
efficacy also remain to be clarified.79'80 One study
administering CDB-2914 to new LNG-IUS users in an
attempt to prevent breakthrough bleeding found that the
initial beneficial effect was temporary. With ongoing
treatment, the placebo group appeared to have a more
favourable bleeding pattern, even though there were no
significant differences in acceptability measures.79 This
study highlighted the important difference between
prevention and treatment of an undesired side effect and
concluded that there is possibly more potential for PRMs
to improve than to prevent unscheduled bleeding in users
of POC.79
Other indications
Alternative applications of PRMs beyond the context of
gynaecology have also been proposed, either utilising the
antiglucocorticoid effects of some compounds, or in non-
gynaecological conditions that are sensitive to sex steroids.
The use of PAs in the treatment of breast cancer was
envisaged very soon after their discovery.81 Since then,
many other applications for PRMs have been considered
and reviewed.87 Clinical trials have mostly been conducted
with mifepristone.
Preclinical and clinical studies exploring the potential
of mifepristone for the management of breast cancer
succeeded in demonstrating a response of tumour growth
inhibition.83 A Phase II study with daily administration of
200 mg mifepristone in women with untreated metastatic
breast carcinoma concluded that its use as a single agent
could not be supported.84 However, an additive
antiproliferative effect was demonstrated when PAs were
combined with anti-estrogens such as tamoxifen or with an
aromatase inhibitor, suggesting that PRMs may have a
place in the endocrine therapy of breast cancer as part of a
combination regime.85 The potential of PAs for the
prevention of breast cancer has also been evaluated. In
premenopausal women, the administration of 50 mg
mifepristone every other day for 3 months has been shown
to block breast epithelial cell proliferation, implying a
possible protective effect.86 In another study, mice lacking
the rodent version of the breast cancer susceptibility gene
BRCAI were given mifepristone, which inhibited
mammary tumorigenesis.87 The results of these studies
appear to support a potential preventive role for PRMs,
particularly in women who have been identified as being at
increased risk of developing breast cancer.
Mifepristone has also been used in cases of inoperable
meningioma after it was established that this tumour type is
modulated by female sex hormones and commonly
expresses PR.88>89 There may be further benefits in the
management of other tumour types,90 and a response of
human ovarian carcinoma cell lines has been reported in an
in vitro study.91 Whilst the antiglucocorticoid activity of
mifepristone may result in commonly undesired side
effects, it also constitutes the basis for its advantages in the
management of Cushing's syndrome.92-93 Overall, the
broad medical applicability of mifepristone has been
appreciated for almost two decades, but political issues
surrounding its association with termination of pregnancy
have hampered further development.94
Summary
Preclinical and clinical studies have demonstrated the
potential role for PRMs in the management of benign
gynaecological conditions. Mifepristone is licensed for use
in termination of pregnancy but its potential advantages for
use in contraception, management of HMB, uterine
fibroids and endometriosis as well as in non-
gynaecological and oncological conditions have also been
highlighted. Further development of related compounds
has been obstructed by the controversial political issues
regarding their abortifacient properties. The potential of
asoprisnil to become a novel treatment for HMB,
symptomatic uterine fibroids and endometriosis has been
demonstrated and accompanied by a favourable safety and
tolerability profile in all clinical studies to date. Ulipristal
has recently been licensed for use in postcoital
contraception, and the potential applicability of other
PRMs has also been explored.
Early studies with mifepristone reported endometrial
morphological changes as hyperplastic, but these have
subsequently been described in further detail as cystic
glandular dilatation without increased mitotic activity. No
pre-malignant changes have been reported in response to
treatment with PRMs. The unique morphological features
demonstrated in endometrium following administration of
PRMs are now recognised.36 In the future, it is hoped that
long-term studies will confirm the safety as well as the
efficacy of these compounds.
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Effect of asoprisnil on uterine
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BACKGROUND: The selective progesterone receptor modulator asoprisnil suppresses uterine bleeding and decreases leiomyoma volume
while maintaining follicular phase estrogen concentrations. For safety of potential clinical applications, any proliferative effect of asoprisnil on
uterine tissues, particularly endometrium, needs to be established.
METHODS: In a double-blind, randomized, placebo-controlled study (continuation of previously published trial No. NCT00I50644
(Williams et a/., 2007 and Wilkens et al., 2008)), 33 patients with symptomatic uterine leiomyomata received placebo, 10 or 25 mg asoprisnil
daily for 12 weeks before hysterectomy. Proliferation markers Ki-67 and anti-phospho-histone H3 (PH3) were immunolocalized in endome¬
trium, myometrium and leiomyoma tissue. Endometrial PTEN (phosphatase and tensin homologue, a tumour suppressor gene) expression
was also assessed by immunohistochemistry. PH3-positive glandular and stromal cells were counted per measured endometrial area. Endo¬
metrial Ki-67 expression was assessed using stereological methods. Stained myometrial and leiomyoma cells were counted per 10 fields
(x250). PTEN immunostaining was quantified using a histoscore. Each asoprisnil group was compared with placebo (secretory phase)
with significance at 0.05 level.
RESULTS: Endometrial epithelial proliferation and PTEN expression were not significantly different between placebo and asoprisnil groups.
Decreased stromal Ki-67 expression (P < 0.05) suggested any effect of asoprisnil on endometrial proliferation to be inhibitory. Immunolo-
calization of PTEN expression was not different between treatment groups in any tissue compartments. Myometrial Ki-67 expression
decreased following asoprisnil 25 mg (P < 0.05).
CONCLUSIONS: Asoprisnil does not induce proliferation of uterine tissues and does not suppress endometrial PTEN expression.
Key words: asoprisnil / uterine tissues / proliferation / phosphatase and tensin homologue
Introduction
Selective progesterone receptor modulators (SPRM) are a novel class
of progesterone receptor ligands exhibiting mixed and/or partial
agonist and antagonist activity. Asoprisnil is the first SPRM that has
been clinically evaluated in patients with symptomatic uterine fibroids
and endometriosis (Chwalisz et al., 2005b; Wilkens et al., 2008).
Asoprisnil is a I I (3-benzaldoxime-substituted steroidal SPRM that
shows a high degree of uterine selectivity (Schubert et al., 2005).
Previously conducted clinical studies have shown asoprisnil to rever-
sibly suppress uterine bleeding by primarily targeting the endometrium
(Chwalisz et ai, 2005a). Asoprisnil has further been demonstrated to
reduce the volume of uterine fibroids in a dose-dependent manner
(Chwalisz et al., 2005b). It has, therefore, potential for the medical
management of symptomatic uterine fibroids, which commonly
cause heavy menstrual bleeding as well as pressure-related symptoms.
Asoprisnil and other structurally related SPRMs demonstrated
endometrial antiproliferative effects in non-human primates (Chwalisz
et al., 2005b; Schubert et al., 2005). In cynomolgus monkeys, asoprisnil
induced profound endometrial atrophy in the presence of early luteal
phase estrogen concentrations (Brenner et al., 2005). This effect was
accompanied by a decrease in the proliferation markers Ki-67 and
© The Author 2009. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved.
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anti-phospho-histone H3 (PH3). Similar endometrial antiproliferative
effects were described in the macaque endometrium with mifepris¬
tone (Slayden and Brenner, 1994) and other progesterone receptor
antagonists (antiprogestogens) including ZK 137 316 (Slayden et a/.,
1998), The exact mechanism of the endometrial antiproliferative
effects of SPRMs and antiprogestogens remains poorly understood
in spite of extensive studies conducted in non-human primates
(Brenner and Slayden, 2005).
We previously described the effects of asoprisnil on the mor¬
phology of the endometrium, myometrium and leiomyomata in
patients with symptomatic uterine leiomyomata treated with asoprisnil
for 3 months prior to hysterectomy (Williams et a/., 2007). The results
of this study showed that asoprisnil suppressed endometrial prolifer¬
ation, as evidenced by a low mitotic index in endometrial glands and
stroma, which is consistent with the studies conducted in non-human
primates. However, differences in endometrial morphology in
response to asoprisnil treatment were noted in humans compared
with macaques. Although this study also revealed a decrease in endo¬
metrial thickness, unique endometrial morphology was observed in
women treated with asoprisnil for 3 months. This was characterized
by weakly secretory endometrial glands with scarce or absent
mitotic activity, variable stromal changes ranging from stromal
compaction to focal pre-decidual reaction and thickening of the
walls of spiral arterioles. These unusual morphological appearances
were further referred to as 'non-physiologic secretory effects' or
'endometrial SPRM effects' (Williams et al., 2007).
The clinical and histological effects of asoprisnil described above
have been demonstrated in the presence of follicular phase estrogen
concentrations (Wilkens et al., 2008). Concern has previously been
expressed that administration of a compound with progesterone
antagonistic activity may leave the endometrium at risk of hyperplastic
or even malignant changes due to exposure to unopposed estrogen.
Previous studies have reported features of endometrial hyperplasia
following administration of the progesterone antagonist mifepristone
(Eisinger et al., 2003). However, hyperplasia was not observed with
use of low doses of 2 or 5 mg mifepristone, which after administration
to 90 women for 120 days resulted in suppression of endometrial pro¬
liferation marker expression (Ki-67 and mitotic index) (Baird et al.,
2003). No study or case report has described complex hyperplasia
or cytological atypia. No endometrial hyperplasia or evidence of unop¬
posed estrogen effects have been described with asoprisnil after treat¬
ment for up to 3 months (Chwalisz et al., 2005a, 2007).
Endometrial proliferation can be assessed in full thickness endo¬
metrial biopsies by means of Ki-67 and PH3 immunohistochemistry.
The nuclear antigen Ki-67 can be detected in all phases of the replicat¬
ing cell (GI, S, G2 and M) representing the growth fraction of a cell
population (Gerdes et al., 1984; Endl and Gerdes, 2000). More
recently, Ki-67 has been described to play a role in ribosomal RNA
synthesis as well as mitosis and may therefore also be expressed in
non-proliferating cells (Bullwinkel et al., 2006). The Ki-67 index is
less specific than the mitosis-specific marker PH3, which is only
expressed during the actual phase of mitosis (M) (Brenner et al.,
2003). When proliferation of normal endometrium in different
phases of the menstrual cycle is assessed using various proliferation
markers, they all show a high proliferation index during the prolifera¬
tive phase with a significant decrease in the secretory phase. There is a
high correlation between the direct mitotic count and the PH3 count,
while the Ki-67 index shows the same trend but is less specific
(Brenner et al., 2003).
PTEN (phosphatase and tensin homologue) expression in endo¬
metrial tissue can be studied as a marker of early carcinogenesis.
PTEN is a tumour suppressor gene product, which has been described
as a gatekeeper for initiation of carcinogenesis in the endometrium
(Mutter, 2001; Daikoku et al., 2008). Loss of PTEN function has
been demonstrated to occur as an early event in endometrial carcino¬
genesis and has therefore been suggested as a biomarker for prema-
lignant disease even in histologically normal endometrium (Mutter
et al., 2000, 2001). The PTEN tumour suppressor gene is inactivated
in up to 83% of endometrioid endometrial adenocarcinomas, the most
common form of endometrial cancer, which has also been associated
with the risk factor of exposure to unopposed estrogen (Mutter,
2001). It has been shown that exogenous hormones can alter PTEN
expression. Progesterone has been shown to play an important role
in eliminating PTEN-deficient endometrial cells when administered ^
via a progestin-impregnated intrauterine device (Orbo et al., 2006) ^
or systemically (Zheng et al., 2004). A compound with partial =2.
progesterone antagonist activity may raise the concern of an unfavour-
able effect on PTEN expression and therefore on the potential to 2.
influence the predisposition to latent endometrial precancerous o
lesions.
The objective of this study, which is a continuation of the above- -jf
mentioned study (Williams et al., 2007), was to investigate in detail ^
the effects of asoprisnil on proliferation of human endometrial, myo-
metrial and leiomyoma tissues and on endometrial PTEN expression. .3
0
1
Materials and Methods f
c
Study design £-
This was a Phase II multi-centre, double-blind, randomized, placebo- Jj
controlled study of asoprisnil administered for 12 weeks. The study o-
group was composed of 33 premenopausal women from four centres 0
(Edinburgh, Southampton, Glasgow, Liverpool) in good general health
with symptomatic uterine fibroids, who were scheduled for hysterectomy ^
mostly due to heavy menstrual bleeding (Williams et al., 2007; Wilkens co
et al., 2008). Each subject had at least one intramural, non-pedunculated M
submucosal or subserosal fibroid with a diameter of at least 2 cm con- g
firmed by ultrasonography. Other inclusion criteria included age over 18
years, regular menstrual cycles of 17-42 days, negative pregnancy test,
serum FSH of <30mlU/ml, a minimum washout period of 2 months
for oral contraceptive users, agreement to use double-barrier method of
contraception throughout the study until hysterectomy and a normal
cervical smear. All subjects were required to have a normal endometrial
biopsy report based on an adequate specimen taken within 3 months of
screening for entry into the study. The study was performed according
to the ethical principles of the Declaration of Helsinki (1989 revision).
The Institutional Review Board (Multicentre Research Ethics Committee)
approved the protocol. All subjects voluntarily signed a full informed
consent form.
Subjects were randomly assigned to one of three parallel treatment
groups in a 1:1:1 ratio to receive daily doses of asoprisnil 10, 25 mg or
placebo. Asoprisnil or placebo capsules were supplied in blister cards of
identical appearance packaged in sealed kits. The drug was self adminis¬
tered as a single oral dose taken once daily. Treatment was initiated no
later than the fifth day of the subject's menstrual cycle and continued
for at least 12 weeks. Hysterectomy was performed within 24 h after
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the final dose of drug. Blood specimens for determination of estradiol (E2)
and progesterone were collected within 24 h prior to hysterectomy. Com¬
pliance was monitored by the subjects returning all used and unused study
medication blister cards.
Sample collection
After removal of the uterus in the operating theatre, the unfixed speci¬
men was placed on ice and taken without delay to the local pathology
laboratory. The specimen was oriented and a probe inserted through
the external os of the cervix to define the position of the cavity. The
uterus was opened using a long-bladed knife along the plane of the
probe. The opened specimen was then placed in an adequate volume
of 10% buffered formaldehyde and allowed to fix overnight. For large
specimens, parallel parasagittal slices 2 cm in thickness were made to
permit adequate fixation. The following day, the pathologist sampled
the specimen for routine diagnostic reporting and took additional
blocks for study assessment. Study blocks included full thickness endo¬
metrium with underlying myometrium. Leiomyomata were also
sampled. All study samples were processed by routine methods for par¬
affin wax, and 5 p,m sections prepared. Endometrial assessment was
carried out by microscopic examination of haematoxylin-eosin stained
sections. Phase of cycle was assessed using the updated conventional
descriptive Noyes criteria of the normal menstrual cycle as described
in Blaustein's Pathology of the Female Genital Tract (Mutter and Fer-
enczy, 2002).
Immunohistochemistry
Five-micrometre paraffin sections were de-waxed in Histoclear (National
Diagnostics, Atlanta, GA, USA) for 10 min before rehydration in descend¬
ing grades of alcohol. The slides were washed with 0.01 M phosphate-
buffered saline (PBS; pH 7.4; Sigma) and pressure-cooked in 0.01 M
sodium citrate (pH 6) for 5 min at setting 2/high (Tefal, Clipso, Notting¬
ham, UK) for antigen retrieval. The tissue sections were cooled for 20 min
and then washed again in PBS before blocking endogenous peroxidase
activity by immersion in 3% hydrogen peroxide for 10 min at room
temperature. After washing in PBS, the subsequent protocol differed for
the two proliferation markers Ki-67 and PH3.
Ki-67 immunohistochemistry
Slides were incubated in non-immune horse serum (NHS; Vector Labora¬
tories Inc, UK) in PBS for 20 min at room temperature in order to block
non-specific binding of the primary antibody. The primary antibody Ki-67
Novocastra NCL-Ki67-MM I (Novocastra, Newcastle-upon-Tyne, UK;
1: 100 dilution in NHS/PBS) was added and the slides incubated for
30 min at 37°C. For the negative controls, the primary antibody was
replaced with non-immune mouse immunoglobulin (Ig)GI antibody at a
matched antibody concentration to the Ki-67 antibody (1:1000). Sub¬
sequently, the sections were washed in PBS with added Tween 20
(PBST) before incubating in biotinylated horse anti-mouse antibody
(Vector Laboratories) for 30 min at room temperature. Following
another wash in PBST, an avidin-biotin-peroxidase complex
(ABC-HRP; Vectorstain Laboratories) was applied for 30 min at room
temperature before the final wash with PBST.
PH3 immunohistochemistry
At room temperature, sections were incubated in avidin (Vector Labora¬
tories) for 15 min, rinsed in PBS and then incubated in biotin (Vector
Laboratories) for a further 15 min. To block non-specific binding of the
primary antibody, slides were incubated in non-immune goat serum
(NGS; Autogen Bioclear Cat# 7) in PBS with 5% bovine serum albumin
(BSA; Sigma Cat# A-7888) for 20 min at room temperature. The primary
antibody PH3 (Cat# 06-570, Upstate Biotechnology, Buckingham, UK;
1: 1000 dilution in NGS/PBS/BSA) was added and the slides incubated over¬
night at room temperature. For the negative controls, the primary antibody
was replaced with non-immune rabbit antibody IgG at a matched antibody
concentration to H3 (1:1000). Sections were washed in PBST before incu¬
bating in anti-rabbit envision kit (EnVision+ System-HRP, DAKO Cytoma-
tion) for 30 min at room temperature and washing again with PBST.
After the final wash with PBST, the protocols for both proliferation
markers Ki-67 and PH3 were then followed by the addition of the chroma-
gen 3, 3'-diaminobenzidine (DAKO). The reaction was stopped with dis¬
tilled water when nuclear staining was detected by inspection under the
microscope. Harris's haematoxylin was used for counterstaining. The sec¬
tions were then dehydrated and finally mounted with Pertex (Cellpath pic,
Hemel Hempstead, UK).
PTEN immunohistochemistry
For PTEN immunohistochemistry, the paraffin sections were de-waxed,
rehydrated and pressure-cooked as described earlier. After cooling o
down for 20 min, the sections were transferred to the Bond-X immunos-
taining machine and processed using the Bond Refine Polymer Detection §
kit (Cat. No DS9800 Vision BioSystems Bond™, Newcastle-upon-Tyne, §"
UK). The primary antibody was PTEN (NCL-PTEN, Novocastra; 1:600 =»,
dilution in Bond Antibody diluent, Vision BioSystems) and IgG from the ^
same species and at the same concentration was used as the negative zr
control (Mouse IgG i kappa, Sigma). Sections were dehydrated and "p
mounted as described earlier. 3=
Scoring 3
In myometrium and leiomyoma tissue, Ki-67 and PH3 immunostaining was §
~+\
assessed by randomly selecting 10 fields at x250 magnification and count¬
ing all stained cells. To quantify the amount of staining in endometrium, "o'
stereological methods were applied and varied for assessment of Ki-67
and PH3, respectively. For assessment of PTEN immunostaining in endo-
metrium, a histoscore was applied by two independent observers as pre- o
viously described (Aasmundstad et al., 1992). A separate histoscore was
applied to surface epithelium, glandular epithelium, stroma, perivascular ■<
cells and endothelium, respectively. z
Ki-67 |
Inspection of the endometrial tissue after immunostaining for Ki-67 gave ho
the impression of scanty staining in the majority of sections. In order to ^
quantify the level of immunoreactivity, stereological methods were used
as previously described (Mahood et al., 2005). The program used was
Image-Pro plus 4.5.1 with Stereology-Pro 5.0 plug-in software (Media
Cybernetics UK, Wokingham, Berkshire, UK) in combination with an
Olympus BH-2 microscope fitted with a Prior automatic stage (Prior
Scientific Instruments Ltd, Cambridge, UK). With the aid of the software,
random fields were selected for counting and grids were placed over the
fields at x 250 magnification. All 432 intersections of a grid were defined
as points, and all points falling over tissue were counted as one of the fol¬
lowing categories: (a) unstained epithelial cell, (b) stained epithelial cell, (c)
unstained stromal cell, (d) stained stromal cell and (e) lumen (i.e. the
empty space within glands or vessels). The proportion of tissue occupied
by each of these categories was expressed as a percentage of total points
counted.
The number of fields counted was dependent on obtaining a percentage
SE value of <10%. For all but four tissue sections, 10 fields (i.e. 4320
points) were sufficient to obtain a percentage SE of <10% for the
categories of unstained cells and lumen. For three of the remaining
tissue sections, 50 fields (i.e. 21 600 points) and in one case 20 fields
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(i.e. 8640 points) were counted. The number of points occupied by
stained epithelial or stromal cells was counted in a total of 50 fields for
all tissue sections. According to the statistical formula for sample size
calculations, 50 fields (or 21 600 points) are sufficient to detect a
proportion of 0.01% of stained cells assuming a null hypothesis of
0.00001%. Therefore, the point count was limited to 50 fields for all
tissue sections (Kirkwood and Sterne, 2003).
PH3
Inspection of the endometrial tissue after staining for PH3 revealed very
scanty immunostaining. In order to quantify the positive immunoreactivity
in the tissue sections, the total number of stained epithelial and stromal
cells in all sections was counted. Stereological methods were used to
determine the area of endometrium in each section. The program used
was Image-Pro plus 4.5.1 with Stereology-Pro 5.0 plug-in software
(Media Cybernetics UK) in combination with an Olympus BH-2 micro¬
scope fitted with a Prior automatic stage (Prior Scientific Instruments
Ltd). The cell count was expressed as the number of stained cells per
mm2 endometrium.
Statistical analysis
For statistical analysis, each group of asoprisnil-treated subjects (10 and
25 mg) was compared with a subgroup of placebo-treated subjects who
had undergone hysterectomy in the secretory phase of their menstrual
cycle. The Wilcoxon's rank sum test was used for this analysis and signifi¬
cance was determined at 0.05 level using Hochberg's multiple comparison
procedure.
Results
A total of 33 patients were included in the study. Placebo and asopris¬
nil groups had a well-matched distribution for age, weight and height
(Table I). Ten subjects had been treated with placebo, 12 had received
10 mg asoprisnil and I I had received 25 mg asoprisnil for an average
of 95 days. There was satisfactory drug compliance in all groups. Two
placebo-treated subjects had undergone hysterectomy in the prolifera¬
tive phase of their menstrual cycle and were excluded from the stat¬
istical analysis. The remaining eight placebo-treated subjects had been
in the secretory phase of their cycle and constituted the subgroup for
comparison to the asoprisnil-treated groups.
Proliferation marker expression was low in all asoprisnil-treated
subjects as well as placebo-treated subjects in the secretory phase
in all uterine tissues. There was high proliferation marker expression
in the endometrium of the two placebo-treated subjects in the prolif¬
erative phase of the menstrual cycle.
Expression of Ki-67 and PH3 in endometrium
Assessment of proliferation marker expression in endometrial stroma
is suggestive of a suppressive effect of asoprisnil (Fig. I A). Following
the method of quantifying Ki-67 immunostaining as described earlier,
the median of grid points occupied by stained cells in endometrial epi¬
thelium and stroma was <2% in specimens from both asoprisnil- and
placebo-treated subjects. Following asoprisnil administration, there
was a statistically significant and dose-dependent decrease in Ki-67
expression in endometrial stroma (Fig. I A) compared with the
placebo-treated subjects in the secretory phase of their menstrual
cycle. There was no statistically significant difference between treat- O
ment groups in Ki-67 expression in endometrial glandular epithelium S
(Fig. I B). The median of counted stained endometrial cells following o"
immunostaining for PH3 was generally very low in epithelium and §-
stroma of both asoprisnil- and secretory phase placebo-treated sub- ^
jects (<3/mm2). There was no statistically significant difference ^
between treatment groups (Fig. 2). The PH3 data were normalized =r
to the total area of endometrium. The data were also assessed in
relation to only epithelial or stromal cells, and those results were jT
comparable and did not add to the results as presented.
CD
•p
Expression of Ki-67 and PH3 in myometrium g,
and leiomyomata JL
There also appeared to be a suppressive effect of asoprisnil on myo-
metrial proliferation. There was very low PH3 expression in both £.0)
asoprisnil- and secretory phase placebo-treated groups (median of o
less than 10 stained cells per 10 fields at x250 magnification), and
the differences were not statistically significant. There was however
a dose-dependent decrease in Ki-67 expression in both asoprisnil-
treated groups compared with the secretory phase placebo-treated ,»
subjects, but only the difference between asoprisnil 25 mg and co
secretory phase placebo reached statistical significance (Table II). o
Table I Demographic data for patients with symptomatic uterine leiomyomata given placebo or asoprisnil daily for 12
weeks before hysterectomy
Variable Treatment group
Placebo (n = 10) Asoprisnil 10 mg (n = 12) Asoprisnil 25 mg (n = II) All subjects (n = 33)
Age (years)
Mean (SD) 41.8 (3.6) 45.1 (3.5) 44.6 (6.0) 43.9 (4.6)
Min-Max 37-48 39-50 35-52 35-52
Weight (kg)
Mean (SD) 73.4 (1 1.7) 73.8 (17.7) 75.9 (1 1.8) 74.4 (13.8)
Min Max 54 89 45-105 60-96 45-105
Height (cm)
Mean (SD) 165.3 (6.4) 164.3 (4.7) 165.6 (7.3) 165.1 (6.0)

































Figure I Ki-67 expression in endometrial stroma (A) and glands
(B) following administration of asoprisnil.
Ki-67 expression is quantified by percentage of grid points overlying a stained
glandular or stromal ceil respectively, following the stereological projection of a
grid over several views of a tissue section. In the box plots, the box spans
between lower and upper quartiles with the horizontal line within it represent¬
ing the median; the whiskers extend to the minimum and maximum obser¬
vations; the cross represents the mean. Each asoprisnil group is compared
with placebo (secretory phase) using Wiicoxon's rank sum test. In stroma,
both asoprisnil groups have a statistically significantly lower expression of
Ki-67 than placebo using Hochberg's multiple comparison procedure at 0.05
level; in glands, neither difference between an asoprisnil group and placebo
is statistically significant.
Assessment of Ki-67 and PH3 expression in leiomyoma tissue
revealed a similar trend. There was very low PH3 expression in
tissue sections from asoprisnil- and placebo-treated subjects, and
the differences between groups were not statistically significant.
There was an apparent reduction in Ki-67 expression in both
asoprisnil-treated groups, but the differences did not reach statistical
significance (Table III).
Endometrial expression of PTEN
There was no difference in immunohistochemical detection of PTEN
expression between treatment groups in any of the tissue compart¬
ments assessed. PTEN immunhistochemistry resulted in a nuclear
staining pattern with similar intensity in glandular epithelium and
stroma (Fig. 3). The staining intensity was strongest in the surface epi¬
thelium (median histoscores of 125-180) and only weak in endo¬


































Figure 1 PH3 expression in endometrial stroma (A) and glands (B)
following administration of asoprisnil.
PH3 expression is quantified as stained glandular or stromal cells per mm2
endometrium following a count of all stained cells in the available tissue
section and steneological measurement of the endometrial area. Each asoprisnil
group is compared with placebo (secretory phase) using Wiicoxon's rank sum
test None of the differences between an asoprisnii group and placebo are stat¬
istically significant. PH3, anti-phospho-histone H3.
perivascular cells and 30-45 for endothelium). In asoprisnil and
placebo groups, there were inter-individual variations independent
of the treatment received with some subjects showing very weak
and others quite strong staining. However, there was no significant
difference between treatment groups (Fig. 4).
Blood concentrations of E2 and progesterone
E2 and progesterone levels were measured within 24 h prior to hyster¬
ectomy (Table IV). The mean E2 value was lower in the 25-mg asopris¬
nil group compared with both placebo and 10-mg asoprisnil groups.
Mean progesterone values were substantially lower in both asoprisnil-
treated groups compared with placebo. Although variability across the
groups was high, the median progesterone values revealed the same
pattern.
Discussion
This study shows that asoprisnil administered daily for 12 weeks exerts
an inhibitory effect on endometrial proliferation and proliferation of
myometrium and leiomyomata.
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Table II Proliferation marker expression in myometrium by immunohistochemistry
Placebo/secretory
Median
Ki-67: count of stained cells per 10 fields at x250 80.0













Each asoprisnil group is compared with placebo using Wilcoxon's rank sum test; $ denotes statistical significance at 0.05 level using Hochberg's multiple comparison procedure. PH3,
anti-phospho-histone H3.
Table III Proliferation marker expression in leiomyoma by immunohistochemistry
Placebo/secretory Asoprisnil iOmg Asoprisnil 25 mg
Median Median P-value Median P-value
Ki-67: count of stained cells per 10 fields at x250 237.0 66.0 0.078 86.0 0.088
PH3: count of stained cells per 10 fields at x250 5.5 3.0 0.355 4.0 0.707
Each asoprisnil group is compared with placebo using Wilcoxon's rank sum test.
Within the placebo group in this study, endometrial glands and
stroma showed high proliferation marker expression in subjects who
had undergone hysterectomy in the proliferative phase of their men¬
strual cycle compared with low expression in subjects in the secretory
phase, as previously reported (Brenner et a/., 2003). Proliferation
marker expression following 12 weeks of treatment with asoprisnil
was low in most uterine tissues and comparable to the low level of
proliferation observed in the placebo-treated subjects in the secretory
phase. There was no difference in PH3 expression between
treatment groups in endometrium, myometrium or leiomyoma
tissue, a likely reflection of the very scanty immunostaining. Ki-67
expression in endometrial epithelium was not significantly different
in asoprisnil-treated subjects compared with placebo-treated subjects
in the secretory phase. Asoprisnil had a dose-dependent inhibitory
effect on proliferation in endometrial stroma as indicated by decreased
Ki-67 expression. There was no evidence of altered endometrial
PTEN expression by administration of asoprisnil. Dose-dependent
suppression of proliferation was demonstrated similarly in myome¬
trium but was only significant with the higher dose of asoprisnil. Pro¬
liferation of leiomyoma tissue appeared to be inhibited by asoprisnil
even though the differences did not reach statistical significance.
The endometrial antiproliferative effect of asoprisnil demonstrated
in this study is consistent with previous clinical trial reports. Prolifer¬
ation marker expression was suppressed or unchanged compared
with the secretory menstrual cycle phase. In a previous trial, various
doses of asoprisnil (5 mg once daily to 50 mg twice daily) were admi¬
nistered to healthy premenopausal women for 28 days. In endometrial
biopsies collected following treatment (with a Pipelle® endometrial
sampler), there was no evidence of endometrial hyperplasia or
other appearances suggestive of an unopposed estrogen effect. Impor¬
tantly, there was a common finding of a unique endometrial appear¬
ance, which has since been classified as 'non-physiologic secretory
effect' and which has not been previously described with any
hormonally active agent (Chwalisz et a/., 2005a). This appearance,
now referred to as 'SPRM endometrial effect', seems to reflect the
mixed progesterone agonistic/antagonistic properties of asoprisnil in
the human endometrium.
In a further trial with administration of 5, 10 or 25 mg asoprisnil to
women with uterine leiomyomata for 12 weeks, Pipelle® endometrial
biopsies were also obtained following treatment. Histological assess¬
ment revealed similar findings. There was no case of endometrial
hyperplasia or cytological atypia. A majority of endometrial samples
following asoprisnil treatment showed distinct changes consistent
with the 'SPRM endometrial effect' (Chwalisz et a/., 2007). In a
39-week toxicity study with asoprisnil in adult cynomolgus monkeys,
the endometrium appeared atrophic with suppressed gland prolifer¬
ation and stromal compaction. Some glands appeared dilated and
cystic in the absence of any hyperplastic features (DeManno et o/.,
2003). However, this study neither showed secretory changes in
endometrial glands nor thickening of the wall of spiral arterioles.
Studies in non-human primate models have been crucial in the dis¬
covery and development of SPRMs and have provided valuable insight
into their possible mechanisms of action (Chwalisz et a/., 2006). Endo-
metria from monkeys as well as humans have shown a distinct mor¬
phological response following exposure to SPRMs pointing to an
antiproliferative effect (Wolf et al., 1989). However, comparisons
between monkeys and humans have also indicated some important
differences highlighting the need for caution when extrapolating
results from non-human primate studies to the human. This may be
due to differences in the steroid receptor pharmacology of the
monkey and human endometrium (Chwalisz et al., 2006). It is possible
that the balance between agonist and antagonist effect of asoprisnil is
in favour of the agonist side in humans. This could result from species
differences in metabolic end-products or from species-specific cellular
environments creating a different balance of coactivator and compres¬
sor expressions (Chwalisz et al., 2008). The findings of secretory
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endometrial gland changes and formation of thick-walled endometrial
spiral arteries following treatment with asoprisnil were unique to the
human endometrium and had not previously been observed in the
monkeys. Suppression of proliferation marker expression due to aso¬




Figure 3 PTEN expression in endometrial stroma (A) and glandu¬
lar epithelium (B) following administration of asoprisnil.
PTEN expression is quantified by applying a histoscore (0-300). Each asopris¬
nil group is compared with placebo (secretory phase) using Wilcoxon's rank
sum test. None of the differences between an asoprisnil group and placebo
are statistically significant. PTEN. phosphatase and tensin homologue.
metria. Endometrial Ki-67 and PH3 expression was suppressed in
cynomolgus monkeys treated with 10, 30 or 90 mg/kg asoprisnil for
90 days. The suppression was significant when compared with
samples from the placebo group in the proliferative cycle phase
(Brenner et al., 2005). There was no significant difference between
asoprisnil-treated monkeys and monkeys in the secretory cycle
phase corresponding to the findings in this study. There was no differ¬
entiation into separate tissue compartments (stroma and epithelium)
in the monkey studies, while this study showed that in the human
Ki-67 expression particularly in endometrial stroma is significantly sup¬
pressed after 3 months asoprisnil treatment.
The exact mechanism of action of the endometrial antiproliferative
effect of SPRMs has still not been fully elucidated. It has been
suggested that the endometrial effects of asoprisnil are mediated by
the endometrial vasculature and in particular the spiral arteries (Chwa-
lisz et al., 2000), which may be targeted via the perivascular cells
(Chwalisz et al., 2006). This hypothesis appears to be supported by O
the striking effect of asoprisnil on the formation of thick-walled |
spiral arterioles in humans. However, the absence of similar morpho- 5.
a»
o.
may be another pathway, and more recently the role of the endo- o.
metrial androgen receptor (AR) has been emphasized as a potential o





mechanism of the endometrial antiproliferative effect (Brenner et al.,
2002; Brenner and Slayden, 2005). Androgens are known to inhibit
estrogenic effects in the primate endometrium, and AR has been §
shown to be up-regulated by treatment with various progesterone
antagonists and SPRMs in monkeys and mifepristone in humans _g
(Brenner et al., 2002, 2005). Moreover, it was possible to suppress o
the endometrial antiproliferative effect induced by progesterone o1
antagonists by adding the AR antagonist flutamide (Slayden and
Brenner, 2003). These findings imply that a functional AR is required
for SPRMs to exert their antiproliferative effect on the endometrium.
Previous in vitro studies have suggested asoprisnil to have a cell type- o
specific antiproliferative effect on uterine leiomyoma cells compared □-
with normal myometrial cells (Chen et al., 2006). A direct effect of ^
asoprisnil on leiomyoma cells may result in suppressed growth and ^
therefore reduced fibroid volume as previously reported (Chwalisz ^
et al., 2007). The concomitant suppression of myometrial proliferation 5°
observed in this study suggests there may be an additional mechanism o
of action, for example, an impact on uterine artery blood flow. Both o
Figure 4 PTEN immunolocalization in endometrium; scale bar 100 p.m.
Placebo group in secretory cycle phase; inset—negative control (A). Treatment group asoprisnil 25 mg (B).
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Table IV Blood E2 and progesterone concentrations
within 24 h of hysterectomy
Treatment group
Placebo Asoprisnil Asoprisnil
(n = 10) 10 mg 25 mg
(n = 12) (" = II)
Estradiol (ng/ 13.4 ± 9.1 13.2 + 8.3 5.0 + 4.2
dl), mean + SD
Progesterone (ng/dl)
Mean + SD 759.5 + 689.2 354.8 + 503.3 56.5 + 78.4
Median 596 43 23
asoprisnil (Wilkens et al., 2008) and mifepristone (Reinsch et a/., 1994)
have been shown to reduce uterine artery blood flow.
This study has demonstrated that endometrial PTEN expression is
not altered by administration of asoprisnil. This finding, together with
the low endometrial Ki-67 and PH3 expression after 3 months treat¬
ment, supports the conclusion that the effect of asoprisnil on endome¬
trium is antiproliferative and does not promote carcinogenesis. It
justifies the assumption that the feature of cystically dilated glands
occasionally found in asoprisnil-treated endometria is not associated
with hyperplasia and is not pre-malignant.
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Effects of the Selective Progesterone Receptor
Modulator Asoprisnil on Uterine Artery Blood Flow,
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Hysterectomy
Julia Wilkens, Kristof Chwalisz, Cong Han, Jane Walker, lain T. Cameron, Susan Ingamells,
Alexandra C. Lawrence, Mary Ann Lumsden, Dharani Hapangama, Alistair R. W. Williams,
and Hilary 0. D. Critchley
Centre for Reproductive Biology (J.Wi., H.O.D.C.) and Department of Pathology (A.R.W.W.), University of Edinburgh, Edinburgh EH16 4TJ,
United Kingdom; TAP Pharmaceutical Products Inc. (K.C., C.H.), Lake Forest, Illinois 60045; Royal Infirmary (J.Wa.), Edinburgh EH16 4SA,
United Kingdom; Developmental Origins of Health and Disease Division (DoHaD) (I.T.C., S.I., A.C.L.), University of Southampton,
Southampton S016 6YD, United Kingdom; Department of Obstetrics and Gynaecology (M.A.L.), University of Glasgow, Glasgow G37 2ER,
United Kingdom; and Department of Obstetrics and Gynaecology (D.H.), University of Liverpool, Liverpool L8 7SS, United Kingdom
Introduction: Asoprisnil, a novel orally active selective progesterone receptor modulator, is being
studied for the management of symptomatic uterine leiomyomata. The exact mechanism of action
is not yet discerned. The primary objectives of this double-blind, randomized, placebo-controlled
study included evaluation of the effect of asoprisnil on uterine artery blood flow. Furthermore, we
assessed effects of asoprisnil on leiomyoma symptoms.
Patients and Methods: Thirty-three premenopausal patients scheduled for hysterectomy due to
symptomatic uterine leiomyomata were recruited in four centers and treated with 10 or 25 mg
asoprisnil or placebo for 12 wk before surgery. At baseline and before hysterectomy, all patients
underwent sonographic assessment to measure impedance to uterine artery blood flow, deter¬
mined by resistance index and pulsatility index, as well as volumes of largest leiomyoma and uterus.
In addition, patients recorded intensity and frequency of menstrual bleeding on a menstrual
pictogram. Each asoprisnil treatment was compared with placebo.
Results: The increased pulsatility index in both asoprisnil groups and the statistically significantly
increased resistance index within the 25-mg asoprisnil group suggest a moderately decreased
uterine artery blood flow. Analysis of menstrual pictogram scores showed a statistically significant
larger decrease in frequency and intensity of bleeding for both asoprisnil groups compared with
placebo. Bleeding was suppressed by asoprisnil 25mg in 91 % of patients. Asoprisnil treatment was
well tolerated when administered daily for a 12-wk period, and no serious adverse events occurred.
Conclusion: Asoprisnil moderately reduced uterine artery blood flow. This effect may contribute
in part to the clinical effects of asoprisnil. (7 Clin Endocrinol Metab 93: 4664-4671, 2008)
Uterine leiomyomata are benign smooth muscle tumors orig¬i ating from the myom trium. They are pr sent in up to
70% of women even though asymptomatic in over half of the
cases with 20-25% of women of reproductive age clinically af-
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fected (1, 2). The commonest symptoms are heavy menstrual
bleeding (HMB) and pressure symptoms. With currently limited
options for medical therapy, uterine leiomyomata are the second
most frequent indication for hysterectomy in the United Kingdom
Abbreviations: ANCOVA, Analysis of covariance; AE, adverse event; E,G, estrone gluc-
uronide; ELA, evidence of luteal activity; HMB, heavy menstrual bleeding; MP, menstrual
pictogram; NELA, no evidence of luteal activity; NSAID, nonsteroidal antiinflammatory
drug; PdG, pregnanediol glucuronide; PI, pulsatility index; Rl, resistance index; UFS-QOL,
Uterine fibroid symptom and health-related quality-of-life.
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(3, 4). In the United States, 600,000 hysterectomies are per¬
formed annually with HMB as the most common indication (5).
There is growing evidence that progesterone and the proges¬
terone receptor play a key role in fibroid growth and develop¬
ment. Contrary to previous understanding that leiomyoma
growth is mainly estrogen related, recent data from clinical and
in vitro studies indicate that progesterone plays a pivotal role (6,
7). Some clinical studies have shown that synthetic progestins
reverse the effect of GnRH agonists on leiomyoma volume,
which indirectly indicates the effects of GnRH agonists on
leiomyomata may be due partly to cessation of progesterone
secretion (8). Furthermore, a reduction in mean leiomyoma vol¬
ume was demonstrated in small, uncontrolled, clinical studies
with the progesterone receptor antagonist mifepristone (9).
Mifepristone has been shown to reduce uterine artery blood flow
in patients with uterine leiomyomata (10). Collectively, these
data suggest that progesterone may have a stimulatory effect on
leiomyoma growth.
Asoprisnil (J867) is a novel, orally active and selective pro¬
gesterone receptor modulator (SPRM), which exhibits partial
and mixed agonist and antagonist effects on various progester¬
one target tissues in animals and humans (11-13). Asoprisnil
exhibits endometrial antiproliferative effects in nonhuman pri¬
mates in the presence of follicular-phase estradiol levels (11,14).
The effects of 3 months treatment with asoprisnil in women
with uterine leiomyomata have been reported. Asoprisnil sup¬
pressed uterine bleeding in 28, 64, and 83% of subjects at 5,10,
and 25 mg, respectively, and reduced leiomyoma and uterine
volumes (15).
The current study was designed to evaluate the mechanism of
action of asoprisnil in patients with symptomatic leiomyomata
scheduled for hysterectomy. The primary objectives were to as¬
sess the effects of asoprisnil on uterine artery blood flow through
measurements of impedance (resistance and pulsatility indices).
The effects on endometrial, myometrial, and leiomyomata mor¬
phology, have been reported elsewhere (16). Furthermore, we
investigated effects of asoprisnil on leiomyoma symptoms, in¬
cluding semiquantitative assessment of uterine bleeding using a
menstrual pictogram (MP), and ovarian activity.
Subjects and Methods
Women studied
Premenopausal women were recruited from four centers (Edinburgh,
Southampton, Glasgow, and Liverpool). All subjects were in good health
and scheduled for hysterectomy due to symptomatic uterine leiomyo¬
mata, mostly due to HMB. Each patient had at least one leiomyoma
(diameter a 2 cm) or multiple small leiomyomata (uterine volume a 200
cm3) confirmed by ultrasonography. In all cases, the clinical decision for
hysterectomy was taken before recruitment. Inclusion and exclusion cri¬
teria were applied as previously described (16). Patients were required to
have a washout period of 2-12 months for hormonal medications before
screening. Non-steroidal anti-inflammatory drugs (NSAIDs) and tran-
examic acid were permitted during screening and treatment periods. All
patients provided informed consent. The study protocol was approved
by the Multicenter Research Ethics Committee.
Study design
This was a phase II, multicenter, randomized, double-blind, placebo-
controlled study of asoprisnil administered to patients with symptomatic
uterine leiomyomata for 12 wk. Dose selection was based on previous
phase I and II studies. A treatment regime with doses of 10 and 25 mg
asoprisnil for a duration of 12 wk had been shown to effectively suppress
uterine bleeding and reduce leiomyoma and uterine volumes while being
safe and well tolerated (15).
Screening procedures and enrollment were carried out as previously
described (16). Subjects in three parallel dose groups in a 1:1:1 ratio
received once-daily oral doses of asoprisnil of 10 or 25 mg asoprisnil or
placebo. They and all study personnel were blinded to treatment groups.
Treatment was initiated no later than the fifth day of the patient's men¬
strual cycle and continued for 12 wk until hysterectomy. Hysterectomy
was performed within 24 h of the final dose. Throughout the study, each
patient was closely monitored for occurrence of adverse events (AEs) and
standard laboratory safety parameters.
Sonographic assessment
Color Doppler imaging by transvaginal ultrasound was employed to
determine blood flow of the uterine arteries before the first study drug
dose and after 12 wk. Blood flow was estimated using two impedance
indices: resistance index (RI) and pulsatility index (PI) defined as follows:
RI = systolic — end diastolic peak velocity/systolic peak velocity; PI =
systolic — end diastolic peak velocity/time-averaged maximum velocity
(17). For each impedance index, two measurements were taken from left
and right arteries, respectively; each side's index was calculated using the
mean of the two, and further analyses used the mean of both sides (18).
Study sites used the same color Doppler imaging methods. Scans were
performed by the same ultrasonographer at each site. The largest leiomy¬
oma and uterus were measured and the volumes estimated using the
volume of an ellipsoid. The position of the fibroids within the uterus was
not specifically recorded further to previous evidence that symptoms of
HMB do not appear to correlate with fibroid location (19).
MP
At screening, patients were issued a MP in a daily diary to be kept
throughout the study. Patients recorded daily any uterine bleeding.
Whenever uterine bleeding exceeded spotting, the amount of blood loss
was quantified and documented in the MP. Patients were supplied with
standardized sanitary products. The MP scores, representing blood loss
in milliliters, were calculated as described previously (20) and then
summed for each patient for the last full menstrual cycle before random¬
ization menses normalized to 28 d and for each 28-d treatment period,
producing a total score for each subject for baseline, wk 1-4, wk 5-8,
and wk 9-12. The number of days with bleeding was calculated from the
diaries for the pretreatment cycle and the three 28-d treatment periods.
To evaluate improvement in uterine bleeding, change of MP scores and
of days with bleeding from baseline to each month and final month was
calculated and summarized. The percentage of subjects with suppression
of uterine bleeding during the treatment period was calculated for each
treatment group.
Uterine fibroid symptom and health-related
quality-of-life (UFS-QOL) questionnaire
Before commencing the study drug and before hysterectomy, patients
completed the Uterine Fibroid Symptom and Health-Related Quality-
of-Life questionnaire (UFS-QOL) (21) with its subscales of concern, ef¬
fect on activities, energy/mood, control, self-consciousness, sexual func¬
tion, and symptom severity.
Ovarian activity
Urine aliquots (first voided urine of the day) were collected twice
weekly during screening and throughout the treatment period and frozen
at -20 C for subsequent analysis. Ovarian activity was determined by
assessing urinary pregnanediol glucuronide (PdG) and estrone glucuro-
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nide (EjG) levels, which were measured using ELISA. Hormone concen¬
trations were corrected for creatinine excretion and expressed as ratios
of the creatinine concentration to urine volume (22).
Evidence of luteal activity (ELA) vs. no evidence of luteal activity
(NELA) was determined from urinary PdG levels using two algorithms
(23); in the first algorithm, a PdG level was considered ELA if it was at
least three times the minimum 3-concentration moving average of the
past 4 wk; the second algorithm had an additional criterion that, to be
considered ELA, a PdG level had to be at least 0.5 mmol/mol creatinine.
For each 4-wk period and each treatment group, the percentage of pa¬
tients with NELA and 95% exact confidence intervals were calculated.
Ovarian follicular activity during treatment was determined by com¬
paring E^ concentrations during the 12-wk treatment period to pre-
treatment follicular phase concentrations (baseline). Based on the
method described by Brown et al. (24), ovarian activity was labeled as
continued (E^ & 50% above baseline on at least two occasions, sepa¬
rated by al3 d, with no E,G concentrations &50% above baseline),
partially suppressed (EjG concentration &50% above baseline on at
least one occasion while not meeting the definition of continued follicular
activity), or totally suppressed (E,G < 50% above the baseline through¬
out treatment period). Number and percentage of patients belonging to
each category were calculated for each treatment group.
Data analysis and statistical methods
Comparison of each asoprisnil treatment with placebo was per¬
formed using pairwise comparisons within the framework of analysis of
covariance (ANCOVA) models for assessments of change in RI, PI, and
MP scores, number of days with bleeding, and UFS-QOL scores. The
ANCOVA models for RI and PI included factors of treatment and in¬
vestigator as fixed effects and baseline value as a covariate, whereas the
models for MP scores, number of days with bleeding, and UFS-QOL
scores included treatment as a factor and baseline value as a covariate.
In addition, a paired t test was performed for RI and PI on the change from
baseline to final visit for each treatment group. Percent change in volume of
the largest leiomyoma and the uterus was compared between each asoprisnil
group and placebo using Wilcoxon's rank sum test. Percentage of patients
with suppression of uterine bleeding was compared by Fisher's exact test.
For efficacy endpoints, Hochberg's multiple comparison method was ap¬
plied to control for pairwise comparisons at a significance level of 0.05. No
statistical inference was performed on safety variables.
The planned sample size for this study was 15 patients per treatment
arm. This sample size would provide greater than 95% power to detect
Subjects screened Screen failures






FIG. 1. Patient enrollment: numbers of patients at different stages of the clinical study.
a 0.08 difference in RI between the asoprisnil and the placebo group
using a two-tailed two-sample t test with a common SD of 0.05 (with a
0.05 significance level).
The study was closed with a total of 33 patients. With 11 patients per
group and assumptions as above, the power to detect a 0.08 difference
in RI was 94%.
Results
Patient demographics
Thirty-three patients were enrolled. Thirteen screen failures
occurred. Ten, 12, and 11 patients received placebo and 10 and
25 mg asoprisnil, respectively. All 33 patients completed the
study including 12 wk treatment, the scheduled hysterectomy,
and follow-up after 6 wk (Fig. 1).
Treatment and placebo groups were well matched regarding
race, age, height, and weight (Table 1). Drug compliance was
satisfactory in all groups. No patients developed withdrawal
criteria during the study or received the wrong treatment or an
incorrect dose. Three patients (one on placebo and two on 25 mg
asoprisnil) took tranexamic acid to control menstrual bleeding,
but the median use per month was nil in each group. Median
intake of NSAIDs was higher in the 10-mg asoprisnil group (1.2
d/month) than in the placebo or 25-mg asoprisnil groups (me¬
dian of nil per month). During treatment, NSAIDs were primar¬
ily taken for headache, joint, or muscular pain and for dysmen¬
orrhea. The differences between groups were not expected to
influence study results.
Effects on uterine artery blood flow
Neither asoprisnil group had a change from baseline to final
visit in RI that was statistically significantly different from pla¬
cebo. There was, however, a statistically significant increase in
RI from baseline to final visit within the 25-mg asoprisnil group,
indicating decreased uterine artery blood flow (Table 2).
The PI increased statistically signifi¬
cantly from baseline to final visit in both
asoprisnil groups compared with placebo,
indicating decreased uterine artery blood
flow. From baseline to final visit, the PI in¬
creased in the 25-mg asoprisnil group al¬
though unchanged after asoprisnil 10 mg
with a statistically significant decrease within
the placebo group (Table 2).
Effects on volume of largest
leiomyoma and uterus
From baseline to final visit, the median
percent change in largest leiomyoma vol¬
ume showed a decrease after 25 mg aso¬
prisnil (-25.8%) and a small increase in the
placebo group (4.9%), with a very minor
decrease after asoprisnil 10 mg (—0.4%).
The differences between each asoprisnil
group and placebo in percent change of larg¬
est leiomyoma volume or uterine volume
were not statistically significant.
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TABLE 1. Demographic data at baseline
Treatment group
Variable Placebo (n = 10) Asoprisnil 10 mg (n = 12) Asoprisnil 25 mg (n = 11) All subjects (n = 33)
Race, n (%)
Black 1 (10) 2(16.7) 1 (9.1) 4(12.1)
Caucasian 9 (90) 10(83.3) 10 (90.9) 29 (87.9)
Age (yr)
Mean (sd) 41.8 (3.6) 45.1 (3.5) 44.6 (6.0) 43.9 (4.6)
Min-Max 37-48 39-50 35-52 35-52
Weight (kg)
Mean (sd) 73.4(11.7) 73.8(17.7) 75.9(11.8) 74.4 (13.8)
Min-Max 54-89 45-105 60-96 45-105
Height (cm)
Mean (sd) 165.3 (6.4) 164.3 (4.7) 165.6 (7.3) 165.1 (6.0)
Min-Max 158-177 156-172 157-178 156-178
Race, age, weight, and height distribution across the three treatment groups. Max, Maximum; Min, minimum.
Effects on uterine bleeding
Treatment with asoprisnil led to a substantial decrease in
uterine bleeding. There was a large mean reduction in blood loss
in the final month compared with baseline in both asoprisnil
groups, which was statistically significantly different from the
mean increase in the placebo group (Table 3). These decreases
were already apparent during the first 4 wk of treatment.
Patients treated with 10 and 25 mg asoprisnil had bleeding of
7.0 and 8.0 d on average at baseline, which decreased to 1.2 and
0.2 d in the final month, respectively. The placebo group had a
mean number of 7.3 bleeding days at baseline and the final
month. The difference between asoprisnil groups and placebo
was statistically significant (P < 0.001). The decrease in the
asoprisnil groups was evident during the first month and con¬
tinued throughout the treatment period. Suppression of uterine
bleedingwas experienced by 33% ofpatients treated with lOmg
asoprisnil and 91% treated with 25 mg, compared with none of
the patients in the placebo group. The difference between the
25-mg asoprisnil and placebo groups was statistically significant
(P < 0.001).
UFS-QOL
Results of the UFS-QOL total score, and in particular the
subscales of concern, activities, control, and self-consciousness,
showed statistically significant improvement from baseline to
final visit for both asoprisnil groups compared with placebo,
indicating an effect on quality of life. Reduced symptom se¬
verity was observed in both asoprisnil groups but was statis¬
tically significant only with 25 mg asoprisnil compared with
placebo (Fig. 2).
TABLE 2. Analysis of Rl and PI
Treatment group Between-groups P value3


































































Mean changes of Rl and PI (impedance indices to quantify uterine artery blood flow as determined by color Doppler imaging) from baseline to final visit in the three
treatment groups (placebo, 10 mg asoprisnil, and 25 mg asoprisnil). NA, Not applicable.
a From ANCOVA model for change from baseline to final visit including fixed effects of treatment and investigator and baseline mean RI/PI as a covariate.
b A t test was performed on change from baseline to final visit for each treatment group.
c Statistical significance at 0.05 level.
d Statistical significance at 0.05 level using Hochberg's multiple-comparison procedure.
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TABLE 3. MP scores
Treatment group P value3












Baseline 213.0 ± 128.0 156.7 ± 103.8 217.9 ±115.4 NA NA
Final month 225.6 ± 232.7 2.4 ± 4.9 2.5 ± 8.1 NA NA
Change from baseline 12.6 ± 150.6 -154.3 ± 105.2 -215.4 ± 114.1 0.001b <0.001b
to final month
Mean changes of MP scores (in milliliters) from baseline to final month in the three treatment groups (placebo, 10 mg asoprisnil, and 25 mg asoprisnil). NA, Not
applicable.
a From ANCOVA model for change from baseline to final month with fixed effect of treatment and baseline score as a covariate.
b Statistical significance at 0.05 level using Hochberg's multiple-comparison procedure.
Ovarian activity
Urinary PdG levels (Table 4) were used to calculate luteal
activity for three different time periods during treatment. In the
25-mg asoprisnil group, 70-80% of patients showed NELA
during wk 9-12 of treatment compared with up to 20% in the
placebo group. Dose-dependent suppression of luteal activity
was apparent during wk 1-4 of treatment with 10-20% of pa¬
tients showing NELA in the placebo group compared with 33%
in the 10-mg asoprisnil and 80-90% in the 25-mg asoprisnil
group.
Follicular activity indicated by urinary EjG levels (Table 4)
was partially or totally suppressed in 22% of patients on placebo
compared with 33% on 10 mg asoprisnil and 60% on 25 mg
asoprisnil. Continued follicular activity was seen in 78% of pa¬
tients in the placebo group vs. 67 and 40% in the 10- and 25-mg
asoprisnil groups, respectively. These results suggest a dose-de¬
pendent suppressive effect of asoprisnil on follicular activity.
Safety parameters
No asoprisnil-treated patient had a serious AE. No AEs led to
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* Statistically significant at 0.05 level compared to placebo







FIG. 2. Analysis of UFS-QOL questionnaires. Mean changes in UFS-QOL total score and subscales (concern,
activities, energy/mood, control, self-consciousness, sexual function, and symptom severity) from baseline
to final visit in the three treatment groups (placebo, 10 mg asoprisnil, and 25 mg asoprisnil) are shown.
The significance of the difference of change from baseline between placebo and asoprisnil groups was
determined using Flochberg's multiple-comparison procedure at 0.05 level. For symptom severity, a lower
score corresponds to a lower severity; for other scales, a higher score indicates a better quality of life.
by at least four patients in any group during treatment were
headache, nasopharyngitis, nausea, back pain, perioperative
complications, and abdominal pain. AEs exhibited no drug-re¬
lated or dose-dependent pattern. There were no clinically mean¬
ingful mean changes from baseline in hematology, chemistry,
and urinalysis laboratory values.
Discussion
The primary outcome of this study was evaluation of the effects
of 3 months treatment with asoprisnil on uterine artery blood
flow. Furthermore, effects of asoprisnil on uterine bleeding and
quality of life measures were assessed in patients scheduled for
hysterectomy due to symptomatic leiomyomata.
Asoprisnil treatment was associated with a moderately de¬
creased uterine artery blood flow. There was a rapid reduction in
uterine bleeding, evidenced by MP scores, and an improvement
in quality of life measures.
Previous clinical studies suggested uterine artery blood flow
to be important for leiomyoma growth (25). Pharmacological
agents such as GnRH analogs (26) and
danazol (27), which reduce leiomyoma
volume, have been shown to reduce uter¬
ine artery blood flow. Furthermore, the
progesterone antagonist mifepristone has
been demonstrated to decrease uterine ar¬
tery blood flow and reduce the size of the
leiomyomatous uterus (10).
The effect of asoprisnil on uterine artery
blood flow was assessed in this study to in¬
vestigate a possible mechanism of action in
patients with uterine leiomyomata. Ill and
PI were measured in uterine arteries to show
a statistically significant effect on PI in both
groups treated with asoprisnil and a trend
toward increased III compared with pla¬
cebo. These findings suggest a moderate in¬
hibitory effect of asoprisnil on uterine artery
blood flow.
Asoprisnil has previously been shown to
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TABLE 4. Urinary E,G and PdG levels
Treatment group
Placebo (n = 10)
Mean ± sd
Asoprisnil 10 mg (n = 12)
Mean ± sd




































Mean levels of urinary E,G and PdG collected twice weekly over 4-wk intervals during the screening cycle and during treatment with placebo, 10 mg asoprisnil, 25 mg
or asoprisnil. E,G and PdG levels were measured using ELISA and hormone concentrations corrected for creatinine excretion, levels are expressed as ratios of the
creatinine concentration (E,G in micromoles per mole and PdG in millimoles per mole).
and indirect mechanisms likely to be involved. With the recog¬
nition that progesterone stimulates fibroid development and
growth (6, 7), antiproliferative properties would be expected in
a compound with partial progesterone antagonist effects. There
is growing evidence from in vitro studies that asoprisnil sup¬
presses proliferation and induces apoptosis in cultured leiomy¬
oma cells while failing to show a similar effect on myometrial
cells (28, 29). Evidence to date suggests that asoprisnil has se¬
lective antiproliferative effects on leiomyoma cells via down-
regulation of growth factors and their receptors and induction of
apoptosis (29) mediated by the PR. This is in contrast to the mode
of action of GnRH analogs, which down-regulate ovarian es¬
trogen and progesterone secretion via the pituitary gland to
achieve a reduction in total uterine volume (30), whereas aso¬
prisnil specifically decreases leiomyoma size. The present and
previous studies have shown the antiproliferative effects of aso¬
prisnil to occur in the presence of circulating follicular-phase
estrogen concentrations (15).
Asoprisnil induces a constellation of endometrial morpho¬
logical changes, which have been described as a nonphysiological
secretory effect. In particular, administration of asoprisnil is as¬
sociated with profound vascular changes with increased num¬
bers of thick-walled stromal arterioles specific to the endome¬
trium (16). These changes are associated with low levels of
mitotic activity in endometrial glands and stroma, and no ad¬
verse endometrial findings such as endometrial hyperplasia or
atypia have been demonstrated.
A further novel feature of this study is measurement of ovar¬
ian activity by assessing urinary PdG and EtG twice weekly
throughout the treatment period. There was an apparent dose-
dependent suppression of luteal activity in asoprisnil-treated pa¬
tients. Most patients experienced continued or only partially
suppressed follicular activity on treatment with asoprisnil.
It should be stressed that luteinization in this study was de¬
fined based on urinary PdG concentrations typical for the normal
luteal phase. Hence, luteal phase PdG may be indicative of either
ovulation or a luteinized unruptured follicle. Serial ultrasound
examinations of the dominant follicle and more frequent mea¬
surement of ovarian and pituitary hormones would be needed to
determine the effects of asoprisnil on ovulation.
Previous studies have consistently reported asoprisnil to exert
its clinical effects including suppression of menstruation in the
presence of follicular-phase estrogen concentrations (15, 31).
The risk of hypoestrogenism is the main limiting factor for the
long-term use of GnRH analogs (32), which are currently often
the only option for symptom control in patients with uterine
fibroids seeking to avoid surgery.
The clinical effects of asoprisnil administered for 12 wk dur¬
ing this double-blind, placebo-controlled study are consistent
with previous reports (15). A profound effect on menstrual
bleeding was clearly demonstrated accompanied by a reduction
in the severity of fibroid-related symptoms. Asoprisnil has pre¬
viously been shown to dramatically reduce menstrual bleeding in
women with (15) and without (31) fibroids. In this study, the
effect of asoprisnil on endometrial bleeding was quantified using
the MP. Consistent use of standardized sanitary products and
provision of visual analogs on the pictogram allowed for quan¬
tification of menstrual blood loss, as previously described (20).
Significant reductions were already apparent after the first
month, highlighting a rapid effect of asoprisnil on uterine bleed¬
ing. Number of days with bleeding also markedly decreased in
asoprisnil groups in a dose-related manner. Similarly, there was
a dose response in the percentage of patients experiencing sup¬
pression of uterine bleeding. Treatment with 25 mg asoprisnil
achieved suppression of uterine bleeding in 91% of patients,
some of whom presented with MP scores of over 200 ml (defi¬
nition of HMB is blood loss over 80 ml) (33). HMB is commonly
difficult to manage in the presence of fibroids and frequent in¬
dication for hysterectomy. In this and previous studies (14, 15),
asoprisnil has been shown to control uterine bleeding indepen¬
dent of size and location of uterine fibroids.
The mechanism of suppression of menstrual bleeding during
asoprisnil treatment is not understood. Asoprisnil has previously
been shown to reversibly suppress menstruation at doses of 10
mg/d or higher in women with regular menses. This effect was
irrespective of the impact on luteal-phase progesterone concen¬
trations indicative of luteinization (31). The results of the present
study are consistent with these findings. Collectively, these ob¬
servations strongly suggest that asoprisnil suppresses menstrual
bleeding primarily via an endometrial effect. Asoprisnil induces
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unique morphological changes in endometrial arterioles and
stroma (16), and these changes are likely to contribute to the
suppression of menstrual bleeding.
Asoprisnil-trcated patients demonstrated statistically signif¬
icantly greater improvements than placebo patients in most of
the disease-specific UFS-QOL domains. Responses to the UFS-
QOL questionnaire were grouped into subscales, as previously
described (21). The mean change from baseline to the final visit
indicated improvement in both asoprisnil groups compared with
placebo on all subscales. These quality of life measures indicate
a significant impact of asoprisnil on patients' perception of the
severity of their symptoms and their quality of life. Every patient
in this study had experienced symptoms significant enough to
consent to major surgery for benign disease. In this study, treat¬
ment with asoprisnil was well tolerated. There were no prema¬
ture terminations, and all patients completed the study with good
compliance.
In conclusion, we have made the novel observations that aso¬
prisnil reduces uterine artery blood flow while substantially
decreasing menstrual blood loss and improving quality of life
measures in patients with symptomatic uterine leiomyomata
scheduled for hysterectomy. A moderate reduction in uterine
artery blood flow was demonstrated by change in resistance and
pulsatility indices. This effect may contribute to leiomyoma vol¬
ume reduction, even though it is unlikely to be the primary mech¬
anism. Decreased blood loss was evidenced by MP evaluation
and improvement of quality of life by responses to the UFS-QOL.
All these effects were observed in the presence of continued or
only partially suppressed ovarian follicular activity in the ma¬
jority of patients. The 10- and 25-mg doses of asoprisnil were
safe and effective when administered daily for a 12-wk period.
Further studies are needed to determine safety and efficacy pro¬
files of asoprisnil when administered beyond 12 wk.
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ACKGROUND: Asoprisnil is a selective progesterone receptor modulator with mixed progesterone agonist/
4tagonist activity which controls uterine bleeding via an endometrial effect. This study examined full-thickness endo-
ictrial, leiomyoma and myometrial morphology in hysterectomy specimens from patients with uterine leiomyomata,
>ter treatment with asoprisnil for 3 months. METHODS: In this double-blind, randomized, placebo-controlled study,
5 subjects with uterine leiomyomata were randomized to receive asoprisnil 10,25 mg or placebo for an average of 95
ays prior to hysterectomy. Samples of endometrium, myometrium and leiomyoma tissue were subjected to systema-
c morphological assessment with quantification of mitotic activity. RESULTS: In patients treated with 10 or 25 mg
ioprisnil, a unique pattern called 'non-physiologic secretory effect' was evident in endometrium, recognizable
irough partially developed secretory glandular appearances and stromal changes. Endometrial thickness was
icreased, and there were low levels of mitotic activity in endometrial glands and stroma. Unusual thick-walled mus-
ilar arterioles and prominent aggregations of thin-walled vessels were present in endometrial stroma, but not in
yometrium or non-endometrial vascular beds. Mitotic activity was decreased in leiomyomata. CONCLUSIONS:
soprisnil induces unique morphological changes and is associated with low levels of glandular and stromal prolifer-
■ion in endometrium, and in leiomyomata. These changes are likely to contribute to the amenorrhoea experienced
fter exposure to the medication.
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itroduction
soprisnil is a member of a developing class of selective pro-
ssterone receptor modulators (SPRMs) being studied in
omen with symptomatic uterine leiomyomata. SPRMs are
ogesterone receptor (PR) ligands that exert clinically relevant
:sue-selective progesterone agonist, antagonist or partial or
ixed agonist/antagonist effects on various progesterone
rget tissues in an in vivo situation depending on the biological
tion studied (Chwalisz et al., 2005b). Asoprisnil, a steroidal
I (3-benzaldoxime-substituted SPRM, exhibits mixed pro-
:sterone agonist/antagonist activities in animals (DeManno
al., 2003; Schubert et al., 2005), and high degree of
erine selectivity in women (Chwalisz et al., 2005a). In
contrast to pure progesterone antagonists that inhibit ovulation
and do not show tissue-selective effects, asoprisnil suppresses
uterine bleeding in the presence of follicular phase estrogen
concentrations irrespective of the effects on ovulation. It con¬
trols uterine bleeding in a dose-dependent manner by an
unknown mechanism and appears to target endometrium
specifically (Chwalisz et al., 2005a). In addition, asoprisnil
exerts endometrial antiproliferative effects in non-human pri¬
mates (Chwalisz et al., 2005b) and reduces leiomyoma
volume in humans (Chwalisz et al., 2003). These effects
provide the rationale for its use in the treatment of uterine leio¬
myomata, in which abnormal uterine bleeding is a common
symptom.
>96 © The Author 2007. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
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Uterine effects of asoprisnil
Uterine leiomyomata (fibroids or myomas) are common
benign smooth muscle neoplasms originating in myometrium.
They occur in at least 50% of women of reproductive age,
and although many are asymptomatic, they commonly lead
to troublesome symptoms of heavy menstmal bleeding, as
well as pressure symptoms and infertility. Symptoms attribu¬
table to leiomyomata are the primary indication for 200 000-
300 000 hysterectomies performed each year in the USA
among premenopausal women (Schwartz, 2001). At present,
there is no entirely satisfactory medical treatment for manage¬
ment of women with symptomatic leiomyomata.
The present randomized double-blind placebo-controlled
study was therefore designed to allow detailed histological
assessment of full-thickness endometrium, myometrium and
leiomyomata in samples from hysterectomy specimens of
patients with symptomatic leiomyomata who had been admi¬
nistered 10 or 25 mg asoprisnil daily for 12 weeks prior to
surgery. These doses were selected as previous studies
(Chwalisz et al., 2005a, b) have shown dose-dependent revers¬
ible suppression of menstruation at doses < 10 mg, and dose-
dependent reduction of leiomyomata and uterine volume.
The focus of this study was on the endometrial effects. The
endometrium seems to be the most sensitive target for SPRMs,
since the effects of asoprisnil on uterine bleeding and endo¬
metrial morphology were evident at doses that did not mark¬
edly inhibit luteinization indicative of ovulation and ovarian
estrogen secretion. In addition, compounds with partial pro¬
gesterone antagonist effects have the potential to induce 'unop¬
posed' estrogen effects on the endometrium and create,
therefore, concerns about endometrial safety. Finally, early
studies with asoprisnil revealed that this compound induces
unique changes in the endometrium, characterized as 'non-
physiologic secretory effects' that have not been described
with any known pharmacological agent before (Chwalisz
et al., 2005a). It was clear in this and other unpublished
studies that hitherto undescribed changes were present in the
endometria of asoprisnil-treated patients, and conventional
assessment using the criteria of Noyes et al. (1950) was not
appropriate. The evaluation of full thickness, highly oriented
endometrial specimens obtained during hysterectomy provided
a unique opportunity to study the effects of asoprisnil in all
layers of the endometrium, including the basalis, which is not
accessible by Pipelle endometrial biopsies.
Materials and Methods
Women studied
The study group was composed of premenopausal women volunteers
from four centres (Edinburgh, Southampton, Glasgow and Liverpool)
in good general health with a menstmal cycle between 17 and 42 days,
and symptoms related to overall fibroid size, pressure and/or heavy
uterine bleeding (per protocol), who were scheduled for hysterectomy.
Each patient had at least one intramural non-pedunculated, submuco¬
sal or subserosal fibroid with a diameter of at least 2 cm or multiple
small fibroids with uterine volume >200 cm3 on ultrasonography.
Other inclusion criteria included age over 18 years; negative preg¬
nancy test; a washout period of 2-12 months for hormonal therapies;
serum FSH of <30mIU ml ' at commencement; agreement to use
double barrier method of contraception (condom/diaphragm/sponge
plus spermicide) throughout the study until hysterectomy, unless sur¬
gically sterile by bilateral tubal ligation or vasectomy of partner and
normal Papanicolaou (PAP) test. Subjects were not permitted to
enter the study without a normal endometrial biopsy report based on
an adequate specimen taken within 3 months of commencement.
Screening data were collected in the clinic by study nurses or gynae¬
cologists. All subjects voluntarily signed a full informed consent form.
The study was performed according to the ethical principles of the
Declaration of Helsinki (1989 revision) and the protocol was approved
by the Institutional Review Board (Multicentre Research Ethics
Committee).
Study design
This was a Phase 2 multicentre randomized double-blind placebo-
controlled study of asoprisnil administered for 12 weeks. Dose selec¬
tion was based upon data from Phase I and Phase II studies (publi¬
cations in preparation) in which asoprisnil at doses of 5, 10, and
25 mg has been shown to be safe in subjects treated for 12 weeks. Aso¬
prisnil 10 and 25 mg doses and the 12-week duration of treatment were
chosen because they were effective for treatment of excessive bleed- q
ing, in reducing leiomyoma and uterine volumes and in decreasing g
mass effect symptoms, such as pelvic pressure and bloating, over a
3-month treatment period. ^
At baseline, screening procedures (performed within 45 days of 2.
study commencement) included pelvic and breast examination, com- g1
plete physical examination, PAP test (ThinPrep® Pap Test, Cytyc 3
Corp), ECG, transvaginal ultrasound, endometrial biopsy (Unimar ~
Pipelle® Endometrial Suction Curette, Medscand), contraception "EL
counselling and clinical laboratory investigations: chemistry, haema- jjf
tology, urinalysis, endocrine panel, lipid profile, coagulation screen 3
and serum and urine pregnancy tests. After successful enrollment •§
based on inclusion and exclusion criteria, women were sequentially °
assigned subject numbers in ascending numerical order that encoded 9,
the assignment of the woman, via a randomization schedule, to one "o'
of the three treatment arms of the study. Subjects were randomized g
to one of three parallel dose groups in a 1:1:1 ratio to receive daily
doses of asoprisnil 10, 25 mg or placebo. Subjects and all study per- b
sonnel were blinded to treatment groups. Asoprisnil or placebo '-0
tablets were supplied in blister cards of identical appearance, supplied ■<
to the site packaged in sealed kits. Drug was self-administered as an §
oral dose taken once daily. Treatment was initiated no later than the S
fifth day of the subject's menstrual cycle, and continued for 12 ^
weeks, when subjects were to undergo hysterectomy within 24 h of "
the final dose of drug. The subjects returned all used and unused 2
study medication blister cards at 8-week and final visits so that verifi- °
cation of medication compliance could be monitored. The effects of
asoprisnil on clinical and safety parameters will be reported
separately.
Hysterectomy and processing of uterine samples
After removal of the uterus, the unfixed specimen was placed on ice
immediately and taken without delay to the local pathology labora¬
tory, where the study pathologist or deputy was on hand to open and
sample the specimen. The specimen was oriented and a probe inserted
through the external os of the cervix to define the position of the
cavity. The uterus was opened using a long-bladed knife along the
plane of the probe. The opened specimen was then placed in an ade¬
quate volume of 10% buffered formaldehyde and allowed to fix over¬
night. For large specimens, parallel parasagittal slices 2 cm in
thickness were made to permit adequate fixation overnight. The fol¬
lowing day, the pathologist sampled the specimen for routine diagnos¬
tic reporting, and took additional blocks for study assessment. The
additional blocks consisted of three blocks from the uterine fundus.
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id-corpus and isthmus, respectively, ideally to include full thickness
om endometrium, myometrium and serosal surface, but in any case
eluding full thickness of endometrium with underlying myome-
ium. Endometrial samples were taken from areas away from leio-
yomata wherever possible. Leiomyomata were separately sampled.
11 specimens were processed by routine methods to paraffin wax,
id 3 p.m haematoxylin-eosin sections were prepared by microtomy
id mounted on glass slides. Histological sections of endometrium
ere considered unsuitable for assessment if a leiomyoma was
esent within 10 mm of the endometrium.
istological assessment of endometrium
uring Phase I studies with asoprisnil, it became clear that SPRMs
eluding asoprisnil induce unique changes in the endometrium that
innot be assessed by currently used criteria of endometrial dating
e. the Noyes criteria) (Noyes et al., 1950), because of differential
fects on glands and stroma. As a result, TAP Pharmaceutical Pro-
lcts Inc., Lake Forest, IL, Diagnostic Cytology Laboratories, India-
ipolis, IN, USA, and a group of expert gynaecological pathologists
iveloped a list of diagnostic criteria that allows for classification of
langes induced by SPRMs ('Dictionary of Endometrial Biopsy Diag-
>ses for Clinical Trials with SPRMs'—data on file). This system sup-
ements the conventional descriptive criteria of the normal menstrual
■cle as described by Noyes, and in Blaustein's Pathology of the




Simple tubules, minimum undulation
Simple tubules, undulation as seen in normal
proliferative phase
Tubules, undulation as seen in early secretory
phase
Glands with morphology of mid or late secretory
phase
Mixed (less than 80% show one pattern)
No cystic dilation








Between 1:5 and 1:1
>1:1 and <3:1
>3:1
'Flattened' (cell height < cell width)
'Cuboidal' (cell height = cell width)
'Columnar' (cell height > cell width)
No cytoplasmic vacuolation
Sub and/or supranuclear vacuolation








Present in 1-2 glands
Present in >2 glands, up to 50%
Present in >50% of glands
.bnormal folding patterns as seen in disordered proliferative pattern,









Female Genital Tract (Mutter and Ferenczy, 2002), but includes
additional categories that are considered characteristic of the effects
of SPRMs.
Haematoxylin-eosin stained sections of full-thickness endome¬
trium and underlying myometrium from fundus, mid-corpus and
isthmus and samples of fibroids were evaluated by a gynaecological
pathologist blinded to treatment groups. The maximum single endo¬
metrial thickness on each section was measured using an eyepiece
micrometer. Overall endometrial appearances were classified accord¬
ing to the classification system described earlier. Individual histologi¬
cal characteristics of endometrial glands, stroma and vessels were
analysed by assigning a descriptive subcategory, as shown in
Tables 1 and 2. Myometrium was assessed for any histological
changes or abnormalities, and for the presence or absence of adeno-
myosis. Leiomyomata were assessed for histological type (usual, cel¬
lular, epithelioid, symplastic, myxoid, leiomyoma with heterologous
elements, other) and for degenerative effects (no degenerative
changes, hyaline degeneration, cystic degeneration, myxoid or
mucoid degeneration, coagulative necrosis, calcification, fatty
degeneration).
Non-endometrial tissues, when submitted with the hysterectomy
specimens, were also examined histologically. These comprised
samples of ovaries, Fallopian tubes and cervix. As these were the
only non-uterine tissue samples available, it was of particular interest
to assess the vascular beds to determine whether the changes in endo¬
metrial vessels were specific to that site, or could be seen in other
tissues.
Assessment of mitotic activity
Glandular and stromal mitoses per unit area of endometrium were
quantified separately by counting the number of unequivocal mitotic
figures present per 10 high-power microscope fields of endometrium
(Olympus BX51,x40 objective, field diameter 0.55 mm). Counting
was commenced in the area identified by prior microscopic assessment























<50% show normal mural muscularisation
>50% show normal mural muscularisation






bAtrophic defined as stromal cells have nucleus/cytoplasm (NC) ratio >1.
"Abnormal arterial vessels similar to those seen in stroma of endometrial
polyps.
1 Number of vessel aggregates ('tangles') per slide.
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to show the greatest density of mitoses, and a minimum of 10 non-
overlapping fields randomly selected for counting thereafter. The
same method was used to assess mitotic activity in leiomyomata,
but uninvolved myometrial tissue was not assessed in this way as it
shows no mitotic activity.
Data analysis and statistical methods
For the overall diagnostic category of endometrium as well as categ¬
orical assessments of morphological features in glands and stroma,
number and percentage of patients in each category were summarized
for each treatment group and each of the three locations (uterine
fundus, mid-corpus and isthmus), with no statistical inference per¬
formed. For endometrial thickness measured by eyepiece micrometer,
mean and standard deviation were calculated for each treatment group
and each of the three locations. Although not prespecified, the thick¬
ness was also compared, for each location separately, between the
placebo group and the combined asoprisnil group, using r-tests. The
multiplicity resulting from the three locations was adjusted for using
Hochberg's multiple comparison procedure.
No sample size calculation was performed for this mechanism of
action study. Although a power analysis was carried out for resistance
index (primary efficacy endpoint), and a uterine blood flow parameter
assessed with colour Doppler imaging in this study, none was per¬
formed for morphological characteristics as no statistical inference
was to be performed on these characteristics.
Results
Demographic information
There were 10, 12 and 11 subjects, respectively, who received
placebo, asoprisnil 10 and 25 mg. Twenty-nine subjects were
Caucasian and four were black. Placebo and asoprisnil
groups (10 and 25 mg) were well matched with respect to
age (mean 41.8, 45.1 and 44.6 years, respectively), weight
(mean 73.4, 73.8 and 75.9 kg) and height (165.3, 164.3 and
165.6 cm). The treatment period for this study was between
July 2003 and March 2005. Drug compliance was satisfactory
in all groups. On average, the subjects took the study drug for
95 days. All hysterectomies were performed within 2 days of
the last dose of study drug.
Histological evaluation of endometrium
Baseline endometrial biopsies taken prior to commencement of
medication all showed normal histological appearances, classi¬
fied as inactive (10%), proliferative (28%), menstrual (7%) or
secretory—cycling/physiologic (55%).
In 29 subjects, endometrial samples from fundus, mid-
corpus and isthmus were taken, and were available for
histological assessment. Table 3 shows the overall diagnostic
category assigned to endometrium from three locations
(fundus, mid-corpus and isthmus) in specimens from subjects
taking placebo, 10 or 25 mg asoprisnil. In fundus, mid-corpus
and isthmus (this order will be used throughout the text),
respectively, normal secretory appearances (cycling/physio-
logic) were seen in five of seven, five of seven and five of
seven samples from patients taking placebo, whereas speci¬
mens from patients taking 10 or 25 mg asoprisnil showed
normal secretory appearances in 1 of 10, 2 of 10 and 0 of 10
and in 1 of 11, I of 11 and 0 of 10, respectively. In contrast,
a non-physiologic secretory effect was found in 7 of 10, 5 of
10 and 5 of 10 samples from patients taking 10 mg asoprisnil,
and 8 of 11, 8 of 11 and 5 of 10 samples from patients taking
25 mg. The diagnosis of non-physiologic secretory effect was
assigned in one of seven, zero of seven and one of seven
samples from patients receiving placebo.
Overall description of endometrial morphology
associated with asoprisnil
Endometrium of patients treated with asoprisnil showed a com¬
bination of morphological features affecting glands, stroma and
vessels. Although none of these features was on its own specific
for asoprisnil, the occurrence of several features together
allowed designation of the endometrium as showing the 'non-
physiologic secretory effect'. In this pattern, the endometrial
glands showed some features associated with secretory differ¬
entiation, often with serpentine or tortuous profiles, composed
of columnar epithelial cells with infrequent or absent mitotic
activity (see Fig. 1A as an example). However, glands rarely
showed any evidence of active secretion, as cytoplasmic
vacuolation was absent in most cases. There was a tendency
for cystic dilatation of glands, but no abnormal folding patterns
or increase in gland-stroma ratio above normal (Fig. IB). The
stroma showed a tendency for increased cellularity without evi¬
dence of decidual change. One of the most consistent changes
with asoprisnil was the effect on vessels, of which there were
two characteristic appearances. First, thick-walled muscular-
ized vessels, similar to those seen in the stroma of the
common benign endometrial polyp, were commonly found in
the stroma of asoprisnil-treated patients (Fig. 1C), but were
not identified in any subjects receiving placebo. Secondly,
aggregates of thin-walled vessels were seen at all levels of
Tabic 3. Overall diagnostic category assigned to endometrium in specimens from subjects taking placebo, 10 or 25 mg asoprisnil
Site in uterus Placebo, n (%) Asoprisnil 10 mg, n (%) Asoprisnil 25 mg, n (%)
Fundus Corpus Isthmus Fundus Corpus Isthmus Fundus Corpus Isthmus
n = 1 n = l n — 1 n= 10 n= 10 n = 10 n= 11 72= 11 n = 10
Diagnostic category
Inactive 0(0) 0(0) 0(0) 0(0) 1 (10) 1 (10) 1 (9) 1 (9) 3 (30)
Normal proliferative 1 (14) 1 (14) 1 (14) 2 (20) 2 (20) 3 (30) 1 (9) 0(0) 1 (10)
Normal secretory 5(71) 5(71) 5(71) 1 (10) 2 (20) 0(0) • 1 (9) 1 (9) 0(0)
Non-physiologic secretory 1 (14) 1 (14) 0(0) 7 (70) 5(50) 5 (50) 8 (73) 8 (73) 5(50)
Unsatisfactory 0(0) 0(0) 1 (14) 0(0) 0(0) 1 (10) 0(0) 1 (9) 1 (10)
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;ure 1. (A) Glands show a sinuous or serpentine profile, similar to the architecture of glands seen in the mid-secretory phase of the menstrual
:le. (B) Glands frequently show cystic dilatation. Note the thick-walled vessel in endometrial stroma. (C) Thick-walled muscularized vessel in
iometrial stroma. (D). Dilated thin-walled vessels in thin endometrium with widely dispersed sinuous glands in loose non-decidualized stroma.
: endometrium, from within stratum basalis to just beneath
rface epithelium (Fig. ID). These were not specific to aso-
snil, as they were occasionally observed in placebo-treated
tients, but they were much more common among asoprisnil-
ated patients. In asoprisnil-treated patients, endometrium
is commonly thin (Fig. ID) and frequently it was not possible
distinguish stratum basalis from the stratum functionalis.
e morphological features associated with asoprisnil were
ailar in the thin endometrium of both basalis and
ictionalis.
lividual features of endometrial glands
ith asoprisnil, cytoplasmic secretory vacuolation was rela-
ely infrequent (up to 30%) in patients taking 10 mg, and
sent from glands in all locations in all patients taking
mg. With asoprisnil, gland architecture varied from simple
>ules with minimal undulation to a tortuous appearance
enabling that of the mid- or late secretory phase. Simple
rnlar gland architecture with minimal undulation was more
Timonly seen in endometrium from the isthmus in patients
:ing 25 mg (40%) than in fundus or mid-corpus (9%). Aso-
snil 25 mg led to some degree of cystic gland dilatation in
uterine locations but especially in the isthmus (80% com-
•ed to 29% with placebo). No differences in the frequency
other glandular architectural abnormalities, such as the
aormal folding patterns seen in the disordered proliferative
pattern (Mutter and Ferenczy, 2002) were identified between
asoprisnil-treated patients and controls. The predominant epi¬
thelial cell type seen in glands in all locations was comparable
between asoprisnil and placebo, consisting of tall columnar
cells showing a degree of nuclear stratification that did not
vary significantly between treatment groups. Epithelial cell
nuclei showed no cytological atypia in any patient. Although
a systematic assessment was not performed, histologically
there was no apparent difference in numbers of apoptotic
glandular cells between asoprisnil-treated patients and
controls.
Mitotic activity in endometrial glands and stroma
Mitotic activity for endometrial glands is shown in Table 4 and
for stroma in Table 5. As five out of seven, five out of seven
and five out of seven samples from placebo-treated patients
showed normal secretory endometrial appearances in which
mitoses are very infrequent or absent, and only one out of
seven, one out of seven and one out of seven specimens
showed normal proliferative appearances (Table 3), mitotic
activity cannot properly be compared between asoprisnil-
treated patients and the placebo group. However, it is notable
that in the group of patients treated with 25 mg asoprisnil, no
mitotic activity in endometrial glands was identified in any
specimen except for one sample of fundic endometrium in
one patient. At least 70% of specimens from patients taking
30
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Table 4. Mitotic activity in endometrial glands
Site in uterus Placebo, n (%) Asoprisnil 10 mg, n (%) Asoprisnil 25 mg, n (%)
Fundus Corpus Isthmus Fundus Corpus Isthmus Fundus Corpus Isthmus
n — 1 n = 1 n = 1 n = 10 n=10 n = 10 n= 11 n= 11 n = 9
No. of gland mitoses per 10 HPP
0 5(71) 5(71) 4(57) 5(50) 5 (50) 5(50) 9 (82) 10(91) 9 (100)
1 0(0) 0(0) 0(0) 3 (30) 2 (20) 2(20) 1 (9) 0(0) 0(0)
2-5 1 (14) 0(0) 1 (14) 1 (10) 2 (20) 0(0) 0(0) 0(0) 0(0)
>5 1 (14) 2(29) 1 (14) 1 (10) 1 (10) 1 (10) 0(0) 0(0) 0(0)
Unsatisfactory 0(0) 0(0) 1 (14) 0(0) 0(0) 2 (20) 1 (9) 1 (9) 0(0)
aHigh-power field (HPF) (Olympus BX51, 40 x objective, field diameter 0.55 mm).
10 mg asoprisnil showed one mitosis or less per 10 high-power
fields (HPF) in endometrial glands. In endometrial stroma,
patients who received 25 mg asoprisnil showed absence of
mitotic activity in 8 out of 11, 9 out of 11 and 9 out of 9 asses¬
sable slides, and with 10 mg, 1 mitosis or less per 10 HPF was
seen in 7 out of 10, 10 out of 10 and 8 out of 10 assessable
slides.
Stromal changes
Stromal decidual change was seen around vessels in a speci¬
men from fundus only in one patient taking 25 mg asoprisnil,
but in the remaining assessable samples from patients taking
either 10 or 25 mg asoprisnil there was no decidual change
identified. In contrast, decidual change was present in endo¬
metrial stroma in three of seven, three of seven and three of
seven samples from patients taking placebo. With asoprisnil,
there was an increased frequency of stromal compactness in
all uterine locations, compared with placebo. Stroma was
assessed as compact in zero of seven, zero of seven and one
of seven placebo samples, compared to 6 of 10, 3 of 10 and
3 of 10 samples from patients taking 10 mg asoprisnil and 6
of 11, 5 of 11 and 7 of 10 on 25 mg.
Endometrial thickness
Table 6 shows the mean single layer thickness of the endome¬
trium, as measured by eyepiece micrometer on histological sec¬
tions, for specimens from patients taking placebo, 10 or 25 mg
asoprisnil. There was no statistically significant difference in
endometrial thickness between placebo and combined asopris¬
nil groups, although there was a trend for decreased thickness
with asoprisnil treatment.
Vessels
Aggregates or leashes of thin-walled vessels were seen with
increased frequency in endometrial stroma of asoprisnil-treated
patients compared with controls (Table 7). Samples from
patients on placebo showed the presence of at least one aggre- o
gation of thin-walled vessels in 2 of 7, 1 of 7 and 0 of 7, S
whereas these were present in 3 of 10, 5 of 10 and 2 of 10 o
samples from patients on 10 mg asoprisnil and in 5 of 11, 5 g-
of 11 and 4 of 10 on 25 mg.
Thick-walled vessels, similar to those seen in the stroma of ^
endometrial polyps, were seen with increased frequency com- zr
pared with controls in all uterine locations in patients treated "R
with asoprisnil. Such vessels were not seen in any samples 5
from placebo subjects, whereas they were found in 2 of 10, 3 3
of 10 and 1 of 10 samples from patients on 10 mg asoprisnil p
and in 5 of 11, 5 of 11 and 3 of 10 on 25 mg. ^
Although there are some similarities, the changes associated §
with asoprisnil differ from those associated with endometrial g
polyps. In the latter, thick-walled vessels occur in the stroma 3
of a rounded, projecting polypoid mass in which gland crowd- S"
ing may be observed, and the stroma frequently has a collage- <§
nous appearance. After 12 weeks treatment with asoprisnil, °"
gland crowding is not seen, the stroma does not appear promi- §
nently collagenized, and the endometrium remains flat and <;
often thinned. •<
GO
Non-endometrial vascular beds o
There were 12 ovaries from eight patients, 15 Fallopian tubes °
from 10 patients and 10 cervices available for assessment of
vascular beds in non-endometrial tissues. No specific histologi¬
cal abnormalities were observed.
Table 5. Mitotic activity in endometrial stroma
Site in uterus Placebo, n (%) Asoprisnil 10 mg, n (%) Asoprisnil 25 mg, n (%)
Fundus Corpus Isthmus Fundus Corpus Isthmus Fundus Corpus Isthmus
n — 1 n = 1 n = 1 n = 10 w=10 n=10 n= 11 n = 11 n = 9
No. of stromal mitoses per 10 HPF1
0 3(43) 2 (29) 3(43) 6 (60) 7 (70) 6 (60) 8 (73) 9 (82) 9 (100)
1 2(29) 1 (14) 0(0) 1 (10) 3 (30) 2 (20) 1 (9) 0(0) 0(0)
2-5 0(0) 4(57) 3 (43) 3 (30) 0(0) 0(0) 1 (9) 1 (9) 0(0)
>5 2 (29) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 0(0)
Unsatisfactory 1 (9) 0(0) 1 (14) 0(0) 0(0) 2(20) 1 (9) 1 (9) 0(0)
aHigh-power field (Olympus BX51, 40 x objective, field diameter 0.55 mm).
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ible 6. Mean endometrial thickness measured by eyepiece micrometei■ on histological sections from hysterectomy specimens
erine
:ation
Placebo Asoprisnil 10 mg Asoprisnil 25 mg
n Mean SD n Mean SD n Mean SD
ndus 7 3.60 1.988 10 2.62 1.307 11 2.79 1.718
id-corpus 7 4.06 2.018 10 2.14 0.977 11 2.22 1.098
hmus 6 3.05 1.907 9 2.26 1.840 10 1.27 0.625
= total no of cases. The apparent trend of decreasing endometrial thickness with asoprisnil at both doses is not statistically significant at 0.05 level.
ible 7. Endometrial stromal vessels
te in uterus Placebo, n (%) Asoprisnil 10 mg, n (%) Asoprisnil 25 mg, n (%)
Fundus Corpus Isthmus Fundus Corpus Isthmus Fundus Corpus Isthmus
n = 1 n = 1 n = 1 n = 10 n = 10 n = 10 n = \ \ n= 11 n = 10
sssels
tin walleda 2 (29) 1 (14) 0 (0) 3 (30) 5 (50) 2 (20) 5 (45) 5 (45) 4 (40)
lick walledb 0 (0) 0(0) 0(0) 2(20) 3 (30) 1 (10) 5 (45) 5 (45) 3 (30)
ggregates of thin-walled vessels present,
hick-walled muscularized vessels present.
yometrium
yometrium samples were obtained from all 33 patients and
orphological assessments were performed. Adenomyosis
as infrequent (present in one control subject, one taking
) mg and four taking 25 mg asoprisnil). No further abnormal-
es or changes were identified in these samples.
nomyomata
istological evaluation of the largest leiomyoma of each
'sterectomy specimen showed 29 of 30 to be of the usual
stological type, and one to be of cellular type. Degenerative
tanges (hyaline or myxoid/mucoid changes, or coagulative
■crosis) were seen in 4 of 9 leiomyomata from the placebo
oup, 8 of 12 in the 10 mg and 7 of 9 in the 25 mg asoprisnil
oup. In the placebo group, mitotic activity was not
entifiable in one of eight leiomyomata, and in the range
-2 mitoses per 10 HPF in the remaining seven of eight
sessable leiomyomata (Table 8). In the 10 mg asoprisnil
oup, 8 of 12 showed no identifiable mitoses and 4 of 12
owed 1-2 mitoses per 10 HPF. In the 25 mg asoprisnil
oup, six of nine showed no mitoses, two cases showed 1-2
itoses per 10 HPF and one case showed 3-5 mitoses per
) HPF.
ible 8. Mitotic activity in largest leiomyoma
>. of mitoses Placebo (N= 9), Asoprisnil 10 mg Asoprisnil 25 mg
r 10 HPF" n (%) (AM 12), n (%) (AM9), n (%)
1 (11) 8(67) 6(67)
-2 7 (78) 4(33) 2 (22)
-5 0(0) 0(0) 1 (ID
5 0(0) 0(0) 0(0)
isatisfactory 1 (11) 0(0) 0(0)
igh-power field (Olympus BX51, 40 x objective, field diameter 0.55 mm).
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Discussion
Asoprisnil has a variety of clinical effects that have so far not
been described with any other pharmaceutical agent. It controls
uterine bleeding in a dose-dependent manner without causing
suppression of estradiol from follicular phase levels and irre¬
spective of the effects on luteinization (Chwalisz et al.,
2005a). In patients with leiomyomata, it suppresses heavy
uterine bleeding, reduces leiomyoma and uterine volumes
and has beneficial effects on pressure-related symptoms
(Chwalisz et al., 2003). These distinctive clinical effects are
associated with equally distinctive morphological effects on
endometrium, and the existing compendium of pathological
diagnoses does not include appropriate categories to describe
the effects of asoprisnil on endometrium. Early clinical
studies (Chwalisz et al., 2005a) have examined the asoprisnil
effect in endometrial biopsies taken by Pipelle aspiration
after treatment for 28 days. The present study, however, has
allowed for the first time, a detailed morphological investi¬
gation of samples of full thickness endometrium and under¬
lying myometrium, mostly well oriented and undisrupted by
the sampling procedure after a 3-month asoprisnil treatment.
Most of the subjects recruited were suffering symptoms of
heavy uterine bleeding associated with fibroids, and the endo¬
metrium cannot, therefore, be considered functionally normal.
Although efforts were made to sample endometrium at least
10 mm away from the nearest fibroid, it is known that vascular
changes occur in the endometrium of these patients, and results
must be interpreted with caution. However, the baseline endo¬
metrial biopsies taken at screening were within normal limits
histologically.
The majority of asoprisnil-treated subjects showed endo¬
metrial morphology that was consistently recognizable as
showing a 'non-physiologic secretory effect', a category that
was assigned in only one placebo-treated subject. It was
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present to a similar extent in all three uterine locations sampled
(fundus, mid-corpus and isthmus), and was seen in a higher
proportion of subjects on 25 mg of asoprisnil. This appearance
is unfamiliar to histopathologists, as it is not seen in normal
cycling endometrium or in any described condition, and is
believed to reflect the partial agonist/antagonist effect of aso¬
prisnil described in animal studies (DeManno et al., 2003). The
histological features defining the effect are endometrial glands
showing tortuosity similar to the architecture of the secretory
phase, but with a rarity of secretory activity or cytoplasmic
vacuolation. Glands frequently showed cystic dilatation,
however, and although nuclear stratification was present,
there was a paucity of mitotic activity. Appearances of cystic
glandular dilatation are frequently associated in the minds of
histopathologists with simple hyperplasia of endometrium,
but the non-physiologic secretory effect differed in that gland¬
ular crowding was absent, cystic change was often focal invol¬
ving one or two glands in a field of non-dilated glands and
mitotic activity was very sparse or absent. Gland dilatation is
a feature commonly seen in the inactive, non-secretory endo¬
metrium of the perimenopausal and post-menopausal woman,
and is not considered indicative of glandular secretory activity.
It may in fact represent glands in which the opening to the
surface has become occluded, perhaps, as a consequence of
the lack of secretory activity.
In this 3-month study, endometrial thickness was not
increased in the asoprisnil group compared with placebo, and
indeed the trend was for mean endometrial thickness to be
less than that of placebo. With asoprisnil, the endometrial
stroma showed increasing compactness without decidual
change, but the most characteristic stromal effect involved
vessels. Aggregations of thin-walled vessels were seen in endo¬
metrial stroma more frequently in asoprisnil-treated patients
than in placebo-treated patients. Additionally, vessels with
thickened muscularized walls were seen with greater frequency
in asoprisnil patients than in controls.
The mechanism of amenorrhoea induced by asoprisnil is not
known, but it is probable that the drug exerts a specific effect on
endometrial vessels through action on the PR. This may
involve perivascular cells that express PR, and are believed
to be pivotal in control of menstruation (Kelly et al., 2002),
or other stroma-mediated events. The perivascular cells are
intimately apposed to the endothelial cells of spiral arterioles,
and are believed to respond to falling progesterone concen¬
trations by initiating vasoconstriction-vasodilatation cycles
with resulting hypoxia leading to endometrial sloughing.
Although no specific histological changes were seen in perivas¬
cular cells in this study, the results of detailed immunohisto-
chemical studies are not yet available.
The thick-walled aggregates of vessels resemble those seen
in the stroma of endometrial polyps, and it is likely that in
asoprisnil-treated subjects these evolve from the thinner-walled
aggregates as time goes on. The process appears specific to
endometrium, as no similar changes were identified in the
limited range of non-endometrial tissues examined in this
study. In the endometrium, it is possible that there is an
active process of angiogenesis stimulated by hypoxia through
an action on the perivascular cells. However, the development
of vascular aggregates may be analogous to the stromal vessels
of endometrial polyps, where it is believed that focal areas of
non-shedding endometrium persist for several cycles to form
the polyp. In both situations, therefore, endometrium is not
shed at menstruation, and this may be the mechanism
whereby such morphologically abnormal vessels develop.
However, although some similarities with stromal changes of
endometrial polyps were observed, with asoprisnil, the endo¬
metrium remained flat and often thin, without gland crowding
and without prominent stromal collagen. It is notable that there
was a low incidence of polyp formation in the asoprisnil-
treated patients in this study, with only one small polyp
found in one subject taking 10 mg.
No histological changes were found in this 3-month study to
give cause for concern about the development of malignant or
premalignant changes. Glands were specifically assessed in
each sample to identify features of cytological atypia, but
none was found. The glandular architectural changes did not
suggest complex hyperplasia, and although there was in some o
cases a superficial resemblance to simple cystic hyperplasia,
this was merely due to the presence of dilated glands, 8^
whereas the other features of simple hyperplasia were g.
lacking. Moreover, endometrial thickness was not increased; g*
indeed, the trend (which was not statistically significant) was 3
for a decreasing endometrial thickness in asoprisnil-treated |t
patients. It is important that histopathologists are made aware
of the potential diagnostic pitfalls of misdiagnosing endo- |
metrial polyps and simple hyperplasia, particularly in curettage S
or aspiration biopsies of endometrium from asoprisnil-treated "5
patients. §•
There are some morphological similarities between the 3-.
endometrial effects of asoprisnil in this study, and those of
the PR antagonist mifepristone, but there are also significant »
differences. Cystic glandular dilatation with inactive epithelial b
appearances is common to both, and there is an antiprolifera- 10
tive effect (Baird et al., 2003; Narvekar et al., 2004). "g
However, no specific vascular changes have been identified 3
in the stroma in mifepristone-treated endometrium, and IF
glands show a less tortuous morphology, generally showing co
simple tubular appearances or cystic dilatation. This suggests g
an absence of agonist activity and a pure antagonist effect g
with mifepristone on PR, whereas with asoprisnil, the gland
tortuosity probably reflects a partial agonist effect in addition
to antagonist action.
In this study, comparison of mitotic activity in endometrium
between treatment and control groups is limited, as five out of
seven subjects in the control group showed secretory phase
appearances in which mitoses are not expected to be present.
However, it is notable that the low level of mitotic activity in
the asoprisnil treatment groups is in keeping with the results
of studies of asoprisnil in primates (Brenner and Slayden,
2005), and may have parallels in studies of other PR ligands
such as mifepristone, in which an antiproliferative effect has
also been described (Baird et al., 2003; Narvekar et al., 2004).
Mitotic activity was also decreased in leiomyomata in
patients receiving asoprisnil, and in keeping with this, degen¬
erative changes were also more common. This is consistent
with the observed diminution in leiomyoma volume in patients
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ceiving asoprisnil (data not shown). However, no histological
fferences were found in the non-leiomyomatous myometrium
itween placebo and asoprisnil groups. Asoprisnil does not
em to induce any noticeable changes in the myometrium.
In conclusion, this study has shown that asoprisnil adminis-
red as 10 or 25 mg daily doses for 3 months leads to the
■velopment of unique histological appearances in the endo-
etrium. As well as consistent effects on gland morphology,
ick-walled muscular vessels are seen in the stroma which
(pear to be specific to endometrial tissue. The mechanism
uterine bleeding suppression is still unknown, but it may
volve interaction between asoprisnil, perivascular cells and
liral vessels. This study reports, for the first time, a detailed
'aluation of endometrial changes induced with asoprisnil
ter a 3-month treatment, based on the full-thickness endo-
etrial samples obtained during hysterectomy. Histopatholo-
sts examining endometrial biopsy specimens from
oprisnil-treated patients need to be aware of the unique
PRM effects' induced by asoprisnil (and perhaps other com-
tunds of this class) to avoid misclassifying appearances as
mple hyperplasia or polyps, which share some of the features
it have significant differences.
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Menorrhagia, mechanisms and targeted therapies
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Purpose of review
Efficient treatment options for the increasing complaint of
heavy menstrual bleeding are required to avoid the
morbidity associated with major surgery. This review
summarizes recent developments in the nonsurgical
approach to treating menorrhagia.
Recent findings
Even though the mechanism of menstruation has still not
been fully elucidated, there have been promising
developments in the attempt to reduce menstrual blood
loss. The levonorgestrel-releasing intrauterine system has
proven very efficient, and there is a frameless device
suitable for enlarged uterine cavities. The side effect of
breakthrough bleeding has been the main reason for
discontinuing treatment. Recent studies have investigated
options of concomitant therapy with antiprogestogens to
counter this effect. Another group of novel compounds are
selective progesterone receptor modulators, which thus far
have been shown to reduce menstrual bleeding without the
unwanted effect of unscheduled bleeding episodes.
Summary
As menorrhagia is largely a subjective complaint, it is
important for successful therapy to be based on an informed
patient's choice. Currently, lack of evidence-based practice,
poor compliance and unpleasant side effects limit the
success of medical therapies contributing to the amount of
major surgery performed for this indication. If concomitant
therapies succeeded in minimizing the episodes of
breakthrough bleeding with the levonorgestrel-releasing
intrauterine system, its recommendation as a first choice
treatment may be confounded. Further research is needed
into efficiency and safety of selective progesterone receptor
modulators, which appear to have great potential in
reducing menstrual blood loss.
Keywords
heavy menstrual bleeding, informed choice, levonorgestrel-
releasing intrauterine system, medical therapy, selective
progesterone receptor modulators
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Introduction
Menorrhagia is better described as heavy menstrual
bleeding and has classically been defined as blood loss
greater than 80 ml per month [ 1 ]. Even though it is rather
impractical to actually measure the blood loss, it has
recently been shown that the subjective estimate of
the blood loss correlates with the measured loss better
than previously believed [2]. However, it can be ques¬
tioned how useful this criterion of 80 ml is in clinical
practice as management is largely guided by the sub¬
jective complaint of heavy menstrual bleeding rather
than measured figures [3].
According to currently proposed definitions, mcnorrhagia
as a symptom refers to heavy menstrual bleeding
irrespective of aetiology and irrespective of the regularity
of the menstrual cycle. Dysfunctional uterine bleeding is
a diagnosis given to patients with excessive uterine
bleeding after any demonstrable pathology has been
excluded and also comprises both anovulatory and
ovulatory heavy bleeding [4].
Menstrual problems arc among the most common reasons
for specialist referral and account for a third of gynaeco¬
logical outpatient workload. The complaint of monor¬
rhagia is of increasing prevalence. Earlier onset of
menarchc and increased life expectancy as well as the
ability to regulate fertility and less time spent breastfeed¬
ing all contribute to the fact that women experience more
periods in their lifetime than their predecessors a century
ago [4,5]. Due to more demanding lifestyles of working
women, there is probably also a reduced tolerance of
troublesome periods and a trend to seek professional
advice.
As menorrhagia is largely a subjective complaint, the
main aim of treatment has to be improved quality of life.
Expectations of treatment and the treatment options
offered arc influenced by psychosocial and cultural fac¬
tors, as reflected in the wide variation in hysterectomies
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performed for menstrual disturbance [6]. Hysterectomy
rates vary significantly with the patient's educational
background [7] and also with the extent to which women
arc involved in the process of decision-making regarding
the appropriate treatment [8].
Considering the cost and morbidity of a hysterectomy, it
is highly desirable to develop alternative treatment
options for monorrhagia. The trend of women preferably
avoiding major surgery when adequately counselled [8]
and the need for fertility-conserving treatment in an
increasing number of women choosing to postpone child-
bearing to a later age can only add to the urgency of this
quest. The aim of this review is therefore to give an
overview of current knowledge and ongoing research into
medical therapies for mcnorrhagia.
Causes of heavy menstrual bleeding
To date, no clear mechanism has been identified that
would explain the symptom of heavy menstrual bleeding
in women with no other pelvic pathology or systemic
disorder. No correlation has been established between
endometrial histology and objectively measured blood
loss. Neither has there been any evidence of gross ovarian
or hypothalamic-pituitary dysfunction in women com¬
plaining of heavy menses [5], At present, the search for
targeted therapies will therefore have to focus on the
mechanism of menstruation itself in order to try and
modulate this physiological process.
Mechanism of menstruation
In the presence of ovulatory cycles, withdrawal of
progesterone triggers a cascade of molecular and cellular
events within the endometrium, initiating its breakdown
and culminating in menstruation. Studies into the local
endometrial response to progesterone withdrawal suggest
that key inflammatory mediators such as interlcukin-8
(IL-8), monocyte chemotactic peptide-1 and cyclooxy-
genase 2 are uprcgulated [9]. A recent study proposes that
the pathway to stimulate cyclooxygcnase 2 mRNA
expression in endometrial stromal cells following pro¬
gesterone withdrawal is via decreased copper-zinc super¬
oxide dismutasc activity and consequent increase in
reactive oxygen species [10]. Simultaneous inhibition
of prostaglandin dehydrogenase results in an elevation
of prostaglandin concentration (PGE and PGF2a). With a
subsequent influx of leukocytes, menstruation resembles
an inflammatory event [11].
It has been recognized that there is an increased synthesis
of PGE2 and PGE-binding sites in the tissue of women
with monorrhagia. Recent studies into the function of
prostaglandin receptors in endometrium have shown that
prostanoids promote angiogencsis and may have a role
in aberrant neovascularization leading to dysfunctional
uterine bleeding. In particular, the trans-phosphorylation
of receptor tyrosine kinases by prostanoid receptors may
be crucial in this process and may be amenable to
modulation by drug treatment. It has been postulated
that a prostanoid receptor antagonist with a receptor
tyrosine kinase inhibitor may be a promising combination
in the search for an effective therapy of menstrual
disturbances [12*]-
It has been fully appreciated that menstruation is a
multifactorial event which can be divided into two
phases. The first phase is hormone dependent and revers¬
ible with add back of progesterone within 36 h. It
involves vasoconstriction of the endometrial spiral
arteries and cytokine changes. The latter phase is not
reversible by progesterone and includes activation of lytic
mechanisms which arc then inevitable [13]. Activation of
matrix mctalloprotcinascs (MMPs) such as MMP-3
with the potential to degrade the extracellular matrix
can lead to a whole cascade of subsequent activations
of lytic enzymes and eventually to tissue sloughing
and menstrual bleeding [14,15]. So far very little is
known about the mechanism of the subsequent endo¬
metrial repair, even though it is likely to be of equal
importance for the understanding of abnormal uterine
bleeding [15].
Other factors have been shown to contribute to the
menstrual process such as cndothclin with potent vaso¬
constrictor and growth factor properties. The expression
of endothelin and its metabolizing enzyme neutral endo-
peptidase varies across the menstrual cycle and differ¬
ences in cndothclin immunoreactivity have been
identified in the endometrium of women with excessive
menstrual bleeding versus women with normal menstrua¬
tion. It has been postulated that the finding of reduced
endothelin in the endometrium of women with excessive
blood loss is associated with an impairment of post-
menstrual vasoconstriction to cease the bleeding and
impairment of endometrial regeneration and repair
[16,17],
The role and timing of hypoxia in the whole process is
the subject ofcurrent research. It has been acknowledged
that vascular endothelial growth factor (VEGF), a
prominent angiogenic factor, is stimulated by hypoxia
and plays an important role in the menstrual process [9],
Both hypoxia and VEGF may well be involved in the
aetiology of abnormal bleeding, and a further under¬
standing of the exact mechanisms will facilitate the
development of effective drug therapies.
Uterine pathology
Structural abnormalities of the uterus such as endometrial
polyps, adenomyosis and leiomyomata arc well known
to be causative factors of excessive uterine bleeding.
Detection of such pathology and ruling out the presence
Menorrhagia, mechanisms and targeted therapies Osei and Critchley 413
of malignancy arc the main reasons for investigations
in a woman presenting with heavy menstrual blood
loss.
Lciomyomata, or uterine fibroids, are the most common
benign pelvic tumours of the female genital tract, affect¬
ing approximately 20-25% of all women of reproductive
age [18]. However, not all uterine fibroids arc sympto¬
matic. A recent study showed no correlation between
menstrual blood loss and number, size and location of the
fibroids. Only submucous fibroids were consistently
associated with heavy menstrual blood loss. It was also
found that the majority of fibroids except those in a
subserosal location do distort the uterine cavity which
possibly accounts for their potential to cause symptoms
[18].
Due to the inconsistent association between uterine
fibroids and heavy uterine bleeding and the fact that
the report of menstrual disturbances is influenced by
psychosocial factors [6], a study was undertaken to
investigate whether women report different symptoms
after being given a diagnosis of uterine fibroids. However,
there was no evidence that symptom reporting was
influenced by the knowledge of the diagnosis [19].
It is still largely unknown how exactly lciomyomata cause
abnormal uterine bleeding. Abnormalities in the vascu¬
lature of lciomyomatous uteri were described as far back
as 1912 [20], More recently, the molecular mechanisms of
these vascular abnormalities have been investigated.
Several vasoactive growth factors such as basic fibroblast
growth factor, VEGF, heparin-binding epidermal growth
factor, platelet-derived growth factor, transforming
growth factor-/), parathyroid hormone-related protein
and prolactin arc differentially regulated in leiomyomata
and could therefore potentially act as mediators of
leiomyoma-relatcd excessive uterine bleeding. Postulat¬
ing that dysregulated angiogencsis results in abnormal
vessels, which contribute to the symptom of heavy bleed¬
ing, these angiogenic growth factors could be a potential
target for novel therapies. Angiogcnesis as a physiological
process is unique to the female reproductive system.
Usually it is a pathological process occurring in wound
healing and tumour formation. Therefore, modulating
agents arc likely to have minimal side effects and could
have great potential in the treatment of leiomyoma-
related complications [21].
Systemic disorders
Heavy menstrual bleeding may be associated with
systemic disorders such as thyroid, liver or renal disease.
To be considered foremost arc coagulation disorders such
as von Willcbrand's disease (vWD) and platelet defects.
There is an ongoing debate as to whether bleeding
disorders should be screened for in women complaining
of excessive menstrual blood loss. The Royal College of
Obstetricians and Gynaecologists [22] states in its guide¬
line for the management of monorrhagia in secondary
care that tests for bleeding disorders should only be
performed in the presence of other suggestive symptoms
or findings on examination. The evidence supporting
screening for vWD in particular has recently been
reviewed again. vWD was confirmed in 5-20% of women
presenting with heavy menstrual blood loss but there
were insufficient data to justify routine testing [23],
Other studies have found similar [24,25] or even higher
figures [26,27], and another review concluded that
testing for vWD should be considered in the absence
of any other pathology [25], Particular awareness seems
prudent when adolescents present with heavy menstrua¬
tion [28], To avoid the use of the expensive laboratory-
workup to confirm vWD as a screening tool, a simpler
platelet function analyser (PFA-100) has recently
been demonstrated to be both sensitive and specific
in the detection of vWD and other bleeding disorders
[29],
Management of heavy menstrual bleeding
Management of heavy menstrual bleeding can generally
be divided into medical and surgical therapy. Currently
available options have recently been summarized empha¬
sizing the importance of women making their own
informed choices about their treatment [30*].
Surgical procedures, which conserve the uterus and arc
therefore less invasive than a hysterectomy, have been
introduced within the last two decades and arc still the
subject of ongoing research. Endometrial resection or
ablation and uterine artery embolization especially in
the presence of uterine fibroids have all been shown to
improve the symptom of heavy menstrual bleeding
considerably [31-35], Compared with a hysterectomy,
these procedures carry a substantially lower risk of
morbidity [36-38], However, they arc still suboptimal
options for women wishing to retain their fertility. Preg¬
nancy rates following endometrial ablation are below 1%
[39] and associated with a risk of significant morbidity
[40]. The outcome of pregnancies following uterine
artery embolization appears more promising [41] but
experience is still limited. For women who have not
completed their families, drug treatment is therefore
the only option and this review concentrates on medical
therapy of heavy menstrual bleeding.
Medical therapy
The search for the ideal medical therapy, which is
effective, affordable and acceptable, is ongoing. Drug
therapy is the least invasive and expensive option for
managing heavy menstrual bleeding and should be the
initial treatment of choice. Lack of evidence-based
practice, poor compliance and unpleasant side effects
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have limited the satisfaction rates associated with
medical therapy [42**]. In order to make drug therapy
successful, it is as important to individualize the approach
to management and involve the patient in this process as
it is to develop new pharmaceutical agents.
This review focuses on recent studies and developments
regarding the drug treatment of heavy menstrual bleed¬
ing. It is beyond the scope of this review to comment on
all the currently established treatment options, which
have recently been presented in a comprehensive review
[42**].
Nonsteroidal antiinflammatory agents and antifibrinolytics
There is mounting evidence supporting the usefulness of
nonsteroidal antiinflammatory drugs (NSAIDs) which
already have an established place in the treatment of
menstrual disturbances [12*]. More specific cyclooxygen-
ase 2 inhibitors are not yet widely available [43] but may
have an improved side-effect profile and could be more
acceptable than commonly used NSAIDs.
The most commonly prescribed antifibrinolytic agent is
the plasminogen activator inhibitor tranexamic acid.
Even though most studies have demonstrated a favour¬
able side-effect profile with no increased incidence of
thrombogenic events [42**,44], it seems prudent to bear
in mind the potential to cause adverse effects on the
cardiovascular system. A recent case report on a possible
relationship between acute myocardial infarction and
the concomitant use of tranexamic acid and the combined
oral contraceptive pill calls for further evaluation of this
potential association [45].
Progestogens
Progestogens have been used to control menstrual
disturbances by various routes of administration. Cyclical
administration of oral progestogens such as norethister-
one, even though widely used, is ineffective in women
with ovulatory cycles unless prescribed for 21 days from
day 5 of the menstrual cycle [46]. The parenterally
administered long-acting contraceptive agent mcdroxy
progesterone acetate and implants commonly reduce
menstrual blood loss. However, due to a high rate of
adverse effects and concerns regarding the long-term
effects on bone density [47], they are a less favourable
option for treatment of mcnorrhagia in women not requir¬
ing contraception [42**].
The use of oral danazol, an isooxazolc derivative of 17a-
ethinyltcstosteronc, has also been limited by its side-
effect profile. A recent study on the efficacy and safety of
vaginal danazol confirmed the effect of reduced men¬
strual blood loss and regression of endometrial hyperpla¬
sia but also a high rate of discontinuance with the
treatment [48],
The levonorgestrcl-relcasing intrauterine system (LNG-
IUS, Mircna) has become the most favourable route of
administering exogenous progestogens. It has consist¬
ently been shown to reduce menstrual blood loss with
amenorrhoca rates up to 33% by causing endometrial
atrophy [49]. This has led to the recommendation to use
the LNG-IUS as a first-line option to treat monorrhagia
[50],
Recent randomized trials have assessed the efficiency of
the LNG-IUS compared with endometrial resection and
hysterectomy. The LNG-IUS was found to be compar¬
able to endometrial resection in its efficiency in a
randomized trial with 3-year follow-up [51*]. It has been
shown before that even though in the short term surgery
may be more successful [52], the LNG-IUS is as effective
as endometrial resection after the first year [53].
A randomized controlled trial with 5-year follow-up
comparing the outcomes of the LNG-IUS insertion
with hysterectomy found no difference in quality of
life improvement but a significant difference in cost
effectiveness [54**]. The cost of treatment with LNG-
IUS was half of the cost of hysterectomy after 5 years.
The conclusion that the LNG-IUS is the most effective
medical therapy for mcnorrhagia, avoiding major surgery
in 60% of patients, consolidates the recommendation
that it should be a first-line treatment [55]. The LNG-
IUS has also been found to be effective and well tolerated
in women with inherited bleeding disorders in whom
treatment of monorrhagia had previously been unsuc¬
cessful [56].
A more recent development is a 'low-dose' FibroPlant-
LNG-IUS delivering 14 /xg/day. This frameless,
anchored device has been shown to have equally pro¬
found effects on menstrual blood loss and ferritin levels.
Its design accounts for minimized occurrence of pain and
expulsion [57*] and also allows its use in enlarged or
distorted uterine cavities [58].
The most frequent indication for discontinuance of treat¬
ment with progestogens including the LNG-IUS is
unscheduled breakthrough bleeding. Despite extensive
research, as yet no single mechanism has been identified
to explain this phenomenon. Various effects of prolonged
exposure to progestogens on endometrial morphology,
sex steroid receptor expression, expression of inflamma¬
tory mediators and endometrial vasculature have been
studied. Features of leukocyte infiltration and aberrant
angiogenesis leading to increased vascular fragility have
recurrently been described [59-61,62",63-65].
Studies comparing tissue from long-term progestogen
users complaining of unscheduled bleeding with asymp¬
tomatic users in particular have also reported changes in
histological appearance and levels of inflammatory and
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angiogenic factors in symptomatic patients. A recent
study showed that the endometrium from users with
regular cycles predominantly exhibited a progestogen
effect whereas those with irregular bleeding often
demonstrated proliferative endometrium. There were
also signs of stromal breakdown and vascular thrombi
in the tissue from patients with breakthrough bleeding
as well as significantly more intense immunostaining of
IL-13 and IL-15 [66]. Others have shown an increased
number of leukocytes, increased MMP-3 [67] and an
increased level of serum nitric oxide metabolites in
women with irregular bleeding [68]. All these findings
confound the hypothesis that inflammation and dysregu-
latcd angiogenesis are the major contributors causing
this undesirable symptom. However, so far, treatment
of irregular bleeding associated with use of long-term
progestogens is still largely empiric, consisting of sex
steroids and NSAIDs [66].
It has been suggested that aberrant angiogcncsis may
be caused by a reduced local endometrial ratio of angio-
poictins Ang-1 : Ang-2. This may be altered by hypoxia/
repcrfusion injury and subsequent production of free
radicals due to reduced endometrial perfusion which
has been reported in progestogen users [69], Ang-1 and
Ang-2 have complimentary roles in regulating angiogen¬
esis. Both act on the same endothelial receptor Tie-2.
Whilst Ang-1 activates the Tic-2 receptor and is import¬
ant for maintaining vascular integrity, Ang-2 has an
antagonistic effect and enhances vascular permeability
[65], A reduction in the endometrial Ang-1 : Ang-2 ratio
by free radicals would implicate a potential role for
antioxidant therapy, such as vitamin E supplementation.
The activation of stress-activated kinases resulting from
hypoxia/reperfusion injury could be blocked by oxygen
radical scavengers in vitro [69],
Based on the assumption that changes in the endometrial
vasculature do not persist when the endometrium
becomes atrophic as symptoms improve with continued
use of progestogen, it has been considered that prctreat-
ment regimens or concomitant agents to render the
endometrium atrophic may prevent unscheduled bleed¬
ing. Antiprogcstogcns or inhibitors of MMP activity have
been suggested [59,70]. There arc data supporting the
use of the antiprogestogen mifepristone administered
once monthly in combination with the levonorgcstrcl-
releasing subdermal implant to improve the bleeding
pattern [59,71,72]. The antiprogcstogcns ORG 31710
and ORG 33628 have also been used in combination
with the progestogen-only pill dcsogcstrel and were
found to reduce vaginal bleeding. Administering ORG
31710 once monthly to women using dcsogcstrcl resulted
in an improved cycle pattern, albeit the effect was only
temporary [73,74**]. In another trial ORG 33628 was
given in a continuous combined regime with a daily
dose in addition to desogcstrcl and effected a dose-
dependent reduction in bleeding episodes. However, if
progestogens are used for contraception rather than treat¬
ment of excessive bleeding, consideration has to be given
to the compromised inhibition of ovulation that may
occur with the concomitant use of an antiprogestogen
[74—].
Selective progesterone receptor modulators
Subsequent to the original description of the antiproges-
tin mifepristone, numerous related progesterone receptor
ligands with mixed agonist and antagonist properties
have been developed and studied in animal models
and various clinical settings [75]. Different compounds
have varying degrees of progesterone agonistic and
antagonistic properties (Fig. 1) [76], It is notable that
in contrast to progesterone antagonists, selective pro¬
gesterone receptor modulators (SPRMs) have only slight
labour-inducing activity [75], It has been established that
progesterone antagonists as well as SPRMs with partial
agonist activity reduce menstrual blood loss [77], This
antiproliferative effect on the endometrium was unex¬
pected as SPRMs do not suppress ovulation and lead to
increased endometrial expression of estrogen and pro¬
gesterone receptors. The mechanism of suppressed
endometrial growth has not been fully elucidated. There
seems to be a direct effect of SPRMs on the endometrial
vasculature. Increased expression of the androgen recep¬
tor may also be a contributing factor [75,78].
The use of mifepristone for the treatment of uterine
leiomyomata and the associated symptom of heavy men¬
strual bleeding has recently been reviewed, confirming a
reduction in blood loss with amcnorrhoea rates between
63 and 100%. The review included 166 women who
had received 5-50 mg mifepristone for 3-6 months.
Transient elevation of transaminases was noted in 4%
and endometrial hyperplasia was found in 28% of patients
screened [79*]. However, studies using lower doses of
between 2 and 5 mg mifepristone showed an absence of
proliferative activity in the endometrium and even a
significant decrease in the expression of the mitosis
marker phosphorylatcd histonc H3 compared with
controls [80*,81].
The novel SPRM asoprisnil (J867) has also been shown to
cause a dose-dependent suppression of menstruation
[82]. Its effect has been studied in healthy premenopau¬
sal women with regular menstrual cycles [83**] and in
patients with symptomatic uterine fibroids [84**]. So
far, asoprisnil has consistently caused dose-dependent
suppression of endometrial proliferation with consequent
reversible amcnorrhoca in the absence of oestrogen
deprivation. The side effect of unscheduled break¬
through bleeding which has been limiting the usefulness
of long-term progestogens has thus far not been reported
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Figure 1. Properties of selective progesterone receptor modulators (SPRMs)
Spectrum of antagonistic and agonistic activities of
progesterone receptor (PR) ligands based on studies in
in-vivo animal models (guinea pigs, rabbits). ONA,
onapristone; R5020, pure progestin promegestone; J867,
asoprisnil. Source: Reproduced with permission from
Schubert ef a/. [76],
Progesterone
Pure V v J Pure
antagonists SPRMs agonists
with asoprisnil. Overall, the compound has been well
tolerated and had a favourable safety profile [83**,84**].
Further studies are ongoing but the potential of this
compound for the treatment of heavy menstrual bleeding
and other symptoms associated with uterine fibroids
appears promising.
Conclusion
Advances in the development of medical therapies for
heavy menstrual bleeding are highly desirable to reduce
costs of treatment and provide options for women wishing
to retain their fertility.
Studies into the mechanism of menstruation have
pointed out potential targets for modulating pharmaceu¬
tical agents. At present, options of medical therapy
mainly comprise NSAIDs, antifibrinolytics and progesto¬
gens. Whilst the LNG-IUS has proven very effective in
reducing menstrual blood loss, the usefulness of exogen¬
ous progestogens has been limited by the side effect of
unscheduled breakthrough bleeding. The idea of con¬
comitant administration of antiprogestogens to improve
the cycle pattern appears promising but warrants further
research.
Whilst in a majority of women suffering from heavy
menstrual bleeding no pathology can be demonstrated,
uterine fibroids are a common causative factor for this
symptom. Studies into the molecular mechanism of
fibroid-related excessive uterine bleeding have identi¬
fied a variety of angiogenic growth factors as potential
targets for drug therapy with possibly minimal side
effects. Thus far, this approach has not been pursued
any further.
The antiproliferative effect on the endometrium of the
most promising group of compounds, the SPRMs, was
initially unexpected. The mechanism of suppressing the
endometrial growth is still unclear but appears to be
primarily due to a direct effect on the endometrial
vasculature. So far, the SPRM asoprisnil used in clinical
trials studying women with and without uterine fibroids
has consistently led to reversible amenorrhoea without
any breakthrough bleeding. Results of further clinical
studies arc awaited with interest.
Whilst the search for new pharmaceutical agents to
modulate menstrual bleeding is ongoing, it must be
remembered that adequate counselling and involving
the patient in the decision about her treatment is as
important for the success of her therapy as the properties
of any compound.
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